
    <html>
        <body>
            <search-app>
                <article class="result" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
    <h1 itemprop="pageTitle">KR20010008898A - Nucleotide monomer containing six-membered azasugar and antisense oligomers thereof 
      - Google Patents</h1><section itemprop="abstract" itemscope="">
<h2>Abstract</h2>
<div html="" itemprop="content"><abstract lang="EN" load-source="docdb" mxw-id="PA7697479" source="national office">
<div class="abstract">PURPOSE: A nucleotide monomer having azasugar of six-membered ring and an anti-sense oligomer derived from the monomer are provided. The nucleotide monomer has azasugar of six-membered ring substituted with a ribose of five-membered ring and the anti-sense oligomer shows high binding specificity to mRNA and a resistance against nuclease. CONSTITUTION: A nucleotide monomer of formula (1) is characterized by substituting a ribose of five membered ring with azasugar of six-membered ring. In the formula, (i) B is natural nucleobase or deformed nucleobase having or not having a protection group; (ii) R1 is H, alpha or beta-hydroxy, alpha or beta -methoxy, alpha or beta-ethoxy, alpha or beta-lower alkoxy, alpha or beta- methoxyethoxy, alpha or beta-fluoro, alpha or beta-halogen, alpha or beta-aminomethoxy, alpha or beta-aminoethoxy, alpha or beta-aminoalkoxy, alpha or beta -dimethyl amino-oxyethyloxy, alpha or beta-dimethylamino-oxyalkoxy, alpha or beta-O-aryl; (iii) R2 is aralkyl, haloaralkyl, lower alkyl, aryl, hetero aryl, heteroarylalkyl, naphtha, fluorenyl; (iv) X is H or a hydroxyl protection group; and (v) Y is H, phosphate, activated phosphate, activated phosphite or solid supporting structure.</div>
</abstract>
</div>
</section><section itemprop="description" itemscope="">
<h2>Description</h2>
<div html="" itemprop="content"><div class="description" lang="EN" load-source="google" mxw-id="PDES126229008">
<invention-title lang="KO">
<span class="notranslate"> <span class="google-src-text">육환의 아자슈거를 가진 뉴클레오타이드 모노머 및 이를 이용한 안티센스 올리고머{Nucleotide monomer containing six-membered azasugar and antisense oligomers thereof}</span>Nucleotide monomer containing six-membered azasugar and antisense oligomers according to the present invention</span>
</invention-title>
<background-art>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명은 자연형의 뉴클레오타이드의 당인 오환의 리보오스를 육환의 아자슈가로 치환한 하기 화학식 1의 구조를 갖는 뉴클레오타이드 모노머와 하기 화학식 2의 구조를 갖는 안티센스 올리고머 및 그의 제조방법에 관한 것이다.</span>The present invention relates to a nucleotide monomer having a structure represented by the following formula (1) in which a cyclic ribose, which is a sugar of a natural nucleotide, is substituted with azasugar, and an antisense oligomer having the structure represented by the following formula (2), and a method for preparing the same.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">화학식 1</span>Formula 1</span>
</div>
<div class="description-paragraph">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">화학식 2</span>Formula 2</span>
</div>
<div class="description-paragraph">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">단백질은 20개 이상의 아미노산으로 구성되며 매우 복잡하고 다양한 3차 구조를 가지고 있으므로, 단백질에 선택적으로 작용하는 약물을 개발하는 데에는 어려움이 있다.  컴퓨터와 엑스레이 분석법을 이용한 단백질의 3차 구조가 규명됨에 따라 단백질 억제제의 개발이 활발히 진행되어왔으나, 아직 효과적인 단백질 억제제는 개발되지 못한 실정이다.</span>Protein is composed of more than 20 amino acids and has a very complex and diverse tertiary structure, it is difficult to develop drugs that selectively act on the protein. As the tertiary structure of the protein has been identified by computer and X-ray analysis, the development of protein inhibitors has been actively progressed, but no effective protein inhibitors have been developed.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">반면, 유전물질인 핵산을 목표로 하여 약물을 개발하는 경우에는 아데노신(adenosine), 구아노신(guanosine), 시티딘(cytidine), 및 티미딘(thymidine) 또는 우리딘(uridine)의 4개의 뉴클레오타이드만으로 구성되는 핵산이 상보적으로 결합하는 특성을 이용함으로써, 다양한 약물을 개발할 수 있다는 장점이 있다(Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principles" Chem. Rev., 1990, 90, 543-584 ; Cohen et al., "The New Genetic Medicine" Scientific American, 1994, 271, 76-82).</span>On the other hand, when developing a drug targeting a nucleic acid, which is a genetic material, only four nucleotides of adenosine, guanosine, cytidine, and thymidine or uridine are used. By using complementary binding properties of nucleic acids, it is advantageous to develop various drugs (Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principles" Chem. Rev., 1990, 90, 543-584 Cohen et al., "The New Genetic Medicine" Scientific American, 1994, 271, 76-82).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">생체내 단백질의 합성은 그들의 아미노산 서열을 코딩하는 유전자의 발현으로 이루어진다.  즉, 이중나선 구조를 가진 DNA 중 한 가닥만이 mRNA로 전사(transcription)되고 이 mRNA가  단백질로 번역(translation)되는 것이다.  이러한 사실을 기초로 하여 일반적인 단백질을 목표로 하는 약물과는 달리 핵산을 목표로 하는 약물이 개발되었는데, mRNA의 서열과 상보적인 염기 서열을 가진 올리고뉴클레오타이드(oligonucleotides)를 포함하는 약물이 그것이다.  올리고뉴클레오타이드는 mRNA의 서열에 상보적으로 결합하여 mRNA가 단백질로 번역되는 것을 억제함으로써, 질병을 일으키는 독성 단백질의 생산을 차단 또는 감소시키는 작용기전을 갖는다.  이 때, 사용되는 올리고뉴클레오타이드의 서열은 유전정보서열(센스서열)과 반대(안티)를 이루므로, 이를 포함하는 약물을 안티센스 약물이라 하며, 이러한 기술을 안티센스 기술이라 한다.</span>Synthesis of proteins in vivo consists of the expression of genes encoding their amino acid sequences. In other words, only one strand of DNA having a double helix structure is transcribed into mRNA and the mRNA is translated into protein. On the basis of this fact, unlike drugs targeting general proteins, drugs targeting nucleic acids have been developed, which include oligonucleotides having base sequences complementary to those of mRNA. Oligonucleotides have a mechanism of action that complementarily binds to the sequence of mRNA and inhibits the translation of the mRNA into proteins, thereby blocking or reducing the production of toxic proteins that cause disease. At this time, since the sequence of the oligonucleotide used is opposite (anti) to the genetic information sequence (sense sequence), the drug containing the same is called an antisense drug, this technique is called an antisense technology.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">1970년 후반에 스테펜슨과 자메닉은 합성 DNA 조각을 사용하여 바이러스의 단백질 생성을 저해할 수 있음을 밝혔으며(Stephenson et al., Proc. Natl. Acad. Sci. USA, 1977, 95, 285 ; Zamecnik et al., Natl. Acad. Sci. USA, 1977, 95, 280), 또한 1980년대에는 생체시스템 자체 내에서도 안티센스 RNA가 생성되어 유전자의 발현을 조절한다는 사실이 알려졌다(Simons et al., Cell, 1983, 34, 683 ; Mizuno et al., Natl. Acad. Sci. USA, 1984, 81, 1966).</span>In late 1970, Stephenson and Jamenic discovered that synthetic DNA fragments can be used to inhibit protein production of viruses (Stephenson et al., Proc. Natl. Acad. Sci. USA, 1977, 95, 285; Zamecnik et al., Natl. Acad. Sci. USA, 1977, 95, 280), and also in the 1980s it was known that antisense RNA is produced in the biological system itself to regulate gene expression (Simons et al., Cell, 1983, 34, 683; Mizuno et al., Natl. Acad. Sci. USA, 1984, 81, 1966).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이와 같이 자연형의 올리고디옥시뉴클레오타이드(oligodeoxynucleotide)는 그 자체로도 안티센스 효과를 보이나, 이들 자연형은 생체내에서 핵산분해효소인 뉴클리아제(nuclease)에 의해 쉽게 분해되므로, 생체에 투여하였을 때 신속히 분해되어 충분한 약리효과를 기대할 수 없다는 문제점이 있다.  이에 안티센스 올리고머의 구조를 변화시켜 안정성이 증가된 안티센스 약물을 만들기 위한 연구가 활발히 진행되어 왔다.</span>As such, oligodeoxynucleotides of natural form show antisense effects by themselves, but these natural forms are easily degraded by nuclease, a nuclease in vivo, and thus when administered to a living body. There is a problem that can not be expected to decompose quickly enough pharmacological effect. Accordingly, researches to make antisense drugs with increased stability by changing the structure of the antisense oligomers have been actively conducted.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">제 1세대 안티센스 약물은 올리고뉴클레오타이드의 포스페이트(phosphate) 연결 구조를 바꾼 올리고머로, 포스포로치오에이트(phosphorothioate), 메틸포스페이트 등이 알려져 있다.</span>First-generation antisense drugs are oligomers that change the phosphate linkage structure of oligonucleotides, and phosphorothioate, methylphosphate, and the like are known.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">포스포로치오에이트는 포스페이트의 산소 한 개가 황으로 치환된 올리고머로서, mRNA에 대한 결합력은 자연형 DNA보다 떨어지나 뉴클레아제에 대하여 강한 내성을 보이며, 생체외(in vitro) 또는 생체내(in vivo) 시험에서 약리활성을 가짐이 확인되었다.  이러한 제 1세대 안티센스 약물 중, 현재 그 일부는 항바이러스제, 항암제로서 임상시험 중에 있으며, 항바이러스제로서 시판중인 것도 있다(Bennett etal., "Antisense Oligonucleotides: is the glass half full or half empty" Biochem. Pharmacol. 1998, 55, 9-19).  그러나 이들은 독성, 면역반응유발 등의 문제점을 가지고 있어(Stein et al., Current Opinion in Oncology, 1994, 6, 587-594 ; Krieg et al, Nature, 1995, 374, 549 ; O'Brien et al., Leukemia, 1994, 8, 2156), 이러한 단점을 보완할 수 있는 안티센스 약물의 개발을 위한 새로운 전략들이 대두되었는데, 올리고뉴클레오타이드의 포스페이트의 골격을 아마이드나 에테르 등으로 바꾸는 방법, 뉴클레오타이드의 염기의 구조를 변화시키는 방법, 및 리보오스(ribose)당의 구조를 변화시키는 방법에 의한 연구 등이 이에 해당된다(De Mesmaeker et al., "Antisense Oligonucleotides" Acc. Chem. Res. 1995, 28, 366-374).</span>Phosphorothioate is an oligomer in which one oxygen of phosphate is substituted with sulfur. The binding capacity to mRNA is lower than that of natural DNA, but it shows strong resistance to nucleases, and is in vitro or in vivo. The test was confirmed to have pharmacological activity. Some of these first-generation antisense drugs are currently in clinical trials as antiviral and anticancer agents, and some are commercially available as antiviral agents (Bennett et al., "Antisense Oligonucleotides: is the glass half full or half empty" Biochem.Pharmacol 1998, 55, 9-19). However, they have problems such as toxicity and immune response (Stein et al., Current Opinion in Oncology, 1994, 6, 587-594; Krieg et al, Nature, 1995, 374, 549; O'Brien et al. , Leukemia, 1994, 8, 2156), new strategies for the development of antisense drugs to address these shortcomings have emerged, such as the method of changing the backbone structure of nucleotides to amides or ethers. This is the case with the method of changing and the method of changing the structure of the ribose sugar (De Mesmaeker et al., "Antisense Oligonucleotides" Acc. Chem. Res. 1995, 28, 366-374).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">포스포로치오에이트, 메틸포스페이트 등 포스페이트의 연결 부분을 바꾼 올리고머가 제 1세대 안티센스 약물로 불리는 반면, 제 2세대 안티센스 약물은 올리고뉴클레오타이드의 당의 구조에 변화를 중 올리고머를 지칭한다.  이러한 당의 구조에 변화를 준 올리고머에는 2'위치에 메톡시, 메톡시에톡시(Martin et al., Helv. Chim. Acta, 1995, 186, 584) 또는 아미노알콕시기(Griffey et al., J. Med. Chem. 1996, 39, 5100-5109)가 도입된 올리고머, 헥소오스(hexose) 함유 올리고머(Herdewijn et al., In Carbohydrate Modifications in Antisense Research; ACS Symposium Series 580; Sanghvi, Y. S., Cook, P. D., Eds.; American Chemical Society: Washington, DC, 1994; pp 80-99), 펜토오스(pentose) 함유 올리고머(Moser et al., Strategies and Chemical Approaches toward Oligonucleotide Therapeutics. In Perspectives in Medicinal Chemistry; Testa, B. et al., Eds.; Verlag Helvetica Chimica Acta: Basel, 1993, pp 275-97), 4'-아미노리보오스 함유 올리고머 (Scharer et al., J. Am. Chem. Soc. 1995, 117, 6623-6624), 4'-치오리보오스 함유 올리고머(Bellon et al., 4-Thio RNA: a novel class of sugar-modified B-RNA. In Carbohydrate Modifications in Antisense Research; ACS Symposium Series 580; Sanghvi, Y. S., Cook, P. D., Eds.; American Chemical Society: Washington, DC, 1994; pp 68-79), 및 이들의  유도체 등이 있다.</span>Oligomers that replace the phosphate linkages, such as phosphorothioate and methylphosphate, are called first generation antisense drugs, while second generation antisense drugs refer to oligomers that undergo a change in the sugar structure of the oligonucleotides. The oligomers which changed the structure of these sugars include methoxy, methoxyethoxy (Martin et al., Helv. Chim. Acta, 1995, 186, 584) or aminoalkoxy groups (Griffey et al., J. Med. Chem. 1996, 39, 5100-5109) introduced oligomer, hexose containing oligomer (Herdewijn et al., In Carbohydrate Modifications in Antisense Research; ACS Symposium Series 580; Sanghvi, YS, Cook, PD, Eds .; American Chemical Society: Washington, DC, 1994; pp 80-99), pentose-containing oligomers (Moser et al., Strategies and Chemical Approaches toward Oligonucleotide Therapeutics.In Perspectives in Medicinal Chemistry; Testa, B. et al., Eds .; Verlag Helvetica Chimica Acta: Basel, 1993, pp 275-97), 4'-aminoribose containing oligomers (Scharer et al., J. Am. Chem. Soc. 1995, 117, 6623-6624 ), 4'-thioribose containing oligomers (Bellon et al., 4-Thio RNA: a novel class of sugar-modified B-RNA.In Carbohydrate Modifications in Antisense Researc h; ACS Symposium Series 580; Sanghvi, Y. S., Cook, P. D., Eds .; American Chemical Society: Washington, DC, 1994; pp 68-79), and derivatives thereof.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상온(혹은 생체온도) 에서 2본쇄(duplex)로 존재하는 상보서열의 mRNA와 DNA는 온도 상승에 따라 각기 1본쇄(single strand)로 떨어지며, 이의 측정은 온도변화에 따른 UV 흡광도 측정으로 이루어진다.  1본쇄의 UV 흡광도는 2본쇄의 흡광도보다 높아서 온도의 상승에 의해 1본쇄의 양이 증가하면 흡광도도 함께 증가하며, 이 변화곡선은 S자 곡선(sigmoid)을 이룬다.  이 S자 곡선에서 중간정도의 흡광도를 나타내는 때의 온도를 Tm (melting temperature) 이라고 한다.  mRNA에 대한 높은 Tm은 올리고머의 RNA에 대한 높은 친화력(결합력)을 의미하며, 이는 안티센스 분자로서 매우 중요한 요소이다.  이에 여러 연구팀에 의해 2' 위치에 다양한 치환기가 도입된 올리고머의 RNA에 대한 결합력의 성향이 측정되었다(Breslauer et al., Proc. Natl. Acad. Sci. USA, 1986, 83, 3740 ; Freier et al., Nucleic Acids Res. 1997, 25, 4429-4443).</span>At room temperature (or bio temperature), the complementary sequences of mRNA and DNA, which exist in two strands, fall into single strands as the temperature increases, and the measurement is performed by measuring the UV absorbance according to the temperature change. The UV absorbance of one strand is higher than the absorbance of two strands. As the amount of one strand increases due to the increase in temperature, the absorbance also increases, and this change curve forms a sigmoidal curve (sigmoid). The temperature at which a medium absorbance is shown in this S-shaped curve is called Tm (melting temperature). High Tm for mRNA means high affinity (binding capacity) of the oligomer to RNA, which is a very important factor as antisense molecule. Therefore, various research teams have measured the propensity of binding of the oligomers to which the various substituents are introduced at the 2 'position to RNA (Breslauer et al., Proc. Natl. Acad. , Nucleic Acids Res. 1997, 25, 4429-4443).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">제 2세대 안티센스 약물 중 당의 2'-위치에 메톡시기 등이 치환된 염기를 지닌 올리고머의 장점은 mRNA에 대한 높은 Tm(melting temperature)으로, 올리고머의 m-RNA에 대한 높은 Tm은 2' 위치에 도입된 메톡시, 불소와 같은 전기음성기(electronegative group)가 RNA와의 친화도를 높이기 때문이다(Kawasaki et al., J. Med. Chem., 1993, 36, 831-841).</span>Among the second generation antisense drugs, the advantage of oligomers having bases substituted with methoxy groups or the like at the 2'-position of sugars is high Tm (melting temperature) for mRNA, and high Tm for m-RNA of oligomer at 2'-position. This is because the introduced electronegative groups such as methoxy and fluorine increase the affinity with RNA (Kawasaki et al., J. Med. Chem., 1993, 36, 831-841).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">또한, 2' 위치에 메톡시와 같은 알콕시기 등이 도입된 올리고머는 자연형의 DNA에 비하여 뉴클레아제에 대한 내성이 증가한다는 장점이 있다.  이 중 2'-메톡시 치환체는 포스포로치오에이트와 키메릭 올리고머를 구성하여 제 1세대 안티센스 올리고머에 비해 독성이 감소되었으며(Lesnik et al., Biochemistry, 1993, 32, 7832 ; Milligan et al., J. Med. Chem. 1993, 36, 1923), 1997년에 임상시험을 시작하였다(Agrawal et al., Curr. Opin. Chem. Biol., 1998, 2, 519).</span>In addition, oligomers having an alkoxy group such as methoxy introduced at the 2 ′ position have an advantage of increased resistance to nucleases compared to natural DNA. Among these, 2'-methoxy substituents constituted phosphorothioate and chimeric oligomers, reducing toxicity compared to first generation antisense oligomers (Lesnik et al., Biochemistry, 1993, 32, 7832; Milligan et al., J. Med. Chem. 1993, 36, 1923), and began clinical trials in 1997 (Agrawal et al., Curr. Opin. Chem. Biol., 1998, 2, 519).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">한편, 올리고뉴클레오타이드는 안티센스 기술이외에 유전자 크로닝의 하이브리디제이션, 유전자 결함 진단시약 및 중합효소 연쇄반응(PCR)의 시발체(primer) 등 여러 분야에서 이용될 수 있으며(Englisch et al., Ang. Chem. Int. Ed. 1991, 30, 613-629),  단백질의 2차 구조 및 단백질의 구조와 활성의 상관관계를 연구하는 데에도 유용하게 이용될 수 있다(Verma et al., "Modified Oligonucleotides", Ann. Rev. Biochem., 1998, 67, 99-14).</span>In addition to antisense technology, oligonucleotides can be used in various fields such as hybridization of gene cloning, reagents for diagnosis of gene defects, and primers for polymerase chain reaction (PCR) (Englisch et al., Ang. Chem). Int. Ed. 1991, 30, 613-629), and can also be useful in studying the secondary structure of proteins and the relationship between their structure and activity (Verma et al., "Modified Oligonucleotides", Ann. Rev. Biochem., 1998, 67, 99-14).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이에 본 발명자들은 mRNA에 대한 결합력이 높고 뉴클리아제에 대한 내성이 높아 보다 안정적인 새로운 안티센스 약물을 개발하고자 연구한 결과, 오환의 리보오스 대신 육환의 아자슈가를 당의 기본체로 이용하여 일정한 치환기를 붙인 올리고머가 높은 결합력과 안정성을 보이는 것을 확인함으로써 본 발명을 완성하였다.</span>Therefore, the present inventors have studied to develop a new stable antisense drug having high binding ability to mRNA and high resistance to nuclease. As a result, oligomers having a constant substituent using hexacyclic azasugar as a sugar base instead of cyclic ribose were used. The present invention was completed by confirming the high binding strength and stability.</span>
</div>
</background-art>
<technical-field>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 목적은 자연의 뉴클레오타이드의 당인 오환의 리보오스를 육환의 아자슈가(azasugar)로 치환하여 mRNA에 대한 결합력이 높고 뉴클리아제에 대한 내성이 강한 뉴클레오타이드 모노머 및 이를 올리고머의 일부분 혹은 전 부분에 도입하여 제조한 안티센스 올리고머를 제공하는 것이다.</span>It is an object of the present invention to replace cyclic ribose, a sugar of natural nucleotides, with azasugar of hexacyclic nucleotide, which has high binding ability to mRNA and strong resistance to nuclease, and introduced into a part or whole part of oligomer It is to provide an antisense oligomer prepared by.</span>
</div>
</technical-field>
<disclosure>
<tech-solution>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명은 자연형의 뉴클레오타이드의 당인 오환의 리보오스(ribose)를 육환의 아자슈가(azasugar)로 치환한 하기 화학식 1의 구조를 갖는 뉴클레오타이드 모노머 및 그 제조방법을 제공한다.</span>The present invention provides a nucleotide monomer having a structure represented by the following formula (1) in which a cyclic ribose, which is a sugar of a natural nucleotide, is substituted with azasugar of a hexacyclic ring, and a method of preparing the same.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">화학식 1</span>Formula 1</span>
</div>
<div class="description-paragraph">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 화학식 1에서</span>In Chemical Formula 1</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(1) B는 보호기를 갖거나 갖지 않은 자연 뉴클레오베이스 또는 변형된 뉴클레오베이스이고,</span>(1) B is a natural nucleobase or modified nucleobase with or without protecting groups,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(2) R<sup>1</sup>은 수소, α- 또는 β-하이드록시, α- 또는 β-메톡시, α- 또는 β-에톡시 등 α- 또는 β-저분자 알콕시 (lower alkoxy), α- 또는 β-메톡시에톡시, α- 또는 β- 플로로 등 α- 또는 β-할로겐, α- 또는 β-아미노메톡시, α- 또는 β-아미노에톡시 등 α- 또는 β-아미노알콕시, α- 또는 β-다이메틸아미노옥시에톡시 (dimethyl amino oxyethyloxy) 등 α- 또는 β-다이메틸아미노-옥시알콕시, α- 또는 β-O-아실이며,</span>(2) R <sup>1</sup> is hydrogen, α- or β-hydroxy, α- or β-methoxy, α- or β-ethoxy and the like, or α- or β-lower molecular weight alkoxy, α- or β-meth Α- or β-aminoalkoxy, α- or β- such as α- or β-halogen, α- or β-aminomethoxy, α- or β-aminoethoxy, such as oxyethoxy, α- or β-fluoro Α- or β-dimethylamino-oxyalkoxy, α- or β-O-acyl, such as dimethyl amino oxyethyloxy,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(3) R<sup>2</sup>는 수소, 벤질, 메틸벤질, 에틸벤질, 디페닐메틸, 할로디페닐메틸 등 아라알킬 (aralkyl), 니트로벤질, 플루오로벤질 등의 할로아라알킬, 사이아노벤질, 메톡시벤질, 에톡시벤질 등 알콕시벤질,  메틸, 에틸, 프로필, 3차부틸 등의 저분자알킬 (lower alkyl), 페닐, 할로페닐 등의 치환기가 있거나 없는 아릴 (aryl),  헤테로아릴(heteroaryl), 헤테로아릴알킬 (heteroarylalkyl), 나프타릴, 플루오레닐 (Fmoc) 이며,</span>(3) R <sup>2</sup> is hydrogen, benzyl, methylbenzyl, ethylbenzyl, diphenylmethyl, halodiphenylmethyl, such as haloaraalkyl, arano, nitrobenzyl, fluorobenzyl, cyanobenzyl, methoxybenzyl , Aryl, heteroaryl, heteroarylalkyl, with or without substituents such as alkoxybenzyl such as ethoxybenzyl, lower alkyl such as methyl, ethyl, propyl, tert-butyl, phenyl, halophenyl, etc. (heteroarylalkyl), naphtharyl, fluorenyl (Fmoc),</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(4) X는 수소 또는 하이드록실 보호기이며,</span>(4) X is hydrogen or a hydroxyl protecting group,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(5) Y는 수소, 포스페이트, 활성화된 포스페이트, 활성화된 포스파이트(phosphite) 또는 고체지지물이다.</span>(5) Y is hydrogen, phosphate, activated phosphate, activated phosphite or solid support.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">특히, R<sup>1</sup>은 β-메톡시, β-에톡시이고, R<sup>2</sup>는 디페닐메틸인 것이 바람직하다.</span>In particular, it is preferable that R &lt;<sup>1&gt;</sup> is (beta) -methoxy and (beta) -ethoxy and R &lt;<sup>2&gt;</sup> is diphenylmethyl.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">또한, 본 발명은 상기 뉴클레오타이드 모노머를 올리고뉴클레오타이드의 일부분 또는 전 부분에 도입하여 제조하는 하기 화학식 2의 구조를 갖는 안티센스 올리고머 및 그 제조방법을 제공한다.</span>The present invention also provides an antisense oligomer having the structure of Formula 2 prepared by introducing the nucleotide monomer into a part or the entire part of the oligonucleotide and a method for producing the same.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">화학식 2</span>Formula 2</span>
</div>
<div class="description-paragraph">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 화학식 2에서</span>In Chemical Formula 2</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">n은 1∼30이며,</span>n is 1 to 30,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">1) B는 보호기를 갖거나 갖지 않은 자연 뉴클레오베이스 또는 변형된 뉴클레오베이스이고,</span>1) B is a natural nucleobase or modified nucleobase with or without protecting groups,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">2) R<sup>1</sup>은 수소, α- 또는 β-하이드록시, α- 또는 β-메톡시, α- 또는 β-에톡시 등 α- 또는 β-저분자 알콕시(lower alkoxy), α- 또는 β-메톡시에톡시, α- 또는 β- 플로로 등 α- 또는 β-할로겐, α- 또는 β-아미노메톡시, α- 또는 β-아미노에톡시 등 α- 또는 β-아미노알콕시, α- 또는 β-다이메틸아미노옥시에톡시(dimethylamino- oxyethyloxy) 등 α- 또는 β-다이메틸아미노-옥시알콕시, α- 또는 β-O-아실이며,</span>2) R <sup>1</sup> is hydrogen, α- or β-hydroxy, α- or β-methoxy, α- or β-ethoxy such as α- or β-lower molecule alkoxy, α- or β-methoxy Α- or β-halogen, such as ethoxy, α- or β-fluoro, α- or β-aminoalkoxy, α- or β-aminoethoxy, etc. Α- or β-dimethylamino-oxyalkoxy, α- or β-O-acyl, such as methylaminooxyoxyoxy,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">3) R<sup>2</sup>는 수소, 벤질, 메틸벤질, 에틸벤질, 디페닐메틸 등 아라알킬 (aralkyl), 니트로벤질, 플루오로벤질 등의 할로아라알킬, 사이아노벤질, 메톡시벤질, 에톡시벤질 등 알콕시벤질,  메틸, 에틸, 프로필, 3차부틸 등의 저분자알킬 (lower alkyl), 페닐, 할로페닐 등의 치환기가 있거나 없는 아릴(aryl), 헤테로아릴(heteroaryl), 헤테로아릴알킬(heteroarylalkyl), 나프타릴, 할로다이페닐메틸, 플루오레닐(Fmoc)이며,</span>3) R <sup>2</sup> is hydrogen, benzyl, methylbenzyl, ethylbenzyl, diphenylmethyl and other alkoxy such as haloaraalkyl such as aralkyl, nitrobenzyl and fluorobenzyl, cyanobenzyl, methoxybenzyl and ethoxybenzyl Aryl, heteroaryl, heteroarylalkyl, naphtharyl with or without substituents such as lower alkyl, benzyl, methyl, ethyl, propyl, tert-butyl, phenyl, halophenyl, etc. , Halodiphenylmethyl, fluorenyl (Fmoc),</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">4) R<sup>3</sup>는 산소 혹은 황이며,</span>4) R <sup>3</sup> is oxygen or sulfur,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">5) X는 수소 혹은 하이드록실 보호기, 컨쥬게이트기, 혹은 올리고뉴클레오타이드이며,</span>5) X is hydrogen or a hydroxyl protecting group, conjugate, or oligonucleotide,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">6) Y는 수소, 포스페이트, 활성화된 포스페이트, 활성화된 포스파이트, 혹은 고체지지물, 컨쥬게이트기, 올리고뉴클레오타이드이다.</span>6) Y is hydrogen, phosphate, activated phosphate, activated phosphite, or solid support, conjugate group, oligonucleotide.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">특히, R<sup>1</sup>은 β-메톡시, β-에톡시이고, R<sup>2</sup>는 디페닐메틸인 것이 바람직하다.</span>In particular, it is preferable that R &lt;<sup>1&gt;</sup> is (beta) -methoxy and (beta) -ethoxy and R &lt;<sup>2&gt;</sup> is diphenylmethyl.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 화학식 2에서 n은 위와 아래의 뉴클레오타이드를 포함하여 1∼30이며,</span>In Formula 2 n is 1 to 30, including the nucleotides above and below,</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">바람직하게는 6∼21이다.  본 발명의 모노머는 올리고머의 어떤 위치에도 존재할 수 있으나, 올리고뉴클레오타이드에서 연이어 존재하는 것보다 3개 염기 이상의 간격을 두고 있는 것이 결합력을 높이는데 바람직하다.</span>Preferably it is 6-21. The monomer of the present invention may be present at any position of the oligomer, but it is preferable to increase the binding force by three or more bases apart from those present successively in the oligonucleotide.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">또한, 본 발명은 상기의 뉴클레오타이드 모노머, 안티센스 올리고머, 또는 키메릭 올리고머를 유효성분으로 하는 단백질 생산 억제제 또는 차단제용 약학적 조성물을 제공한다.</span>The present invention also provides a pharmaceutical composition for protein production inhibitors or blockers comprising the nucleotide monomer, antisense oligomer, or chimeric oligomer as an active ingredient.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명은 또한 상기의 뉴클레오타이드 모노머, 안티센스 올리고머, 또는 키메릭 올리고머를 유효성분으로 하는 바이러스나 박테리아로 인한 간염질환, 암, 또는 면역질환 치료제용 약학적 조성물을 제공한다.</span>The present invention also provides a pharmaceutical composition for treating hepatitis disease, cancer, or immune disease caused by a virus or bacteria comprising the above nucleotide monomer, antisense oligomer, or chimeric oligomer as an active ingredient.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이하, 본 발명을 상세히 설명한다.</span>Hereinafter, the present invention will be described in detail.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명에서 "저분자알킬(lower molecular alkyl)"이라 함은 탄소 1∼4개를 함유한 알킬기로서, 예를 들면 메틸, 에틸, 프로필, 이소프로필 부틸 등이다.     "저분자알콕시 (lower molecular alkoxy)"라 함은 탄소 1∼4개를 함유한 알콕시기로서, 예를 들면 메톡시, 에톡시, 프로폭시, 부톡시, 이소프로폭시 등이며, 바람직하게는 메톡시, 에톡시이다.</span>In the present invention, "lower molecular alkyl" is an alkyl group containing 1 to 4 carbons, for example, methyl, ethyl, propyl, isopropyl butyl and the like. "Lower molecular alkoxy" is an alkoxy group containing 1 to 4 carbons, for example, methoxy, ethoxy, propoxy, butoxy, isopropoxy and the like, preferably methoxy , Ethoxy.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">"O-아실"이라 함은 O-아세틸, O-에틸카르보닐, O-프로필카르보닐 등이며,   "아릴(aryl)" 이라 함은 페닐, 파라나이트로페닐, 파라브로모페닐과 같이 치환기가 있거나 없는 방향족 탄화족 탄화수소(aromatic hydrocarbon)을 칭하며, "아라알킬(aralkyl)"이라 함은 아릴기를 가진 알킬로서 예를 들면 벤질, 에틸페닐, 디페닐메틸 등이며, 바람직하기는 디페닐메틸이다.</span>"O-acyl" refers to O-acetyl, O-ethylcarbonyl, O-propylcarbonyl and the like, and "aryl" refers to substituents such as phenyl, paranitrophenyl and parabromophenyl. Aromatic hydrocarbons, which may or may not be present, are referred to as "aralkyl", alkyl having an aryl group, for example benzyl, ethylphenyl, diphenylmethyl and the like, preferably diphenylmethyl.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">"헤테로아릴 (heteroaryl)"이라 함은 최소 1개 이상의 황, 질소 등의 헤테로원자(heteroatom)를 가진 5환 혹은 6환기를 칭하며 예를 들면 4-피리딜, 3-티오펜 등이다.  헤테로아릴알킬(heteroaryl alkyl)이라 함은 4-피리딜메틸 등의 최소 1개 이상의 황, 질소 등의 헤테로원자를 가진 5환 혹은 6환기를 가진 알킬을 칭한다.</span>"Heteroaryl" refers to a 5- or 6-cyclic group having at least one heteroatom such as sulfur, nitrogen, and the like, for example 4-pyridyl, 3-thiophene and the like. Heteroaryl alkyl refers to alkyl having 5 or 6 ring groups having at least one hetero atom such as sulfur and nitrogen, such as 4-pyridylmethyl.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">"하이드록실 보호기"라 함은 일반적으로 알려진 하이드록실기 보호기를 말하며, 예를 들면 디메톡시트리틸(4, 4'-dimethoxyltrityl)기, 저분자알카놀 (lower molecular alkanol), TMS 에테르(trimethylsilyl ether), TBDMS 에테르 (tert-butyldimethyl silyl ether) 등을 말하며 바람직하기는 디메톡시트리틸 (4, 4'-dimethoxyltrityl)기이다.</span>The term "hydroxyl protecting group" refers to a generally known hydroxyl group protecting group, for example, dimethoxytrityl (4, 4'-dimethoxyltrityl) group, low molecular alkanol, TMS ether (trimethylsilyl ether) , TBDMS ether (tert-butyldimethyl silyl ether) and the like, preferably a dimethoxytrityl (4, 4'-dimethoxyltrityl) group.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">"뉴클레오베이스"는 자연 뉴클레오베이스 또는 변형된 뉴클레오베이스를 포함한 어떤 조합일 수 있다.  바람하게는 자연 뉴클레오베이스인 아데닌, 시토신, 구아닌, 티민 및 우라실, 또는 보호기를 가진 뉴클레오베이스인 N-벤조일아데닌, N-벤조일시토신 및 N-이소부티릴구아닌이다.  일반적으로 사용될 수 있는 변형된 뉴클레오베이스로는 5-(1-프로피닐)우라실(5-(1-propynyl) uracil), 5-(1-프로피닐)시토신 (5-(1-propynyl)cytosine), 이노신(inosine), 5-메틸시토신(5-methylcytosine), 2,6-다이아미노퓨린(2,6-diaminopurine) 등이 있다.</span>A "nucleobase" can be any combination, including natural nucleobases or modified nucleobases. Preferred are the natural nucleobases adenine, cytosine, guanine, thymine and uracil, or the nucleobases with protecting groups N-benzoyladenine, N-benzoylcytosine and N-isobutyrylguanine. Modified nucleobases that can generally be used include 5- (1-propynyl) uracil, 5- (1-propynyl) cytosine (5- (1-propynyl) cytosine ), Inosine, 5-methylcytosine, 2,6-diaminopurine, and the like.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명에서 "올리고뉴클레오타이드"라 함은 1∼30개의 자연 올리고뉴클레오타이드 또는 이의 포스포로치오에이트 유도체를 말한다.  고체지지물로는 콘트롤드 포어 그래스(controlled pore glass, CPG)(in Oligonucleotide synthesis, a practical approach, M. J. Gait ed., Oxford:IRS press, 1984), 옥사릴-콘트롤드 포어 그래스(oxalyl controlled pore glass)(Alul et al., Nucleic Acids Res. 1991, 19, 1527), 아미노폴리에틸렌글라이콜 (aminopolyethyleneglycol) 유도체의 지지물인 텐타겔 지지물(TentaGel support)(Wright et al., Tetrahedron Lett. 1993, 34, 3373) 및 폴리스티렌/다이비닐벤젠(polystyrene /divinylbenzene)의 공중합체인 포로스(Poros) 등이 있으며, 콘트롤드 포어 그래스(CPG)가 가장 바람직하다.</span>In the present invention, "oligonucleotide" refers to 1 to 30 natural oligonucleotides or phosphorothioate derivatives thereof. Solid supports include controlled pore glass (CPG) (in Oligonucleotide synthesis, a practical approach, MJ Gait ed., Oxford: IRS press, 1984), oxalyl controlled pore glass. (Alul et al., Nucleic Acids Res. 1991, 19, 1527), TentaGel support, a support of aminopolyethyleneglycol derivatives (Wright et al., Tetrahedron Lett. 1993, 34, 3373) ) And Poros, a copolymer of polystyrene / divinylbenzene, and controlled pore grass (CPG) is most preferred.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명에서 "컨쥬게이트기"라 함은 1차 또는 2차 하이드록실기에 공유결합을 통해 부착된 기를 말하며, 올리고머의 흡수를 증가시키는 효과가 있다.  예를 들면, 콜레스테롤(cholesterol), 폴리라이신(polylysine), 포스포리피드 (phospholipids), 바이오틴(biotin), 폴리에틸렌글라이콜(polyethylene glycol), 펜난트롤린 (phenanthroline), 페나진(phenazine), 페난트리딘(phenanthridine), 안트라퀴논(anthraquinone), 아크리딘(acridine), 플로레사인(fluorescein), 로다민 (rhodamine), 쿠오마린(coumarine), 다이(dyes) 등이 있다.</span>In the present invention, the "conjugate group" refers to a group attached through a covalent bond to a primary or secondary hydroxyl group, and has an effect of increasing the absorption of oligomers. For example, cholesterol, polylysine, phospholipids, biotin, polyethylene glycol, phenanthroline, phenazine, phenazine Tridine (phenanthridine), anthraquinone (anthraquinone), acridine (acridine), fluorescein (fluorescein), rhodamine (rhodamine), coumarine (coumarine), dies (dyes) and the like.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 육환의 아자슈가를 갖는 뉴클레오타이드 모노머를 제조하는 방법은 하기 반응식 1∼5에 도시된 바와 같다.</span>Method for producing a nucleotide monomer having aza sugar of the cyclic ring of the present invention is as shown in Schemes 1-5.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">반응식 1은 기본적인 육환 아자슈거 제조한 후 아데닌 핵염기를 당에 부착하여 올리고머 제조에 필요한 유도체를 만드는 방법에 관한 것이고, 반응식 2는 아데닌 이외의 핵염기인 티민, 시토신, 구아닌의 축합법에 관한 것이며, 반응식 3은 아자슈거의 질소에 각종 기를 부착하는 방법에 관한 것이다.  반응식 4는 아자슈거의 C-4위치의 하이드록시기를 환원하여 제거하는 방법에 관한 것이고, 반응식 5는 동 위치의 하이드록시기의 입체화학을 바꾸는 합성경로에 관한 것이다.  반응식 1∼5에 따른 합성경로를 통해, 실시예의 모든 화합물을 포함한 화학식 1의 모노머를 합성할 수 있다.</span>Scheme 1 relates to a method for preparing a basic hexacyclic azasugar and attaching adenine nucleobases to sugars to make derivatives necessary for preparing oligomers, and Scheme 2 relates to condensation of thymine, cytosine, and guanine, other than adenine. , Scheme 3 relates to a method for attaching various groups to nitrogen of Azasugar. Scheme 4 relates to a method for reducing and removing a hydroxy group at the C-4 position of Azasugar, and Scheme 5 relates to a synthetic route for changing the stereochemistry of the hydroxyl group at the same position. Through the synthetic route according to Schemes 1 to 5, it is possible to synthesize the monomer of formula (1) including all the compounds of the examples.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이하, 반응식 1∼5를 구체적으로 설명한다.</span>Hereinafter, Reaction Formulas 1-5 are demonstrated concretely.</span>
</div>
<div class="description-paragraph">
<chemistry num="1">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</chemistry>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기식에서 R<sup>1</sup>은 화학식 1에서 정의한 바와 같다.</span>Wherein R <sup>1</sup> is as defined in formula (1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">반응식 1은 육환의 아자슈거의 합성법에 관한 것이다.  시판되는 글루코즈 유도체로부터 기존에 알려진 방법에 의해 아자슈거를 기본골격으로 하는 디옥시노지리마이신(deoxynohirimycin) 유도체(반응식 1의 화합물 4)를 합성한다(Baxter et al., J. Org. Chem., 1994, 59, 3175-3185).  이 후 합성 과정에서 생성된 모든 중간체 및 최종화합물은 신구조의 화합물이다.</span>Scheme 1 relates to the synthesis of Azasugar of hexacyclic. From a commercially available glucose derivative, a deoxynohirimycin derivative (compound 4 of Scheme 1) based on azasugar is synthesized by a known method (Baxter et al., J. Org. Chem., 1994, 59, 3175-3185). All intermediates and final compounds produced during the synthesis are then compounds of the new structure.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">출발물질로 보호기를 가진 글루코즈 1을 사용하여 다이부틸틴옥사이드(Bu<sub>2</sub>SnO)와 브로민(Br<sub>2</sub>)으로 산화시켜 케톤 화합물 2를 얻고, 이를 산성의 수지를 사용하여 보호기가 제거된 3을 얻는다.  여기에 다이페닐메틸아민(diphenylmethylamine)을 가해 보호하는 동시에 고리화 시켜 육환의 아자슈가 4를 얻는다.  당의 6위치의 1차 알콜기와 5위치의 2차 알콜기를 α,ρ-다이메톡시스티렌(α,p-dimethoxystyrene)으로 보호하여 5를 얻는다.  이 때, 다이올(diol)의 보호를 위하여 α,ρ-다이메톡시스티렌 이외에 여러 다양한 시약이 사용될 수는 있으나, 대부분 반응이 진행되지 않거나 저수율을 가져온다.  이 스티렌 보호기는 1개의 키랄 센타 (chiral center)를 갖고 있어 화합물 5는 2개의 다이아스테레오머(diastereomer)로 얻어진다.  그러나, 이후의 보호기의 분리과정에서 다시 하나의 화합물이 되므로 다이올 보호기가 있는 화합물의 반응들에서는 이성체의 분리가 요구되지 않는다.  화합물 5에 3차 부틸다이메틸실릴클로라이드 (tert-butyldimethyl -silylchloride, TBSCl)와 질산은(AgNO<sub>3</sub>), 및 피리딘을 반응하여 주위가 덜 복잡한 C-3위치의 2차 알콜만을 선택적으로 TBS(tert-butyldimethylsilyl)로 보호한 화합물 6을 합성한다.  여기에 각종 알킬할라이드(alkyl halide)와 소듐하이드라이드(NaH)를 사용하여 알킬레이션하여 7을 얻고, 테트라부틸암모니움플로라이드(tetrabutylammonium fluoride, TBAF)로 C-3위치의 TBS 보호기를 제거하여 8을 제조한다.  8의 알콜기를 미즐레이션(methanesulfonylation)하여 9를 얻은 다음, 소듐하이드라이드, 18-크라운-6를 이용한 아데닌과의 축합반응을 통해 뉴클레오사이드 10을 제조한다.  아데닌 염기의 아민기를 모노벤조일에이션(monobenzoylation)하여 11을 제조하고,이를 80 % 초산으로 처리하여 6위치와 5위치의 보호기를 분리하여 12를 제조한다. 4.4'-다이메톡시트리틸클로라이드(4,4'-dimethoxytrityl chloride)를 12에 처리하여 13을 얻고, 이를 2-사이아노에틸 다이이소프로필클로로포스포아미다이트 (ClP(OCH<sub>2</sub>CH<sub>2</sub>CN)N(iPr)<sub>2</sub>)과 다이이소프로필에틸아민(EtN(iPr)<sub>2</sub>)으로 처리하여 포스포아미다이트(phosphoramidite) 화합물 14를 제조한다.</span>Oxidation of dibutyltin oxide (Bu <sub>2</sub> SnO) and bromine (Br <sub>2</sub> ) using glucose 1 having a protecting group as starting material yields ketone compound 2, which is 3 to remove the protecting group using an acidic resin. . Diphenylmethylamine is added thereto, protected, and cyclized to obtain azashu4 in hexacyclic. The 6-position primary alcohol group and the 5-position secondary alcohol group of the sugar are protected with α, ρ-dimethoxystyrene to obtain 5. In this case, various reagents other than α, ρ-dimethoxystyrene may be used for the protection of diols, but most of the reactions do not proceed or bring low yields. This styrene protecting group has one chiral center so that compound 5 is obtained with two diastereomers. However, the separation of isomers is not required in reactions of compounds with diol protecting groups since the compound becomes one compound in the subsequent separation of the protecting group. Tert-butyldimethylsilylchloride (TBSCl), silver nitrate (AgNO <sub>3</sub> ), and pyridine were reacted with compound 5 to selectively select only TBS (tert- Compound 6 protected with butyldimethylsilyl) was synthesized. Here, alkylated using various alkyl halides and sodium hydride (NaH) to obtain 7, and by removing the TBS protecting group at C-3 position with tetrabutylammonium fluoride (TBAF) 8 To prepare. Nucleoside 10 is prepared by condensation with adenine using sodium hydride, 18-crown-6, by immobilizing an alcohol group of 8 to methanesulfonylation. The amine group of the adenine base monobenzoylation (monobenzoylation) to prepare 11, and treated with 80% acetic acid to prepare a 12 by separating the 6 and 5 position protecting groups. 4.4'-dimethoxytrityl chloride (4,4'-dimethoxytrityl chloride) was treated with 12 to obtain 13, which was 2-cyanoethyl diisopropylchlorophosphoamidite (ClP (OCH <sub>2</sub> CH <sub>2</sub> CN). Phosphoramidite Compound 14 is prepared by treatment with) N (iPr) <sub>2</sub> ) and diisopropylethylamine (EtN (iPr) <sub>2</sub> ).</span>
</div>
<div class="description-paragraph">
<chemistry num="2">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</chemistry>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기식에서 R<sup>1</sup>은 화학식 1에서 정의한 바와 같다.</span>Wherein R <sup>1</sup> is as defined in formula (1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">반응식 2는 아데닌 이외의 뉴클레오베이스(시토신, 티민, 구아닌)를 아자슈거에 축합할 경우의 합성 경로를 나타낸 것이다.  반응식 1의 방법도 가능하나 반응 수율이 낮을 뿐만 아니라, 이성체도 생성되므로, 시토신, 티민, 구아닌 모노머 제조시에는 반응식 2에 따른 미즈노부(Misunobu) 반응법을 사용하는 것이 바람직하다.</span>Scheme 2 shows a synthetic route when condensing nucleobases (cytosine, thymine, guanine) other than adenine to azasugar. Although the method of Scheme 1 is also possible, the yield of the reaction is low, and isomers are also produced. Therefore, the preparation of the cytosine, thymine, and guanine monomers is preferably performed using the Misunobu reaction method according to Scheme 2.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">시토신의 도입은 반응식 1에서 얻은 알콜 화합물 8과 N-벤조일시토신을 사용하며, 티민의 도입은 N-벤조일티민을, 구아닌의 도입은 N<sup>2</sup>-이소부티릴-O<sup>6</sup>[2-(p-나이트로페닐)에틸]구아닌(N<sup>2</sup>-isobutyryl-O<sup>6</sup>[2-(p-nitrophenyl)ethyl] guanine)을 사용하여 트리페닐포스핀(triphenylphosphine)과 DEAD(diethyl azodicarboxylate)와 함께 THF(tetrahydrofuran)의 용매하에서 수행된다.  벤조일티미딘 유도체 16은 암모니아 기체를 이용하여 벤조일 보호기를 제거함으로써 티미딘 유도체 17로 변화시키며, 구아노신 유도체 18의 O<sup>6</sup>의 보호기를 DBU (1,8-diazabicyclo [5.4.0]undec-7-ene)로 제거하여 19를 합성한다.  화합물 15, 17, 19는 반응식 1의 과정 또는 후술할 반응식 3의 과정을 거쳐 올리고머로 합성될 수 있는 모노머로 제조될 수 있다.</span>The introduction of cytosine uses alcohol compound 8 and N-benzoylcytosine obtained in Scheme 1, the introduction of thymine is N-benzoylthymine and the introduction of guanine is N <sup>2</sup> -isobutyryl-O <sup>6</sup> [2- (p-knight phenyl) ethyl] guanine <sup> <sup>(N 2 -isobutyryl-O 6 [</sup> </sup> 2- (p-nitrophenyl) ethyl] using guanine), triphenylphosphine (triphenylphosphine) and DEAD (diethyl azodicarboxylate) and with a solvent THF (tetrahydrofuran) Is carried out under. The benzoylthymidine derivative 16 is changed to thymidine derivative 17 by removing the benzoyl protecting group using ammonia gas, and the protecting group of O <sup>6</sup> of guanosine derivative 18 is DBU (1,8-diazabicyclo [5.4.0] undec-7- ene) to synthesize 19. Compounds 15, 17, and 19 may be prepared as monomers capable of synthesizing into oligomers through the process of Scheme 1 or the scheme 3 described below.</span>
</div>
<div class="description-paragraph">
<chemistry num="3">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</chemistry>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기식에서 R<sup>1</sup>, R<sup>2</sup>, B는 화학식 1에서 정의한 바와 같다.</span>Wherein R <sup>1</sup> , R <sup>2</sup> , B are as defined in formula (1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">반응식 3은 상기 반응식 1과 2에서 얻어진 뉴클레오사이드 유도체들의 6환의 슈거 질소에 여러 가지 다양한 R<sup>2</sup>기를 도입하는 제조방법에 관한 것이다.</span>Scheme 3 relates to a preparation method for introducing various R <sup>2</sup> groups to the sugar nitrogen of the six rings of the nucleoside derivatives obtained in Schemes 1 and 2.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">뉴클레오사이드 유도체 20은 트리플루오로아세트산 (CF<sub>3</sub>COOH) 처리로 화합물 21로 되고 여기에 알킬할라이드를  포타슘카보네이트 (potassium carbonate)나 트라이에틸아민 또는 디메틸아미노피리딘 (dimethylaminopyridine, DMAP)와 함께 반응시키면 아자슈거의 질소위치에 알킬화가 일어나 화합물 22가 합성된다. 이 후 반응식 1에 따른 과정을 거쳐 화합물 23이 합성된다.</span>Nucleoside Derivative 20 is compound 21 by trifluoroacetic acid (CF <sub>3</sub> COOH) treatment, where the alkyl halide is reacted with potassium carbonate, triethylamine or dimethylaminopyridine (DMAP). Alkylation takes place at the nitrogen site of the sugar, whereby compound 22 is synthesized. Thereafter, Compound 23 is synthesized through a process according to Scheme 1.</span>
</div>
<div class="description-paragraph">
<chemistry num="4">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</chemistry>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기식에서 R<sup>2</sup>, B는 화학식 1에서 정의한 바와 같다.</span>Wherein R <sup>2</sup> , B are as defined in formula (1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">반응식 4는 아자슈거 C-4위치의 알콜기를 환원 제거하는 제법에 관한 것이다.  아자슈거 6에 치오카본다이이미다졸(thiocarbondiimidazole)을 반응하여 24를 제조하고, 이를 트라이부틸틴하이드라이드(nBu<sub>3</sub>SnH)로 환원 제거하여 슈거유도체 25를 합성한다.  이 후 반응식 1, 2, 또는 3의 과정을 거쳐 화합물 26, 그리고 27을 합성한다.</span>Scheme 4 relates to a process for reducing and removing alcohol groups at the Azasugar C-4 position. Reaction of azasugar 6 with thiocarbondiimidazole was prepared to prepare 24, which was reduced and removed with tributyltin hydride (nBu <sub>3</sub> SnH) to synthesize sugar derivative 25. Thereafter, compounds 26 and 27 are synthesized through the procedures of Schemes 1, 2, or 3.</span>
</div>
<div class="description-paragraph">
<chemistry num="5">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</chemistry>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 식에서 R<sup>1</sup>, R<sup>2</sup>, B는 화학식 1에서 정의한 바와 같다.</span>Wherein R <sup>1</sup> , R <sup>2</sup> , B are as defined in formula (1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">반응식 5는 아자슈거의 4위치의 탄소에 알콜기의 입체화학을 변화시키는 제법으로, 스원(Swern) 산화법에 의해 6으로부터 27을 얻고, 이로부터 L-셀렉트라이드 (L-selectride)와의 환원반응을 통해 반대위치의 알콜기를 가진 29를 얻는다.   이를 다시 알킬레이션하여 29를 얻고, 전술한 과정에 의해 포스포아미다이트인 30을 얻는다.</span>Scheme 5 is a process for changing the stereochemistry of an alcohol group on carbon in the 4-position of azasugar, obtaining 27 to 6 by Swern oxidation, and reducing the reaction with L-selectride. Get 29 with the alcohol group on the opposite side. This is again alkylated to give 29, and 30 is obtained by the above-mentioned process.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">또한, 본 발명에서는 자연의 뉴클레오타이드의 당인 오환의 리보오스 대신에 육환의 아자슈가를 가지는 뉴클레오타이드 모노머를 올리고뉴클레오타이드의 일부분 또는 전 부분에 도입하여 제조한 안티센스 올리고머의 제조방법을 제공한다.</span>In addition, the present invention provides a method for producing an antisense oligomer prepared by introducing a nucleotide monomer having a hexasaccharide as a nucleotide instead of a cyclic ribose which is a sugar of a natural nucleotide to a part or the entire part of an oligonucleotide.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 올리고머는 고체상 또는 액체상에서 제조될 수 있으나 고체상의 방법이 바람직하다.  고체상에서의 올리고뉴클레오타이드의 구체적인 합성 방법은 Oligonucleotide Synthesis, A Practical Approach, Gait(ed.), IRL Press, Washington D. C. (1984), Caruthers and etal., U.S. Pat. No. 4,458,066 및  4,500,707 등에 기재되어 있다.</span>The oligomers of the present invention may be prepared in either solid or liquid phase, but solid phase methods are preferred. Specific methods of synthesizing oligonucleotides in the solid phase are described in Oligonucleotide Synthesis, A Practical Approach, Gait (ed.), IRL Press, Washington D. C. (1984), Caruthers and et al., U.S. Pat. No. 4,458,066 and 4,500,707 and the like.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 뉴클레오타이드 모노머로부터 합성기의 축합반응을 통해 올리고머가 제조되기 위해서는, 뉴클레오타이드 당에 연결된 한 개의 1차 알콜기는 다이메톡시트리틸기로 치환되고, 한 개의 2차 알콜기는 포스포아미다이트기로 치환되어 야 하며, 또한 핵염기도 티민을 제외하고는 적절한 보호기로 보호되어야 한다.</span>In order to prepare an oligomer through the condensation reaction of a synthetic group from the nucleotide monomer of the present invention, one primary alcohol group linked to a nucleotide sugar is substituted with a dimethoxytrityl group, and one secondary alcohol group is substituted with a phosphoramidite group. Nucleobases should also be protected with appropriate protecting agents, except for thymine.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">화학식 1 구조의 모노머를 올리고뉴클레오타이드의 3'-위치에 도입할 경우 고체지지물에 이 유도체를 부착하여야 한다.  상업적으로 구매할 수  있는 아미노기를 가진 콘트롤드포어 글래스(CPG)를 이용하여 모노머를 헤미석시네이트 (hemisuccinate)로 만들어 메시틸렌-2-설포닐 클로라이드/1-메틸-1H-이미다졸 (mesitylene-2-sulfonyl chloride/1-methyl-1H-imidazole) 하에서 축합반응시켜 완성한다.</span>When introducing a monomer of structure (1) into the 3'-position of the oligonucleotide, the derivative must be attached to a solid support. Mesitylene-2-sulfonyl chloride / 1-methyl-1H-imidazole (mesitylene-2) by the monomer being made hemisuccinate using a controlled pore glass (CPG) with a commercially available amino group It is completed by condensation reaction under -sulfonyl chloride / 1-methyl-1H-imidazole.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">화학식 1 구조의 모노머를 올리고뉴클레오타이드의 3'-끝 위치 외의 위치에 도입할 경우 DNA 합성기를 사용하여 주로 표준 포스포아미다이트 제법을 이용하여 이루어진다(예를 들면 ABI 392 등).  일반적으로 화학식 1의 모노머의 농도와 고체 수지와의 반응시기는 DNA 합성기의 일반적인 포스포아미다이트 시약과 동일하나, 2'위치에 수소이외의 기가 있는 경우는 화학식 1의 모노머 축합반응 시간을 일반적인 60초에서 600초로 연장시키는 것이 바람직하다.</span>When the monomer of the structure of Formula 1 is introduced at a position other than the 3'-end position of the oligonucleotide, it is mainly performed using a standard phosphoramidite method using a DNA synthesizer (for example, ABI 392, etc.). In general, the concentration of the monomer of Formula 1 and the reaction time of the solid resin are the same as those of the general phosphoramidite reagent of the DNA synthesizer, but when there is a group other than hydrogen at the 2 'position, the condensation reaction time of the monomer of Formula 1 is generally It is desirable to extend from 60 seconds to 600 seconds.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">일단 목적하는 올리고머가 만들어지면 이는 고체 지지물로부터 분리되어야 하며 보호기 또한 제거되어야 한다.  이 두 과정은 동시에 행해질 수도 있고 따로 이루어질 수도 있다.  일반적으로 고체지지물은 암모니아수를 상온 처리하여 완성되고 보호기의 분리는 열을 가한 상태에서(일반적으로 55도에서 17시간) 암모니아수를 사용하여 완성된다.  올리고머의 5'-하이드록실기의 보호기는 다이메톡시트리틸기로서, 이의 분리는 합성의 마지막 단계에서 이루어지는데, 이는 DNA 합성기에서 내장된 프로그램을 이용하거나, 80 % 초산, 다이클로로초산(dichloroacetic acid), 트라이클로로초산(trichloroacetic acid)을 사용할 수 있다.</span>Once the desired oligomer is made it must be separated from the solid support and the protecting group must also be removed. These two processes can be done simultaneously or separately. In general, the solid support is completed by treatment with ammonia water at room temperature, and the separation of the protecting group is accomplished by using ammonia water under heat (generally 55 hours at 55 degrees). The protecting group of the 5'-hydroxyl group of the oligomer is a dimethoxytrityl group, the separation of which is carried out at the end of the synthesis, using a built-in program in the DNA synthesizer, or 80% acetic acid, dichloroacetic acid. Trichloroacetic acid may be used.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">모노머의 2'-위치에 알콜기가 있는 경우에는 아이소부티릴기로 보호된 상태에서 DNA 합성기를 사용하여 올리고머를 제조하고, 그 후 일반적인 DNA 합성 제조 과정에서 암모니아에 의해 분리된다.  모노머의 아자슈거 질소위치에 수소가 있는 경우는 플루오레닐기(F-moc)기로 보호되는데, 이 역시 올리고머의 합성 후 일반적인 보호기 분리과정을 통해 같이 분리된다.</span>If there is an alcohol group in the 2'-position of the monomer, the oligomer is prepared using a DNA synthesizer in a protected state with isobutyryl group, and then separated by ammonia in a general DNA synthesis preparation process. When hydrogen is located at the azasugar nitrogen position of the monomer, it is protected with a fluorenyl group (F-moc) group, which is also separated through a general protecting group separation process after synthesis of an oligomer.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명에서는 모노머 및 안티센스 올리고머의 제조에 있어서, 육환의 아자슈거(피페리딘골격, piperidine)의 3-탄소위치에 핵염기(nucleobase)를 부착함으로써 제조과정을 간편하게 하였다.  즉, 아미날(aminal) 위치에 염기를 부착할 경우에는 주로 알파, 베타 위치 모두에 핵염기가 도입이 되어 이성체의 분리가 요구되는데, 본 발명에서는 아미날 위치가 아닌 탄소위치에 염기를 도입하므로써 원하는 베타위치에만 염기가 도입된 뉴클레오타이드를 얻을 수 있다.  또한, 질소 위치에 여러 기(group)를 도입함에 있어서, 그 도입이 용이한 아자슈가를 이용함으로써 강한 염기성 시약을 사용하는 번거로움을 없앴으며, 그 생성물인 질소 위치에 각종 기가 도입된 올리고머들은 RNA에 대한 높은 Tm을 갖는 것으로 보아 mRNA에 대한 친화력이 높은 효과적인 안티센스 약물로 이용될 수 있다.</span>In the present invention, in the preparation of monomers and antisense oligomers, the preparation process is simplified by attaching a nucleobase to the 3-carbon position of hexasaccharide (piperidine skeleton). That is, in the case of attaching a base to an aminal position, nucleobases are mainly introduced at both alpha and beta positions, and separation of isomers is required in the present invention. A nucleotide incorporating a base only at the desired beta position can be obtained. In addition, in the introduction of various groups at the nitrogen position, the use of azasugar, which is easy to introduce, eliminates the trouble of using a strong basic reagent, and oligomers having various groups introduced at the nitrogen position as their products are RNA. It can be used as an effective antisense drug having high affinity for mRNA and high affinity for mRNA.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명에 있어서, 리보오스 대신 육환의 아자슈거를 사용하고 이에 소수성기를 부착시킴으로써, 세포막 투과성의 개선을 가져올 수 있다.  이러한 카르보사이클릭 뉴클레오타이드를 가진 올리고머는 효소에 대한 내성이 높아 안정한 것으로 알려져 있으며, 실제 본 발명의 올리고머는 뉴클레아제에 대한 내성도 또한 자연 DNA에 비해 많이 개선되었다.  또한, 본 발명의 안티센스 올리고머는 포스페이트 연결부위를 일부 혹은 전부 포스포로치오에이트로 바꿈으로 결합력 증가 및 효소에 대한 안정성을 동시에 확보할 수 있다.</span>In the present invention, by using the hexacyclic azasugar instead of ribose and attaching a hydrophobic group to it, improvement of cell membrane permeability can be brought about. Oligomers having such carbocyclic nucleotides are known to be stable due to their high resistance to enzymes. In fact, the oligomers of the present invention have also improved resistance to nucleases in comparison with natural DNA. In addition, the antisense oligomer of the present invention can secure the binding strength and enzyme stability at the same time by replacing the phosphate linkage part or all of the phosphorothioate.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">한편, 본 발명의 뉴클레오타이드 모노머 및 안티센스 올리고머는 중앙에 포스포다이에스터(phosphodiester) 또는 포스포로치오에이트(phosphothioate) 올리고뉴클레오타이드를 함유하는 키메릭 올리고머의 형태로  제조될 수 있다.</span>Meanwhile, the nucleotide monomer and antisense oligomer of the present invention may be prepared in the form of a chimeric oligomer containing phosphodiester or phosphothioate oligonucleotide at the center.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기한 바와 같이 본 발명은 자연의 뉴클레오타이드의 당인 오환의 리보오스 대신에 육환의 아자슈가를 가지는 뉴클레오타이드 모노머 및 이를 올리고머의 일부분 혹은 전 부분에 도입한 새로운 올리고머를 제공한다.  이러한 변형된 뉴클레오타이드는 일반적으로 안티센스 약물의 목표인 RNA에 자연형의 DNA보다 강하게 결합할 뿐만 아니라, 분해효소인 뉴클레아제에 대한 내성을 가지며, 또한 아자슈거의 질소위치에 소수성기를 용이하게 부착함으로써 세포막 투과성도 개선시킬 수 있다.</span>As described above, the present invention provides a nucleotide monomer having hexa-azasugar in place of cyclic ribose, which is a sugar of natural nucleotides, and a new oligomer which is introduced into a part or the entire part of the oligomer. Such modified nucleotides generally bind stronger than natural DNA to RNA, which is the target of antisense drugs, and are resistant to nuclease, a degrading enzyme, and by easily attaching hydrophobic groups to the nitrogen site of Azasugar Cell membrane permeability can also be improved.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 올리고머는 안티센스 올리고뉴클레오타이드가 관여하는 어떤 응용에도 유용하며 특히 mRNA에 강한 결합을 보이므로, 안티센스 약물로 우수한 특성을 지니고 있다.</span>The oligomers of the present invention are useful in any application involving antisense oligonucleotides, and in particular exhibit strong binding to mRNA, and thus have excellent properties as antisense drugs.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">안티센스 치료제의 개발에 있어서, 질병의 원인이 되는 단백질이 알려지고 그 단백질 생산에 직접 또는 간접적으로 작용하는 유전자가 밝혀진 경우에는 그 mRNA의 개시 코돈(initiator codon) 등의 중요한 부분(4∼30개 염기부분)에 선택적으로 작용하도록 디자인할 수 있다(Akhtar etal, Nature Genetics, 1993, 4, 215).  이 때, mRNA에 대한 공격부분은 여러 방법에 의해 결정될 수 있으며(Mishra etal, C. R. Acad. Sci. III, 1994, 317, 977 ; Milner etal, Nat. Biotechnol., 1997, 15, 537), 주로 개시코돈이나 전사 시작 부위(transcritioanl start site)를 공격부분으로 하는 것이 우수한 안티센스 효과를 나타낸다(Bacon etal, Oncogene Res., 1991, 6, 13).  mRNA의 서열이 알려지지 않은 경우에는 유전코드(genetic code)를 이용하여 단백질의 서열을 해석하여 안티센스 올리고머의 목표인 mRNA의 서열을 결정할 수 있으며, 만일 단백질 서열이 알려지지 않은 경우에는 알려진 기술에 의해 단백질을 분리하고 서열을 결정하여 이를 이용할 수 있다.  또한 단백질을 생산하는 mRNA나 DNA를 새로이 분리·규명하고, 그 서열을 알려진 방법으로 연구하여 이를 이용할 수도 있다.</span>In the development of antisense therapies, if the protein causing the disease is known and a gene is identified that acts directly or indirectly on its production, an important part (4-30 bases) such as an initiator codon of the mRNA is known. Part) (Akhtar et al, Nature Genetics, 1993, 4, 215). At this time, the attack site for mRNA can be determined by several methods (Mishra et al, CR Acad. Sci. III, 1994, 317, 977; Milner et al, Nat. Biotechnol., 1997, 15, 537) The use of codons or transcritioanl start sites as an attacking part shows excellent antisense effects (Bacon et al, Oncogene Res., 1991, 6, 13). If the sequence of the mRNA is unknown, the genetic code can be used to analyze the sequence of the protein to determine the sequence of the target mRNA of the antisense oligomer. If the protein sequence is unknown, the protein can be identified by a known technique. It can be used to isolate and determine the sequence. In addition, mRNA or DNA that produces a protein can be newly isolated and identified, and its sequence can be studied and used in a known manner.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">mRNA 서열에 상보하는 안티센스 올리고머의 크기는 4∼30개의 모노머로 구성되는 것이 바람직하며, 7∼22개가 보다 바람직하다.</span>The size of the antisense oligomer complementary to the mRNA sequence is preferably composed of 4 to 30 monomers, more preferably 7 to 22 monomers.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 올리고머는 정상세포, 암세포, 종양세포, 원형질 세포, 무형질세포, 및 바이러스 등을 포함한 다양한 세포에 존재하는 DNA 또는 RNA에 결합할 수 있다.  결합서열은 박테리아 서열, 바이러스 서열, 암세포 서열, 염색체 서열, 미트콘드리아 서열 및 플라스미드 서열 등이 있을 수 있다.  본 발명의 올리고머와 DNA 또는 RNA와의 결합은 단백질 생산을 억제할 수도 있고, 또는 유전자 발현을 억제하는 단백질(억제단백질)의 발현을 억제함으로써, 특정단백질 생산을 촉진할 수도 있다.</span>The oligomers of the present invention can bind to DNA or RNA present in various cells, including normal cells, cancer cells, tumor cells, plasma cells, amorphous cells, and viruses. The binding sequence may include a bacterial sequence, a viral sequence, a cancer cell sequence, a chromosome sequence, a mitochondrial sequence and a plasmid sequence. The binding of the oligomer of the present invention to DNA or RNA may inhibit protein production, or may promote the production of a specific protein by inhibiting the expression of a protein (inhibitory protein) that inhibits gene expression.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">또한, 본 발명의 올리고머는 바이러스나 박테리아로 인한 감염질환, 암 및 면역질환, 심장수술후의 재발협착증 (coronary restenosis) 등의 치료에 사용할 수 있다.  바이러스 질환으로는 에이즈, 간염 B형 및 C형, 허피스 및 사이토메갈로바이러스 (cytomegalovirus) 등이 있으며, 암의 경우에는 목적 서열이 DNA 또는 RNA와 관련된 c-myc, c-erbB-2 등의 온코진(oncogene), 종양 억제 유전자(tumor suppress gene), 및 암과 관련된 단백질 유전자 (protein kinase A, protein kinase C, c-raf kinase, bcl-2, bcr.abl 등의 단백질)  등을 포함하며, 자가면역질환으로는 류마티스관절염, 건선, 크론병, 신경성 다발염, 제1형 당뇨병 및 루푸스 등의 질환이 있다.</span>In addition, the oligomer of the present invention can be used for the treatment of infectious diseases caused by viruses or bacteria, cancer and immune diseases, and coronary restenosis after cardiac surgery. Viral diseases include AIDS, hepatitis B and C, herpes and cytomegalovirus, and in cancer, oncogenes such as c-myc and c-erbB-2, whose target sequences are related to DNA or RNA (oncogene), tumor suppressor gene, and protein genes related to cancer (proteins such as protein kinase A, protein kinase C, c-raf kinase, bcl-2, bcr.abl, etc.) Immune diseases include diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, polyneuropathy, type 1 diabetes and lupus.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 뉴클레오타이드 모노머, 안티센스 올리고머, 또는 키메릭 올리고머는 임상투여시에 비경구 또는 경구로 투여가 가능하다.  경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화학식 1의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (Calcium carbonate), 수크로스 (Sucrose) 또는 락토오스 (Lactose), 젤라틴 등을 섞어 조제된다.  또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다.  경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 캡슐, 동결건조제제, 연고제, 좌제가 포함된다.  비수성용제, 현탁용제로는 프로필렌글리콜 (Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 특히 리포좀 (liposome), PEG화된 리포좀 (PEGylated liposome), 혹은 양이온성 지질 (cationic lipid) 과 같은 올리고머를 세포내로 용이하게 전달시키는 전달체를 사용할 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.</span>The nucleotide monomer, antisense oligomer, or chimeric oligomer of the present invention can be administered parenterally or orally during clinical administration. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, It is prepared by mixing sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, capsules, lyophilized preparations, ointments, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. In particular, a carrier for easily delivering an oligomer such as a liposome, a PEGylated liposome, or a cationic lipid into a cell may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 뉴클레오타이드 모노머, 안티센스 올리고머, 또는 키메릭 올리고머를 단백질 생산 억제제 또는 차단제, 바이러스나 박테리아로 인한 간염질환, 암, 또는 면역질환 치료제로 사용하기 위한 유효용량은  0.1 ∼ 50 mg/kg 이고, 바람직하기로는 0.2 ∼ 2 mg/kg 이다.</span>The effective dose for use of the nucleotide monomer, antisense oligomer, or chimeric oligomer of the present invention as a protein production inhibitor or blocker, as a therapeutic agent for hepatitis, cancer, or immune disease caused by virus or bacteria is preferably 0.1 to 50 mg / kg. The following is 0.2-2 mg / kg.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 올리고머는 세포내의 핵산뿐 아니라 단백질에도 결합할 수 있으므로, 단백질의 연구에 유용하다.  이 때, 단백질은 리셉터, 효소, 리간드 등을 포함하며 유해 단백질의 작용을 억제할 수 있다.</span>Since the oligomer of the present invention can bind not only to nucleic acids in cells but also to proteins, it is useful for the study of proteins. In this case, the protein may include a receptor, an enzyme, a ligand, and the like, and may inhibit the action of harmful proteins.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">또한, 본 발명의 올리고머는 중합효소 연쇄 반응에 시발체로 사용될 수 있으며, PCR에서 안정되고 특이적인 결합을 할 수 있다는 장점을 가지고 있다.</span>In addition, the oligomer of the present invention can be used as a primer for the polymerase chain reaction, and has the advantage of enabling stable and specific binding in PCR.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">본 발명의 올리고머는 또한 핵산의 하이브리디제이션을 이용한 진단시험 시, 탐침(probe)으로 이용할 수 있다(Nucleic Acids Res., 1995, 23, 217).</span>The oligomers of the present invention can also be used as probes in diagnostic tests using hybridization of nucleic acids (Nucleic Acids Res., 1995, 23, 217).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">또한, 본 발명의 올리고머는 보호기의 유무에 관계없이 여러 가지 용도로 쓰일 수 있으며, 또한 정제과정을 거친 후 사용될 수도 있다.  정제방법은 얇은 막 액체 크로마토그래피,  역상 고성능 액체크로마토그래피(reverse phase HPLC), 이온교환크로마토그래피, 또는 전기영동법을 통해 이루어진다.</span>In addition, the oligomer of the present invention may be used for various purposes regardless of the presence or absence of a protecting group, and may also be used after a purification process. Purification methods are accomplished through thin membrane liquid chromatography, reverse phase high performance liquid chromatography, ion exchange chromatography, or electrophoresis.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이하, 본 발명을 실시예에 의하여 상세히 설명한다.</span>Hereinafter, the present invention will be described in detail by way of examples.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">하기 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 내용이 실시예에 의해 한정되는 것은 아니다.</span>The following examples are intended to illustrate the invention and are not intended to limit the scope of the invention.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">모노머 뉴클레오타이드의 합성</span>Synthesis of Monomer Nucleotide</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 1〉 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>Example 1 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) 1, 2-이소프로필리덴-5-케토-α-D-글루코퓨라노즈의 제조</span>(Step 1) Preparation of 1, 2-isopropylidene-5-keto-α-D-glucofuranose</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">다이부틸틴옥사이드(Bu<sub>2</sub>SnO, 48.6 g, 195 mmol)를 메탄올(500 mL)에 녹아 있는 1, 2-이소프로필리덴-D-글루코퓨라노즈(20 g, 91 mmol)에 가한 후 이를 1시간 반 동안 가열 환류하였다.  반응물을 상온까지 식힌 후 용매를 감압 하에서 증류, 제거하였다.  잔사에 메틸렌클로라이드(CH<sub>2</sub>Cl<sub>2</sub>, 500 mL)를 가한 후 이를 O ℃까지 냉각시키고 메틸렌클로라이드(CH<sub>2</sub>Cl<sub>2</sub>, 100 mL)에 녹인 브로민(Br<sub>2</sub>, 5.2 mL. 102 mmol)을 천천히 적가하였다.  적가가 완료되면 같은 온도에서 10분간 교반시킨 후 용매를 감압 하에서 증류, 제거하였다.  용매가 완전히 제거된 잔사(고체)에 메탄올과 헥산을 조금씩 가하여 고체가 완전히 용해된 두 층의 유기층액을 얻었다.  헥산층을 제거하고 메탄올층을 감압하에서 농축시킨 후 이를 컬럼 크로마토그래피(1%/ 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>)로 정제하여 10.4 g의 생성물을 얻었다(수율 53 %).  이는 다음 문헌을 참고하였으나 반응 후의 처리 과정을 통하여 분리시간을 줄이고 수율을 향상시켰다(참고문헌: Baxter, E. W., Reitz, A. B. J. Org. Chem. (1994), vol 59, p. 3175).</span>Dibutyltin oxide (Bu <sub>2</sub> SnO, 48.6 g, 195 mmol) was added to 1, 2-isopropylidene-D-glucofuranose (20 g, 91 mmol) dissolved in methanol (500 mL), followed by 1 hour. Heat reflux for half. After the reaction was cooled to room temperature, the solvent was distilled off under reduced pressure. Methylene chloride (CH <sub>2</sub> Cl <sub>2</sub> , 500 mL) was added to the residue, which was then cooled to O ° C. and bromine (Br <sub>2</sub> , 5.2 mL. 102 mmol) dissolved in methylene chloride (CH <sub>2</sub> Cl <sub>2</sub> , 100 mL) was slowly added dropwise. It was. After the addition was completed, the mixture was stirred at the same temperature for 10 minutes, and the solvent was distilled off under reduced pressure. Methanol and hexane were added little to the residue (solid) from which the solvent was completely removed, and two layers of the organic layer liquid in which the solid was completely dissolved were obtained. The hexane layer was removed and the methanol layer was concentrated under reduced pressure and then purified by column chromatography (1% / 10% MeOH / CH <sub>2</sub> Cl <sub>2</sub> ) to give 10.4 g of product (yield 53%). This was referred to the following literature, but the separation time was improved and the yield was improved through the post-reaction treatment (Ref .: Baxter, EW, Reitz, ABJ Org. Chem. (1994), vol 59, p. 3175).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (D<sub>2</sub>O) δ 1.30 (s, 3H), 1.44 (s, 3H), 4.42 (d, 1H, J=3 Hz), 4.59 (d, 1H, J=3.2 Hz), 4.68 (m, 1H), 4.94 (d, 1H, J=3.3 Hz), 6.06 (d, 1H, J=3.5 Hz).</span> <sup>1</sup> H NMR (D <sub>2</sub> O) δ 1.30 (s, 3H), 1.44 (s, 3H), 4.42 (d, 1H, J = 3 Hz), 4.59 (d, 1H, J = 3.2 Hz), 4.68 (m , 1H), 4.94 (d, 1H, J = 3.3 Hz), 6.06 (d, 1H, J = 3.5 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 5-케토-D-글루코즈의 제조</span>(Step 2) Preparation of 5-keto-D-glucose</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">도웩스 50WX 8-200 수지(69.83 g)를 상기 (단계1)의 표제 화합물(13.65 g, 62.55 mmol)의 증류수(200 mL) 용액에 가하고, 이를 상온에서 36시간동안 교반시켰다.  반응물 속의 수지를 여과제거하고 여액을 동결 건조시켜 10.3 g(수율 92 %)의 생성물을 얻었다.</span>Dows 50WX 8-200 resin (69.83 g) was added to a solution of the title compound (13.65 g, 62.55 mmol) in distilled water (200 mL) of (step 1), which was stirred for 36 hours at room temperature. The resin in the reaction was filtered off and the filtrate was lyophilized to give 10.3 g (92% yield) of product.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (D<sub>2</sub>O) δ 3.12 (t, 1H, J=8.8 Hz), 3.40 (brt, 2H, J=9.9 Hz), 3.51 (d, 1H, J=11.8 Hz), 3.57 (t, 1H, J=10.1 Hz), 4.83 (d, 1H, J=8.2 Hz)</span> <sup>1</sup> H NMR (D <sub>2</sub> O) δ 3.12 (t, 1H, J = 8.8 Hz), 3.40 (brt, 2H, J = 9.9 Hz), 3.51 (d, 1H, J = 11.8 Hz), 3.57 (t, 1H , J = 10.1 Hz), 4.83 (d, 1H, J = 8.2 Hz)</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) (3S,4R,5R,6R)-2-(하이드록시메틸)-N-벤즈하이드릴피페리딘-3,4,5-트리올의 제조</span>(Step 3) Preparation of (3S, 4R, 5R, 6R) -2- (hydroxymethyl) -N-benzhydrylpiperidine-3,4,5-triol</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 (단계 2)에서 제조된 표제화합물(8.24 g, 46.26 mmol)을 메탄올(200 mL)에 녹인 후, 이를 영하 78 ℃에서 아미노다이페닐메탄(6.76 g, 36.89 mmol)과 초산(2.22 g, 36.97 mmol)의 메탄올(300 mL) 용액에  가하였다.  여기에 소듐시아노하이드라이드(NaCNBH<sub>3</sub>, 5.82 g, 92.62 mmol)를 첨가하여 영하 78 ℃에서 두 시간동안 교반한 후, 상온으로 천천히 반응액의 온도를 올렸다.  반응액을 상온에서 이틀간 교반시킨 후 이를 감압증류하여 농축시키고, 여기에 포화 소듐카보네이트(Na<sub>2</sub>CO<sub>3</sub>)용액을 가하였다.  여기에 메틸렌클로라이드를 가하여 추출하고 유기층을 분리한 후, 황산나트륨(Na<sub>2</sub>SO<sub>4</sub>)으로 물을 제거하고 감압농축시켰다.  잔사를 컬럼 크로마토그래피 (CH<sub>2</sub>Cl<sub>2</sub>100% - 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>)로 정제하였다(5.9 g, 수율 39%).</span>The title compound (8.24 g, 46.26 mmol) prepared in (Step 2) was dissolved in methanol (200 mL), which was then diluted to aminodiphenylmethane (6.76 g, 36.89 mmol) and acetic acid (2.22 g, 36.97) at -78 ° C. mmol) in methanol (300 mL) solution. Sodium cyanohydride (NaCNBH <sub>3</sub> , 5.82 g, 92.62 mmol) was added thereto, stirred at −78 ° C. for two hours, and then slowly raised to room temperature. After the reaction solution was stirred at room temperature for two days, it was concentrated by distillation under reduced pressure, and a saturated sodium carbonate (Na <sub>2</sub> CO <sub>3</sub> ) solution was added thereto. Methylene chloride was added thereto, followed by extraction. The organic layer was separated, and then water was removed with sodium sulfate (Na <sub>2</sub> SO <sub>4</sub> ) and concentrated under reduced pressure. The residue was purified by column chromatography (CH <sub>2</sub> Cl <sub>2</sub> 100%-10% MeOH / CH <sub>2</sub> Cl <sub>2</sub> ) (5.9 g, yield 39%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (D<sub>2</sub>O) δ 1.85 (brt, 1H, J=10.5 Hz), 2.38 (brd, 1H, J=9.2 Hz), 2.93 (dd, 1H, J=4.3, 11.3 Hz), 3.06 (brt, 1H, J=8.1 Hz), 3.51 (brm, 2H), 3.67 (brt, 1H, J=5.5 Hz), 3.83 (brd, 1H, J=4.5 Hz), 3.95 (brd, 1H, J=10.1 Hz), 3.99 (brd, 1H, J=4.8 Hz), 4.11 (brs, 1H), 4.22 (brd, 1H, J=11.5 Hz), 5.71 (s, 1H), 7.10 - 7.24 (m, 10H).</span> <sup>1</sup> H NMR (D <sub>2</sub> O) δ 1.85 (brt, 1H, J = 10.5 Hz), 2.38 (brd, 1H, J = 9.2 Hz), 2.93 (dd, 1H, J = 4.3, 11.3 Hz), 3.06 (brt , 1H, J = 8.1 Hz), 3.51 (brm, 2H), 3.67 (brt, 1H, J = 5.5 Hz), 3.83 (brd, 1H, J = 4.5 Hz), 3.95 (brd, 1H, J = 10.1 Hz ), 3.99 (brd, 1H, J = 4.8 Hz), 4.11 (brs, 1H), 4.22 (brd, 1H, J = 11.5 Hz), 5.71 (s, 1H), 7.10-7.24 (m, 10H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4) (3S,4R,5R,6R)-N-벤즈하이드릴-3,4-다이하이드록실-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 4) Preparation of (3S, 4R, 5R, 6R) -N-benzhydryl-3,4-dihydroxyl-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">증류 직후의 메틸렌클로라이드(100 mL)에 상기 (단계 3)의 표제화합물(3.5 g, 1.63 mmol)을 녹이고 α,p-다이메톡시스티렌(1.86 mL)과 피리디니움 p-톨루엔설포네이트(0.92 g, 3.67 mmol)를 가하였다.  반응액을 상온에서 16시간동안 교반한 후, 포화 소듐카보네이트 용액 및 메틸렌클로라이드를 가하여 추출하고 유기층을 분리한 다음 건조, 감압농축시켰다.  잔사를 컬럼 크로마토그래피(10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>)로 정제하였다(다이아스테레오머 A:B = 1.7:1,  3.7g, 수율 76%).</span>The title compound (3.5 g, 1.63 mmol) of (step 3) was dissolved in methylene chloride (100 mL) immediately after distillation, and α, p-dimethoxystyrene (1.86 mL) and pyridinium p-toluenesulfonate (0.92) g, 3.67 mmol) was added. After the reaction solution was stirred at room temperature for 16 hours, saturated sodium carbonate solution and methylene chloride were added thereto, the organic layer was separated, dried and concentrated under reduced pressure. The residue was purified by column chromatography (10% MeOH / CH <sub>2</sub> Cl <sub>2</sub> ) (diastereomer A: B = 1.7: 1, 3.7 g, yield 76%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) 다이아스테레오머(diastereomer) A δ 1.79 (s, 3H), 1.92 (ddd, 1H, J=4.8, 10.7, 10.7 Hz), 2.46 (m, 1H), 2.58 (m, 1H), 3.07 (dd, 1H, J=4.8, 11.3 Hz), 3.37 (dd, 1H, J=8.8, 9 Hz), 3.62 (dd, 1H, J=10.2, 10.5 Hz), 3.81 (s, 3H, OMe), 3.90 (dd, 1H, J=9.2, 9.2 Hz), 4.50 (dd, 1H, J=4.7, 10.8 Hz), 5.04 (s, 1H), 6.89 (d, 2H, J=8.6 Hz), 7.15 - 7.38 (m, 10H), 7.50 (d, 2H, J=8.6 Hz); 다이아스테레오머 B δ 1.54 (s, 3H), 1.92 (ddd, 1H, J=4.8, 10.7, 10.7 Hz), 2.46 (m, 1H), 2.89 (m, 1H), 2.99 (dd, 1H, J=4.8, 11.3 Hz), 3.37 (dd, 1H, J=8.8, 9 Hz), 3.51 (dd, 1H, J=9, 9 Hz), 3.85 (s, 3H, OMe), 3.99 (dd, 1H, J=10.5, 10.5 Hz), 4.44 (dd, 1H, J=3.9, 10.2 Hz), 4.95 (s, 1H), 6.97 (d, 2H, J=8.5 Hz), 7.15 - 7.38 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) Diastereomer A δ 1.79 (s, 3H), 1.92 (ddd, 1H, J = 4.8, 10.7, 10.7 Hz), 2.46 (m, 1H), 2.58 (m, 1H ), 3.07 (dd, 1H, J = 4.8, 11.3 Hz), 3.37 (dd, 1H, J = 8.8, 9 Hz), 3.62 (dd, 1H, J = 10.2, 10.5 Hz), 3.81 (s, 3H, OMe), 3.90 (dd, 1H, J = 9.2, 9.2 Hz), 4.50 (dd, 1H, J = 4.7, 10.8 Hz), 5.04 (s, 1H), 6.89 (d, 2H, J = 8.6 Hz), 7.15-7.38 (m, 10H), 7.50 (d, 2H, J = 8.6 Hz); Diastereomer B δ 1.54 (s, 3H), 1.92 (ddd, 1H, J = 4.8, 10.7, 10.7 Hz), 2.46 (m, 1H), 2.89 (m, 1H), 2.99 (dd, 1H, J = 4.8, 11.3 Hz), 3.37 (dd, 1H, J = 8.8, 9 Hz), 3.51 (dd, 1H, J = 9, 9 Hz), 3.85 (s, 3H, OMe), 3.99 (dd, 1H, J = 10.5, 10.5 Hz), 4.44 (dd, 1H, J = 3.9, 10.2 Hz), 4.95 (s, 1H), 6.97 (d, 2H, J = 8.5 Hz), 7.15-7.38 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5) (3S,4R,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-하이드록실-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘</span>(Step 5) (3S, 4R, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-4-hydroxyl-5,6-O-[(4-methoxyphenyl) ethyl Liden] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">피리딘(8.81 g, 9.01 mmol)과 실버나이트레이트(AgNO<sub>3</sub>, 5.68 g, 33.42 mmol)를 테트라하이드로퓨란 (300 mL)에 녹인 상기 (단계 4)의 표제화합물을 하나의 다이아스테레오머(13.18 g, 28.55 mmol)(혹은 다이아스테레오머 혼합물)에 가하고, 이 반응액을 상온에서 20분간 교반하였다.  여기에 3차 부틸다이메틸실릴클로라이드 (TBDMSiCl, 5.68 g, 37.73 mmol)를 가하여 상온에서 12시간 동안 반응시켰다.  반응액을 여과한 후 감압증류하여 농축시켰다.  포화 소듐바이카보네이트용액 및 메틸렌클로라이드를 가하여 추출하고 유기층을 분리한 후 건조, 감압농축시켰다.  잔사를 컬럼 크로마토그래피(10 % 에틸아세테이트/헥산)로 정제하였다(12 g, 수율 73 %).</span>The title compound of the above (Step 4) obtained by dissolving pyridine (8.81 g, 9.01 mmol) and silver nitrate (AgNO <sub>3</sub> , 5.68 g, 33.42 mmol) in tetrahydrofuran (300 mL) was treated with one diastereomer (13.18 g, 28.55 mmol) (or a diastereomer mixture), and the reaction solution was stirred at room temperature for 20 minutes. Tertiary butyldimethylsilyl chloride (TBDMSiCl, 5.68 g, 37.73 mmol) was added thereto and reacted at room temperature for 12 hours. The reaction solution was filtered and concentrated by distillation under reduced pressure. Saturated sodium bicarbonate solution and methylene chloride were added and extracted. The organic layer was separated, dried and concentrated under reduced pressure. The residue was purified by column chromatography (10% ethyl acetate / hexanes) (12 g, yield 73%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) 다이아스테레오머 A δ 0.00 (s, 3H, Si-Me), 0.07 (s, 3H, Si-Me), 0.84 (s, 9H, Si-tBu), 1.78 (s, 3H, Me), 1.92 (dd, 1H, J=11, 11 Hz), 2.45 (ddd, 1H, J=4.4, 9.7, 9.7 Hz), 2.61 (brs, 1H, OH), 2.90 (dd, 1H, J=4.7, 9.7 Hz), 3.39 (dd, 1H, J=8.7, 8.7 Hz), 3.77 (m, 1H), 3.81 (s, 3H, OMe), 3.98 (dd, 1H, J=10.2, 10.6 Hz), 4.44 (dd, 1H, J=4.5, 10.5 Hz), 5.03 (s, 1H), 6.88 (d, 2H, J=8.8 Hz), 7.14 (d, 2H, J=8 Hz), 7.30 - 7.47 (m, 8H), 7.49 (s, 2H, J=8.8 Hz); 다이아스테레오머 B δ -0.07 (s, 3H, Si-Me), 0.03 (s, 3H, Si-Me), 0.82 (s, 9H, Si-tBu), 1.54 (s, 3H, Me), 1.90 (dd, 1H, J=10.5, 10.5 Hz), 2.48 (ddd, 1H, J=4, 10.4, 10.4 Hz), 2.82 (dd, 1H, J=4.8, 11.4 Hz), 3.38 (dd, 1H, J=9, 9 Hz), 3.52 (dd, 1H, J=8.9, 9.4 Hz), 3.55 (m, 1H), 3.62 (dd, 1H, J=10.5, 10.5 Hz), 3.86 (s, 3H, OMe), 4.39 (dd, 1H, J=4, 9.6 Hz), 4.94 (s, 1H), 6.98 (d, 2H, J=8.8 Hz), 7.15 - 7.47 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) Diastereomer A δ 0.00 (s, 3H, Si-Me), 0.07 (s, 3H, Si-Me), 0.84 (s, 9H, Si-tBu), 1.78 (s, 3H Me), 1.92 (dd, 1H, J = 11, 11 Hz), 2.45 (ddd, 1H, J = 4.4, 9.7, 9.7 Hz), 2.61 (brs, 1H, OH), 2.90 (dd, 1H, J = 4.7, 9.7 Hz), 3.39 (dd, 1H, J = 8.7, 8.7 Hz), 3.77 (m, 1H), 3.81 (s, 3H, OMe), 3.98 (dd, 1H, J = 10.2, 10.6 Hz) , 4.44 (dd, 1H, J = 4.5, 10.5 Hz), 5.03 (s, 1H), 6.88 (d, 2H, J = 8.8 Hz), 7.14 (d, 2H, J = 8 Hz), 7.30-7.47 ( m, 8H), 7.49 (s, 2H, J = 8.8 Hz); Diastereomer B δ -0.07 (s, 3H, Si-Me), 0.03 (s, 3H, Si-Me), 0.82 (s, 9H, Si-tBu), 1.54 (s, 3H, Me), 1.90 ( dd, 1H, J = 10.5, 10.5 Hz), 2.48 (ddd, 1H, J = 4, 10.4, 10.4 Hz), 2.82 (dd, 1H, J = 4.8, 11.4 Hz), 3.38 (dd, 1H, J = 9, 9 Hz), 3.52 (dd, 1H, J = 8.9, 9.4 Hz), 3.55 (m, 1H), 3.62 (dd, 1H, J = 10.5, 10.5 Hz), 3.86 (s, 3H, OMe), 4.39 (dd, 1H, J = 4, 9.6 Hz), 4.94 (s, 1H), 6.98 (d, 2H, J = 8.8 Hz), 7.15-7.47 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 6) (3S,4R,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 6) (3S, 4R, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-4-methoxy-5,6-O-[(4-methoxyphenyl) ethyl Liden] Piperidine Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">아이오도메탄(2.74 g, 19.3 mmol, 1.2 mL)과 소듐 하이드라이드(0.933 g, 233.25 mmol)를 무수 테트라하이드로퓨란(100 mL)에 녹인 상기 (단계 5)의 표제화합물을 다이아스테레오머 A (5.6 g, 9.66 mmol)에 가하고 이 반응액을 질소하 실온에서 2시간 동안 교반하였다.  여기에 소금물(brine)을 가하고 메틸렌클로라이드로 추출한 다음, 유기층을 물로 씻고 건조, 감압농축하였다.  잔사를 컬럼 크로마토그래피 (10 % 에틸아세테이트/헥산)로 정제하였다(5.38 g, 수율 94 %).</span>The title compound of (step 5) was dissolved in iodomethane (2.74 g, 19.3 mmol, 1.2 mL) and sodium hydride (0.933 g, 233.25 mmol) in anhydrous tetrahydrofuran (100 mL). g, 9.66 mmol) and the reaction solution was stirred at room temperature under nitrogen for 2 hours. Brine was added thereto, extracted with methylene chloride, and then the organic layer was washed with water, dried and concentrated under reduced pressure. The residue was purified by column chromatography (10% ethyl acetate / hexanes) (5.38 g, yield 94%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) 다이아스테레오머 A δ 0.00 (s, 3H, Si-Me), 0.06 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.75 (s, 3H, Me), 1.91 (dd, 1H, J=10.8, 10.8 Hz), 2.42 (ddd, 1H, J=3.6, 9.3, 9.3 Hz), 2.87 (dd, 1H, J=5, 11.4 Hz), 3.00 (dd, 1H, J=8.7, 8.7 Hz), 3.63 (s, 3H, OMe), 3.57 (m, 1H), 3.81 (s, 3H, OMe), 3.93 (dd, 1H, J=9, 9 Hz), 3.96 (dd, 1H, J=10, 10 Hz), 4.45 (dd, 1H, J=4.6, 10.8 Hz), 5.02 (s, 1H), 6.89 (d, 2H, J=8.9 Hz), 7.14 - 7.47 (m, 10H), 7.48 (d, 2H, J=8.8 Hz); 다이아스테레오머 B δ -0.07 (s, 3H, Si-Me), 0.05 (s, 3H, Si-Me), 0.82 (s, 9H, Si-tBu), 1.50 (s, 3H, Me), 1.83 (dd, 1H, J=11, 11 Hz), 2.43 (m, 1H, J=3.6, 9.3, 9.3 Hz), 2.79 (dd, 1H, J=5, 11.3 Hz), 2.97 (dd, 1H, J=8.7, 8.7 Hz), 3.52 (dd, 1H, J=9, 9 Hz), 3.53 (dd, 1H, J=10, 10 Hz), 3.67 (s, 3H, OMe), 3.77 (m, 1H), 3.86 (s, 3H, OMe),  4.38 (dd, 1H, J=4, 10.5 Hz), 4.91 (s, 1H), 6.98 (d, 2H, J=8.9 Hz), 7.14 - 7.46 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) Diastereomer A δ 0.00 (s, 3H, Si-Me), 0.06 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.75 (s, 3H , Me), 1.91 (dd, 1H, J = 10.8, 10.8 Hz), 2.42 (ddd, 1H, J = 3.6, 9.3, 9.3 Hz), 2.87 (dd, 1H, J = 5, 11.4 Hz), 3.00 ( dd, 1H, J = 8.7, 8.7 Hz), 3.63 (s, 3H, OMe), 3.57 (m, 1H), 3.81 (s, 3H, OMe), 3.93 (dd, 1H, J = 9, 9 Hz) , 3.96 (dd, 1H, J = 10, 10 Hz), 4.45 (dd, 1H, J = 4.6, 10.8 Hz), 5.02 (s, 1H), 6.89 (d, 2H, J = 8.9 Hz), 7.14- 7.47 (m, 10 H), 7.48 (d, 2H, J = 8.8 Hz); Diastereomer B δ -0.07 (s, 3H, Si-Me), 0.05 (s, 3H, Si-Me), 0.82 (s, 9H, Si-tBu), 1.50 (s, 3H, Me), 1.83 ( dd, 1H, J = 11, 11 Hz), 2.43 (m, 1H, J = 3.6, 9.3, 9.3 Hz), 2.79 (dd, 1H, J = 5, 11.3 Hz), 2.97 (dd, 1H, J = 8.7, 8.7 Hz), 3.52 (dd, 1H, J = 9, 9 Hz), 3.53 (dd, 1H, J = 10, 10 Hz), 3.67 (s, 3H, OMe), 3.77 (m, 1H), 3.86 (s, 3H, OMe), 4.38 (dd, 1H, J = 4, 10.5 Hz), 4.91 (s, 1H), 6.98 (d, 2H, J = 8.9 Hz), 7.14-7.46 (m, 12H) .</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 7)  (3S,4R,5R,6R)-N-벤즈하이드릴-3-하이드록실-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 7) (3S, 4R, 5R, 6R) -N-Benzhydryl-3-hydroxy-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">테트라부틸암모늄 플로라이드(테트라하이드로퓨란에 녹아있는 1 M 용액, 25 mL, 25 mmol)을 테트라하이드로퓨란 (125 mL)에 녹인 상기 (단계 6)의 표제화합물 (4.94 g, 8.38 mmol)에 가하고 실온에서 2.5시간 동안 교반시킨 후 이를 감압증류하였다.  잔사를 컬럼 크로마토그래피(10 - 40 % 에틸아세테이트/헥산)로 정제하였다(3.44 g,수율 86 %).</span>Tetrabutylammonium fluoride (1 M solution in tetrahydrofuran, 25 mL, 25 mmol) was added to the title compound (4.94 g, 8.38 mmol) in (step 6) dissolved in tetrahydrofuran (125 mL) and allowed to stand at room temperature. After stirring for 2.5 hours at distilled under reduced pressure. The residue was purified by column chromatography (10-40% ethyl acetate / hexanes) (3.44 g, yield 86%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) 다이아스테레오머 A δ 1.77 (s, 3H, Me), 1.93 (dd, 1H, J=10.8, 10.8 Hz), 2.47 (ddd, 1H, J=4.7, 10.1, 10.1 Hz), 3.02 (dd, 1H, J=9, 9 Hz), 3.08 (dd, 1H, J=5, 11.2 Hz), 3.71 (s, 3H, OMe), 3.82 (s, 3H, OMe), 4.00 (dd, 1H, J=10.5, 10.5 Hz), 4.03 (dd, 1H, J=9, 9 Hz), 4.51 (dd, 1H, J=4.5, 10.8 Hz), 5.05 (s, 1H), 6.89 (d, 2H, J=8.8 Hz), 7.14 - 7.47 (m, 10H), 7.47 (d, 2H, J=8.8 Hz); 다이아스테레오머 B δ 1.58 (s, 3H, Me), 1.91 (dd, 1H, J=10.5, 10.5 Hz), 2.48 (ddd, 1H, J=4, 10.3, 10.3 Hz), 3.02 - 2.98 (m, 2H), 3.70 - 3.57 (m, 3H), 3.82 (s, 3H, OMe), 3.86 (s, 3H, OMe), 4.45 (dd, 1H, J=4, 10.5 Hz), 4.95 (s, 1H), 6.98 (d, 2H, J=8.8 Hz), 7.16 - 7.39 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) Diastereomer A δ 1.77 (s, 3H, Me), 1.93 (dd, 1H, J = 10.8, 10.8 Hz), 2.47 (ddd, 1H, J = 4.7, 10.1, 10.1 Hz) , 3.02 (dd, 1H, J = 9, 9 Hz), 3.08 (dd, 1H, J = 5, 11.2 Hz), 3.71 (s, 3H, OMe), 3.82 (s, 3H, OMe), 4.00 (dd , 1H, J = 10.5, 10.5 Hz), 4.03 (dd, 1H, J = 9, 9 Hz), 4.51 (dd, 1H, J = 4.5, 10.8 Hz), 5.05 (s, 1H), 6.89 (d, 2H, J = 8.8 Hz), 7.14-7.47 (m, 10H), 7.47 (d, 2H, J = 8.8 Hz); Diastereomer B δ 1.58 (s, 3H, Me), 1.91 (dd, 1H, J = 10.5, 10.5 Hz), 2.48 (ddd, 1H, J = 4, 10.3, 10.3 Hz), 3.02-2.98 (m, 2H), 3.70-3.57 (m, 3H), 3.82 (s, 3H, OMe), 3.86 (s, 3H, OMe), 4.45 (dd, 1H, J = 4, 10.5 Hz), 4.95 (s, 1H) , 6.98 (d, 2H, J = 8.8 Hz), 7.16-7.39 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 8) (3S,4R,5R,6R)-N-벤즈하이드릴-3-메탄설포닐-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 8) (3S, 4R, 5R, 6R) -N-Benzhydryl-3-methanesulfonyl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperi Dean's Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">메탄설포닐 클로라이드(2.15 g, 18.81 mmol)와 트리에틸아민(1.46 mL)을 증류한 메틸렌클로라이드(100 mL)에 녹인 상기 (단계 7)의 표제화합물(2.98 g, 6.27 mmol)에 가하고 1시간동안 교반하였다.  여기에 소듐 바이카보네이트용액 및 메틸렌클로라이드를 가하여 추출하고 유기층을 분리한 다음, 건조시키고 감압농축하였다.  잔사를 컬럼 크로마토그래피(20 % - 50 % 에틸아세테이트/헥산)로 정제하였다 (3.44 g, 수율 99 %).</span>Methanesulfonyl chloride (2.15 g, 18.81 mmol) and triethylamine (1.46 mL) were dissolved in distilled methylene chloride (100 mL) and added to the title compound (2.98 g, 6.27 mmol) in (7) above for 1 hour. Stirred. Sodium bicarbonate solution and methylene chloride were added thereto, extracted and the organic layer was separated, dried and concentrated under reduced pressure. The residue was purified by column chromatography (20% -50% ethyl acetate / hexanes) (3.44 g, yield 99%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) 다이아스테레오머 A δ 1.77 (s, 3H, Me), 2.07 (dd, 1H, J=11, 11 Hz), 2.44 (ddd, 1H, J=4.7, 9.9, 9.9 Hz), 3.09 (s, 3H, OMs), 3.21 (m, 1H), 3.22 (dd, 1H, J=9, 9 Hz), 3.67 (s, 3H, OMe), 3.82 (s, 3H, OMe), 3.99 (dd, 1H, J=10.6, 10.6 Hz), 4.03 (dd, 1H, J=9.1, 9.1 Hz), 4.52 (dd, 1H, J=4.5, 10.9 Hz), 4.59 (ddd, 1H, J=5.2, 10.5, 10.5 Hz), 5.07 (s, 1H), 6.89 (d, 2H, J=8.9 Hz), 7.15 - 7.38 (m, 10H), 7.46 (d, 2H, J=8.9 Hz); 다이아스테레오머 B δ 1.53 (s, 3H, Me), 2.04 (dd, 1H, J=10.9, 10.9 Hz), 2.45 (ddd, 1H, J=4, 10.2, 10.2 Hz), 3.07 (s, 3H, OMs), 3.19 (dd, 1H, J=9.2, 9.2 Hz), 3.60 (dd, 1H, J=4, 10.4 Hz), 3.62 (dd, 1H, J=9.1, 9.1 Hz), 3.73 (s, 3H, OMe), 3.87 (s, 3H, OMe), 4.40 (dd, 1H, J=5.2, 9.3 Hz), 4. 43 (ddd, 1H, J=4.2, 10.8, 10.8 Hz), 4.96 (s, 1H), 6.99 (d, 2H, J=8.8 Hz), 7.14 - 7.39 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) Diastereomer A δ 1.77 (s, 3H, Me), 2.07 (dd, 1H, J = 11, 11 Hz), 2.44 (ddd, 1H, J = 4.7, 9.9, 9.9 Hz) , 3.09 (s, 3H, OMs), 3.21 (m, 1H), 3.22 (dd, 1H, J = 9, 9 Hz), 3.67 (s, 3H, OMe), 3.82 (s, 3H, OMe), 3.99 (dd, 1H, J = 10.6, 10.6 Hz), 4.03 (dd, 1H, J = 9.1, 9.1 Hz), 4.52 (dd, 1H, J = 4.5, 10.9 Hz), 4.59 (ddd, 1H, J = 5.2 , 10.5, 10.5 Hz), 5.07 (s, 1H), 6.89 (d, 2H, J = 8.9 Hz), 7.15-7.38 (m, 10H), 7.46 (d, 2H, J = 8.9 Hz); Diastereomer B δ 1.53 (s, 3H, Me), 2.04 (dd, 1H, J = 10.9, 10.9 Hz), 2.45 (ddd, 1H, J = 4, 10.2, 10.2 Hz), 3.07 (s, 3H, OMs), 3.19 (dd, 1H, J = 9.2, 9.2 Hz), 3.60 (dd, 1H, J = 4, 10.4 Hz), 3.62 (dd, 1H, J = 9.1, 9.1 Hz), 3.73 (s, 3H , OMe), 3.87 (s, 3H, OMe), 4.40 (dd, 1H, J = 5.2, 9.3 Hz), 4. 43 (ddd, 1H, J = 4.2, 10.8, 10.8 Hz), 4.96 (s, 1H ), 6.99 (d, 2H, J = 8.8 Hz), 7.14-7.39 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 9)  {(3R,4R,5R,6R)-N-벤즈하이드릴-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 9) {(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidin-3-yl } Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">아데닌(0.82 g, 6.07 mmol), 소듐 하이드라이드(304 mg, 7.6 mmol), 18-크라운-6(319 mg, 1.21 mmol)을 무수 N,N-다이메틸포름아마이드(75 mL)에 넣고 80 ℃에서 1시간 동안 교반하였다.  이 용액에 무수 N,N-다이메틸포름아마이드(25 mL)에 녹인 상기 (단계 8)의 표제화합물 다이아스테레오머 B(1.67 g, 3.02 mmol) (혹은 다이아스테레오머 A나 A와 B의 혼합물)를 가하고 100 ℃로 가열한 상태에서 16시간 동안 교반하였다.  반응물을 냉각하고 감압증발시킨 후, 에틸아세테이트(400 mL)에 녹이고 포화 소듐 바이카보네이트 용액(25 mL)과 물(50 mL)로 씻어 내었다.  유기층을 건조시키고 감압농축한 후, 잔사를 컬럼 크로마토그래피 (5 % 메탄올/메틸렌클로라이드)로 정제하였다(900 mg, 50 %).</span>Adenine (0.82 g, 6.07 mmol), sodium hydride (304 mg, 7.6 mmol) and 18-crown-6 (319 mg, 1.21 mmol) were placed in anhydrous N, N-dimethylformamide (75 mL) at 80 ° C. Stirred for 1 h. The title compound diastereomer B (1.67 g, 3.02 mmol) (or a mixture of diastereomer A or A and B) of the above (step 8) dissolved in anhydrous N, N-dimethylformamide (25 mL) in this solution. Was added and stirred for 16 hours while heating to 100 ℃. The reaction was cooled, evaporated under reduced pressure, dissolved in ethyl acetate (400 mL) and washed with saturated sodium bicarbonate solution (25 mL) and water (50 mL). The organic layer was dried and concentrated under reduced pressure, and the residue was purified by column chromatography (5% methanol / methylene chloride) (900 mg, 50%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.55 (s, 3H), 2.74 (m, 2H), 2.80 (dd, 1H, J=11.3, 11.5 Hz), 2.98 (m, 1H), 3.37 (s, 3H, OMe), 3.69 (dd, 1H, J=10.4, 10.4 Hz), 3.92 (m, 2H), 3.93 (s, 3H, OMe), 4.47, (ddd, 1H, J=4, 10.6, 10.6 Hz), 4.48 (m, 1H), 5.02 (s, 1H), 6.99 (d, 2H, J=8.8 Hz)), 7.13 - 7.42 (m, 12H), 7.71 (s, 1H), 8.32 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.55 (s, 3H), 2.74 (m, 2H), 2.80 (dd, 1H, J = 11.3, 11.5 Hz), 2.98 (m, 1H), 3.37 (s, 3H, OMe ), 3.69 (dd, 1H, J = 10.4, 10.4 Hz), 3.92 (m, 2H), 3.93 (s, 3H, OMe), 4.47, (ddd, 1H, J = 4, 10.6, 10.6 Hz), 4.48 (m, 1H), 5.02 (s, 1H), 6.99 (d, 2H, J = 8.8 Hz)), 7.13-7.42 (m, 12H), 7.71 (s, 1H), 8.32 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 10) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 10) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">피리딘(100 mL)에  상기 (단계 9)의 표제화합물(1.65 g, 2.78 mmol)을 녹이고 0 ℃로 냉각하였다.  벤조일 클로라이드(1.17 g, 8.34 mmol)를 30분 동안 떨어뜨리고 실온에서 2시간동안 교반하였다.  이를 다시 0 ℃로 냉각시키고 물(2.7 mL)을 가하여 5분간 교반하였다.  암모니아수(5.56 mL)를 실온에서 가하고 15분간 교반 후에 물(500 mL)을 첨가하고 메틸렌클로라이드(200 mL)로 추출하였다.  유기층을 건조시키고 감압농축하였다.  잔사를 컬럼 크로마토그래피 (10 % 메탄올/메틸렌클로라이드)로 정제하였다(1.27 g, 66 %).</span>The title compound (1.65 g, 2.78 mmol) of (step 9) was dissolved in pyridine (100 mL) and cooled to 0 ° C. Benzoyl chloride (1.17 g, 8.34 mmol) was dropped for 30 minutes and stirred at room temperature for 2 hours. It was again cooled to 0 ° C. and water (2.7 mL) was added and stirred for 5 minutes. Ammonia water (5.56 mL) was added at room temperature, after stirring for 15 minutes, water (500 mL) was added and extracted with methylene chloride (200 mL). The organic layer was dried and concentrated under reduced pressure. The residue was purified by column chromatography (10% methanol / methylene chloride) (1.27 g, 66%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.55 (s, 3H), 2.75 (ddd, 1H, J=3, 9.1, 9.1 Hz), 2.82 (dd, 1H, J=11.4, 11.4 Hz), 3.05 (dd, J=4.5, 11.3 Hz), 3.39 (s, 3H, OMe), 3.71 (dd, 1H, J=10.5, 10.5 Hz), 3.82 (dd, 1H, J=9, 9 Hz), 3.88 (s, 3H, OMe), 3.96 (dd, 1H, J=9.1, 10 Hz), 4.49 (m, 2H), 5.03 (s, 1H), 7.00 (d, 2H, J=8.7 Hz), 7.13 - 7.41 (m, 12H), 7.52 (t, 2H, J=6.7 Hz), 7.60 (d, 1H, J=7.1 Hz), 7.91 (s, 1H), 8.02 (d, 2H, J=7.3 Hz), 8.75 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.55 (s, 3H), 2.75 (ddd, 1H, J = 3, 9.1, 9.1 Hz), 2.82 (dd, 1H, J = 11.4, 11.4 Hz), 3.05 (dd, J = 4.5, 11.3 Hz), 3.39 (s, 3H, OMe), 3.71 (dd, 1H, J = 10.5, 10.5 Hz), 3.82 (dd, 1H, J = 9, 9 Hz), 3.88 (s, 3H, OMe), 3.96 (dd, 1H, J = 9.1, 10 Hz), 4.49 (m, 2H), 5.03 (s, 1H), 7.00 (d, 2H, J = 8.7 Hz), 7.13-7.41 (m, 12H ), 7.52 (t, 2H, J = 6.7 Hz), 7.60 (d, 1H, J = 7.1 Hz), 7.91 (s, 1H), 8.02 (d, 2H, J = 7.3 Hz), 8.75 (s, 1H ).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 11) 6-N-벤조일-{(3R,4R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-하이드록시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 11) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-hydroxymethyl-4-methoxypiperidin-3-yl} adenine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">80 % 아세트산(10 g)에 상기 (단계 10)의 표제화합물(1.22 g, 1.75 mmol)을 녹이고 45 - 50 ℃에서 3시간 동안 교반하였다.  메틸렌클로라이드(100 ml)와 포화 소듐 바이카보네이트 용액(20 mL)을 가하고 유기층을 분리한 후, 건조시키고 감압농축하였다.  잔사를 컬럼 크로마토그래피(5 % 메탄올/메틸렌클로라이드)로 정제하였다(543 mg, 55 %).</span>The title compound (1.22 g, 1.75 mmol) of (step 10) was dissolved in 80% acetic acid (10 g) and stirred at 45-50 ° C for 3 hours. Methylene chloride (100 ml) and saturated sodium bicarbonate solution (20 mL) were added, the organic layer was separated, dried and concentrated under reduced pressure. The residue was purified by column chromatography (5% methanol / methylene chloride) (543 mg, 55%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.74 (m, 1H), 2.97 (dd, 1H, J=11, 11 Hz), 3.10 (s, 3H, OMe), 3.19 (dd, 1H, J=4, 12 Hz) 3.78 (dd, 1H, J=8.5, 9.7 Hz), 4.02 (dd, 1H, J=8.5, 8.5 Hz), 4.17 (dd, 1H, J=2, 12 Hz), 4.27 (dd, 1H, J=3.5, 12 Hz), 4.61 (ddd, 1H, J=4.2, 10.5, 10.5 Hz), 5.55 (s, 1H), 7.19 - 7.53 (m, 10H), 7.55 (t, 2H, J=7 Hz), 7.61 (d, 1H, J=7 Hz), 8.02 (s, 1H), 8.04 (d, 2H, J=7.2 Hz), 8.76 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.74 (m, 1H), 2.97 (dd, 1H, J = 11, 11 Hz), 3.10 (s, 3H, OMe), 3.19 (dd, 1H, J = 4, 12 Hz ) 3.78 (dd, 1H, J = 8.5, 9.7 Hz), 4.02 (dd, 1H, J = 8.5, 8.5 Hz), 4.17 (dd, 1H, J = 2, 12 Hz), 4.27 (dd, 1H, J = 3.5, 12 Hz), 4.61 (ddd, 1H, J = 4.2, 10.5, 10.5 Hz), 5.55 (s, 1H), 7.19-7.53 (m, 10H), 7.55 (t, 2H, J = 7 Hz) , 7.61 (d, 1H, J = 7 Hz), 8.02 (s, 1H), 8.04 (d, 2H, J = 7.2 Hz), 8.76 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 12) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 12) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidine-3- Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">4,4'-다이메톡시트리틸 클로라이드(0.752 g, 2.22 mmol)를 피리딘(10 mL)에 녹인 상기 (단계 11)의 표제화합물(500 mg, 0.89 mmol)에 0 ℃에서 가하고 16시간 동안 교반시킨 후 이를 감압농축하고 5 % 소듐 바이카보네이트 용액(10 mL)을 가하였다.  여기에 메틸렌클로라이드(100 mL)를 가하여 추출하고 유기층을 분리한 후, 건조시키고 감압농축하였다.  잔사를 컬럼 크로마토그래피(EtOAc:Hexane:TEA = 50:50:1)로 정제하였다(672 mg, 88 %).</span>To 4,4'-dimethoxytrityl chloride (0.752 g, 2.22 mmol) in pyridine (10 mL) was added to the title compound (500 mg, 0.89 mmol) of the above (step 11) at 0 ° C. and stirred for 16 hours. After concentration, it was concentrated under reduced pressure and 5% sodium bicarbonate solution (10 mL) was added thereto. Methylene chloride (100 mL) was added thereto, followed by extraction. The organic layer was separated, dried and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc: Hexane: TEA = 50: 50: 1) (672 mg, 88%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.68 (m, 1H), 2.78 (m, 1H), 2.97 (dd, 1H, J=11, 11 Hz), 3.09 (s, 3H, OMe), 3.12 (dd, 1H, J=4.2, 11.8 Hz) 3.65 (dd, 1H, J=3.2, 10.4 Hz), 3.793 (s, 3H, OMe), 3.796 (s, 3H, OMe), 4.21 (dd, 1H, J=8.5, 8.5 Hz), 4.63 (ddd, 1H, J=4.2, 10.3, 10.3 Hz), 5.09 (s, 1H), 6.81 (d, 2H, J=8.7 Hz), 6.82 (d, 2H, J=9 Hz), 7.18 - 7.32 (m, 16H), 7.37 (d, 2H, J=8.9 Hz), 7.38 (d, 2H, J=8.9 Hz), 7.51 (t, 2H, J=6.8 Hz), 7.59 (d, 1H, J=7.2 Hz), 8.01 (s, 1H), 8.02 (d, 2H, J=7 Hz), 8.78 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.68 (m, 1H), 2.78 (m, 1H), 2.97 (dd, 1H, J = 11, 11 Hz), 3.09 (s, 3H, OMe), 3.12 (dd, 1H , J = 4.2, 11.8 Hz) 3.65 (dd, 1H, J = 3.2, 10.4 Hz), 3.793 (s, 3H, OMe), 3.796 (s, 3H, OMe), 4.21 (dd, 1H, J = 8.5, 8.5 Hz), 4.63 (ddd, 1H, J = 4.2, 10.3, 10.3 Hz), 5.09 (s, 1H), 6.81 (d, 2H, J = 8.7 Hz), 6.82 (d, 2H, J = 9 Hz) , 7.18-7.32 (m, 16H), 7.37 (d, 2H, J = 8.9 Hz), 7.38 (d, 2H, J = 8.9 Hz), 7.51 (t, 2H, J = 6.8 Hz), 7.59 (d, 1H, J = 7.2 Hz), 8.01 (s, 1H), 8.02 (d, 2H, J = 7 Hz), 8.78 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 13) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 13) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Preparation of oxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 (단계 12)의 표제화합물(654 mg, 0.754 mmol)을 진공 펌프를 이용하여 무수 톨루엔으로 3번 증발시킨 후, 질소하에서 메틸렌클로라이드(7 mL)에 녹이고 N,N-다이이소프로필에틸아민(356 ㎕)을 가하였다.  여기에 2-시아노에틸 N,N-다이이소프로필 클로로 포스포아미다이트(356 ㎕)를 가하였다.  이 반응액을 질소하에서 5시간 동안 교반시킨후, 5 % 소듐 바이카보네이트 용액(10 mL)을 가하고 메틸렌클로라이드(100 mL)로 추출하였다.  유기층을 건조시키고 감압농축하였다.  잔사를 컬럼 크로마토그래피(EtOAc:Hexane:TEA = 50:50:1)로 정제하였다(다이아스테레오머 혼합물 465 mg, 58 %).</span>The title compound (654 mg, 0.754 mmol) of (step 12) was evaporated three times with anhydrous toluene using a vacuum pump, and then dissolved in methylene chloride (7 mL) under nitrogen, followed by N, N-diisopropylethylamine ( 356 μl) was added. To this was added 2-cyanoethyl N, N-diisopropyl chloro phosphoramidite (356 μl). The reaction solution was stirred under nitrogen for 5 hours, then 5% sodium bicarbonate solution (10 mL) was added and extracted with methylene chloride (100 mL). The organic layer was dried and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc: Hexane: TEA = 50: 50: 1) (465 mg of diastereomer mixture, 58%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.04 (d, 6H, J=6.7 Hz), 1.15 (d, 6H, J=6.5 Hz), 1.19 (d, 6H, J=6.5 Hz), 1.21 (d, 6H, J=6.7 Hz), 2.52 (t, 4H, J=6 Hz), 2.63 (d, 1H, J= 11.1 Hz), 2.73 (dd, 1H, J=2, 13 Hz), 2.84 (dd, 1H, J=4, 6 Hz), 2.92 (dd, 1H, J=3.5, 13.5 Hz), 3.27 (s, 3H, OMe), 3.33 (s, 3H, OMe), 3.36 - 3.80 (m, 11H), 3.834 (s, 6H, OMe), 3.838 (s, 6H, OMe), 3.84 (m, 2H), 4.34 (d, 2H, J=11.1 Hz), 4.40 (d, 2H, J=10.6 Hz), 4.68 (s, 1H), 4.70 (s, 1H), 4.77 (m, 2H), 6.83 (d, 8H, J=8.8 Hz), 7.12 - 7.39 (m, 30H), 7.55 (t 4H, J=7 Hz), 7.62 (d, 2H, J=7.2 Hz), 8.07 (d, 4H, J=7.3 Hz), 8.72 (s, 1H), 8.75 (s, 1H), 9.06 (s, 1H), 9.32 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.04 (d, 6H, J = 6.7 Hz), 1.15 (d, 6H, J = 6.5 Hz), 1.19 (d, 6H, J = 6.5 Hz), 1.21 (d, 6H, J = 6.7 Hz), 2.52 (t, 4H, J = 6 Hz), 2.63 (d, 1H, J = 11.1 Hz), 2.73 (dd, 1H, J = 2, 13 Hz), 2.84 (dd, 1H, J = 4, 6 Hz), 2.92 (dd, 1H, J = 3.5, 13.5 Hz), 3.27 (s, 3H, OMe), 3.33 (s, 3H, OMe), 3.36-3.80 (m, 11H), 3.834 (s, 6H, OMe), 3.838 (s, 6H, OMe), 3.84 (m, 2H), 4.34 (d, 2H, J = 11.1 Hz), 4.40 (d, 2H, J = 10.6 Hz), 4.68 ( s, 1H), 4.70 (s, 1H), 4.77 (m, 2H), 6.83 (d, 8H, J = 8.8 Hz), 7.12-7.39 (m, 30H), 7.55 (t 4H, J = 7 Hz) , 7.62 (d, 2H, J = 7.2 Hz), 8.07 (d, 4H, J = 7.3 Hz), 8.72 (s, 1H), 8.75 (s, 1H), 9.06 (s, 1H), 9.32 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ 149.01, 150.07.</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ 149.01, 150.07.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 2〉 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-에톡시피페리딘-3-일}아데닌의 제조</span>Example 2 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethyl-4-ethoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) (3S,4R,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 1) (3S, 4R, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethyl Liden] Piperidine Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 실시예 1의 (단계 5)에서 얻어진 다이아스테레오머 A(혹은 다이아스테레오머 B나 A와 B의 혼합물)를 출발물질로 하여 실시예 1의 (단계 6)과 같은 과정으로 아이오도에탄(EtI)을 사용하여 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 6) using the diastereomer A (or the diastereomer B or a mixture of A and B) obtained in Example 5 (Step 5). Prepared using (EtI).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ -0.02 (s, 3H, Si-Me), 0.07 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.24 (t, 3H, J=7.1 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.75 (s, 3H, Me), 1.91 (dd, 1H, J=10.8, 10.8 Hz), 2.43 (ddd, 1H, J=4.6, 9.4, 9.4 Hz), 2.88 (dd, 1H, J=4.8, 11.5 Hz), 3.08 (dd, 1H, J=8.7, 8.7 Hz), 3.74 (m, 1H), 3.82 (s, 3H, OMe), 3.94 (m, 4H), 4.45 (dd, 1H, J=4.2, 10.3 Hz), 5.03 (s, 1H), 6.88 (d, 2H, J=8.9 Hz), 7.14 - 7.40 (m, 10H), 7.46 (d, 2H, J=8.9 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ -0.02 (s, 3H, Si-Me), 0.07 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.24 (t, 3H, J = 7.1 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.75 (s, 3H, Me), 1.91 (dd, 1H, J = 10.8, 10.8 Hz), 2.43 (ddd, 1H, J = 4.6, 9.4, 9.4 Hz), 2.88 ( dd, 1H, J = 4.8, 11.5 Hz), 3.08 (dd, 1H, J = 8.7, 8.7 Hz), 3.74 (m, 1H), 3.82 (s, 3H, OMe), 3.94 (m, 4H), 4.45 (dd, 1H, J = 4.2, 10.3 Hz), 5.03 (s, 1H), 6.88 (d, 2H, J = 8.9 Hz), 7.14-7.40 (m, 10H), 7.46 (d, 2H, J = 8.9 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2)   (3S,4R,5R,6R)-N-벤즈하이드릴-3-하이드록실-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 2) (3S, 4R, 5R, 6R) -N-benzhydryl-3-hydroxy-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 7)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 7) of Example 1, using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.26 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.76 (s, 3H, Me), 1.93 (dd, 1H, J=10.8, 10.8 Hz), 2.45 (ddd, 1H, J=4.4, 9.7, 10.1 Hz), 3.11 (m, 2H), 3.71 (m, 1H), 3.82 (s, 3H, OMe), 3.99 (m, 1H), 4.03 (dd, 1H, J=4.2, 9 Hz), 4.12 (q, 2H, J=7 Hz), 4.51 (dd, 1H, J=4, 6 Hz), 5.05 (s, 1H), 6.90 (d, 2H, J=9 Hz), 7.14 - 7.36 (m, 10H), 7.45 (d, 2H, J=9 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.26 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.76 (s, 3H, Me), 1.93 (dd, 1H, J = 10.8, 10.8 Hz), 2.45 ( ddd, 1H, J = 4.4, 9.7, 10.1 Hz), 3.11 (m, 2H), 3.71 (m, 1H), 3.82 (s, 3H, OMe), 3.99 (m, 1H), 4.03 (dd, 1H, J = 4.2, 9 Hz), 4.12 (q, 2H, J = 7 Hz), 4.51 (dd, 1H, J = 4, 6 Hz), 5.05 (s, 1H), 6.90 (d, 2H, J = 9 Hz), 7.14-7.36 (m, 10H), 7.45 (d, 2H, J = 9 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) (3S,4R,5R,6R)-N-벤즈하이드릴-3-메탄설포닐-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 3) (3S, 4R, 5R, 6R) -N-benzhydryl-3-methanesulfonyl-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperi Dean's Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 8)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 8) of Example 1, using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.24 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.77 (s, 3H, Me), 2.07 (dd, 1H, J=11.1, 11.1 Hz), 2.43 (ddd, 1H, J=4.5, 9.7, 9.7 Hz), 3.11 (s, 3H, OMs), 3.25 (dd, 1H, J=5.3, 11.3 Hz), 3.32 (dd, 1H, J=9, 9 Hz), 3.71 (q, 2H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.82 (s, 3H, OMe), 4.03 (m, 2H), 4.03 (dd, 1H, J=9, 9 Hz), 4.52 (dd, 1H, J=4.4, 11 Hz), 4.58 (ddd, 1H, J=5.2, 9.8, 9.8 Hz), 5.07 (s, 1H), 6.89 (d, 2H, J=8.8 Hz), 7.13 - 7.37 (m, 10H), 7.44 (d, 2H, J=8.8 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.24 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.77 (s, 3H, Me), 2.07 (dd, 1H, J = 11.1, 11.1 Hz), 2.43 ( ddd, 1H, J = 4.5, 9.7, 9.7 Hz), 3.11 (s, 3H, OMs), 3.25 (dd, 1H, J = 5.3, 11.3 Hz), 3.32 (dd, 1H, J = 9, 9 Hz) , 3.71 (q, 2H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.82 (s, 3H, OMe), 4.03 (m, 2H), 4.03 (dd, 1H, J = 9, 9 Hz), 4.52 ( dd, 1H, J = 4.4, 11 Hz), 4.58 (ddd, 1H, J = 5.2, 9.8, 9.8 Hz), 5.07 (s, 1H), 6.89 (d, 2H, J = 8.8 Hz), 7.13-7.37 (m, 10H), 7.44 (d, 2H, J = 8.8 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4)  {(3R,4R,5R,6R)-N-벤즈하이드릴-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 4) {(3R, 4R, 5R, 6R) -N-benzhydryl-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidin-3-yl } Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 9)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 9) of Example 1 using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.88 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.80 (s, 3H, Me), 2.71 (ddd, 1H, J=4.4, 9.8, 9.8 Hz), 2.90 (dd, 1H, J=11.3, 11.3 Hz), 3.10 (dd, 1H, J=4.7, 11.1 Hz), 3.23 (q, 1H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.76 (q, 1H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.82 (s, 3H, OMe), 3.95 (dd, 1H, J=9.9, 9.9 Hz), 4.07 (dd, 1H, J=10.6, 10.6 Hz), 4.20 (dd, 1H, J=8.9, 8.9 Hz), 4.53 (dd, 1H, J=4.5, 11 Hz), 4.64 (ddd, 1H, J=4.5, 10.8, 10.8 Hz), 5.13 (s, 1H), 6.88 (d, 2H, J=8.8 Hz), 7.14 - 7.47 (m, 12H), 7.73 (s, 1H), 8.31 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.88 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.80 (s, 3H, Me), 2.71 (ddd, 1H, J = 4.4, 9.8, 9.8 Hz), 2.90 (dd, 1H, J = 11.3, 11.3 Hz), 3.10 (dd, 1H, J = 4.7, 11.1 Hz), 3.23 (q, 1H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.76 (q, 1H , J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.82 (s, 3H, OMe), 3.95 (dd, 1H, J = 9.9, 9.9 Hz), 4.07 (dd, 1H, J = 10.6, 10.6 Hz), 4.20 (dd, 1H, J = 8.9, 8.9 Hz), 4.53 (dd, 1H, J = 4.5, 11 Hz), 4.64 (ddd, 1H, J = 4.5, 10.8, 10.8 Hz), 5.13 (s, 1H), 6.88 (d, 2H, J = 8.8 Hz), 7.14-7.47 (m, 12H), 7.73 (s, 1H), 8.31 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 5) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 4)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 10)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 10) of Example 1 using the title compound prepared in (Step 4).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.79 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.81 (s, 3H, Me), 2.73 (ddd, 1H, J=4.4, 9.7, 9.7 Hz), 2.93 (dd, 1H, J=11.5, 11.5 Hz), 3.15 (dd, 1H, J=4.4, 11.3 Hz), 3.22 (q, 1H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.80 (q, 1H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.82 (s, 3H, OMe), 3.98 (dd, 1H, J=9.1, 9.1 Hz), 4.08 (dd, 1H, J=10.6, 10.6 Hz), 4.23 (dd, 1H, J=8.9, 8.9 Hz), 4.54 (dd, 1H, J=4.5, 10.9 Hz), 4.72 (ddd, 1H, J=4.6, 8.8, 9.9 Hz), 5.14 (s, 1H), 6.88 (d, 2H, J=8.8 Hz), 7.14 - 7.56 (m, 15H), 7.95 (s, 1H), 8.03 (d, 2H, J=7.3 Hz), 8.76 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.79 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.81 (s, 3H, Me), 2.73 (ddd, 1H, J = 4.4, 9.7, 9.7 Hz), 2.93 (dd, 1H, J = 11.5, 11.5 Hz), 3.15 (dd, 1H, J = 4.4, 11.3 Hz), 3.22 (q, 1H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.80 (q, 1H , J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.82 (s, 3H, OMe), 3.98 (dd, 1H, J = 9.1, 9.1 Hz), 4.08 (dd, 1H, J = 10.6, 10.6 Hz), 4.23 (dd, 1H, J = 8.9, 8.9 Hz), 4.54 (dd, 1H, J = 4.5, 10.9 Hz), 4.72 (ddd, 1H, J = 4.6, 8.8, 9.9 Hz), 5.14 (s, 1H), 6.88 (d, 2H, J = 8.8 Hz), 7.14-7.56 (m, 15H), 7.95 (s, 1H), 8.03 (d, 2H, J = 7.3 Hz), 8.76 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 6) 6-N-벤조일-{(3R,4R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-하이드록시메틸-4-에톡시피페리딘-3-일}아데닌의 제조</span>(Step 6) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-hydroxymethyl-4-ethoxypiperidin-3-yl} adenine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 5)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 5).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.85 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 2.73 (m, 1H), 2.98 (m, 2H), 3.05 (d, 1H, J=11.2 Hz), 3.20 (dd, 1H, J=4.1, 11.6 Hz), 3.37 (dq, 1H, J=2.3, 7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.81 (dd, 1H, J=9.5, 9.5 Hz), 4.01 (dd, 1H, J=8.4, 8.4 Hz), 4.28 (dd, 1H, J=3.3, 12.1 Hz), 4.59 (ddd, 1H, J=4, 10.3, 10.3 Hz), 5.56 (s, 1H), 7.20 - 7.64 (m, 13H), 8.01 (s, 1H), 8.03 (d, 2H, J=7.3 Hz), 8.76 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.85 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 2.73 (m, 1H), 2.98 (m, 2H), 3.05 (d, 1H, J = 11.2 Hz) , 3.20 (dd, 1H, J = 4.1, 11.6 Hz), 3.37 (dq, 1H, J = 2.3, 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.81 (dd, 1H, J = 9.5, 9.5 Hz), 4.01 ( dd, 1H, J = 8.4, 8.4 Hz), 4.28 (dd, 1H, J = 3.3, 12.1 Hz), 4.59 (ddd, 1H, J = 4, 10.3, 10.3 Hz), 5.56 (s, 1H), 7.20 7.64 (m, 13H), 8.01 (s, 1H), 8.03 (d, 2H, J = 7.3 Hz), 8.76 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 7) 6-N-벤조일-{(3R,4R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸-4-에톡시피페리딘-3-일}아데닌의 제조</span>(Step 7) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethyl-4-ethoxypiperidine-3- Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 6)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 6).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.84 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 2.51 (d, 1H, J=3 Hz), 2.64 (d, 1H, J=8.5 Hz), 2.91 (dq, 1H, J=2.3, 7 Hz), 3.06 (dd, 1H, J=10.9 Hz), 3.15 (dd, 1H, J=4.6, 11.4 Hz), 3.41 (dq, 1H, J=2.3, 7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.66 (dd, 1H, J=3.2, 10.4 Hz), 3.79 (s, 3H, OMe), 3.80 (s, 3H, OMe), 3.81 (m, 1H), 4.22 (dd, 1H, J=2.5, 7.4 Hz), 4.62 (ddd, 1H, J=4.4, 10.4, 10.4 Hz), 5.09 (s, 1H), 6.82 (d, 2H, J=9 Hz), 6.83 (d, 2H, J=9 Hz), 7.18 - 7.65 (m, 22H), 8.01 (s, 1H), 8.03 (d, 2H, J=7.3 Hz), 8.79 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.84 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 2.51 (d, 1H, J = 3 Hz), 2.64 (d, 1H, J = 8.5 Hz), 2.91 (dq, 1H, J = 2.3, 7 Hz), 3.06 (dd, 1H, J = 10.9 Hz), 3.15 (dd, 1H, J = 4.6, 11.4 Hz), 3.41 (dq, 1H, J = 2.3, 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.66 (dd, 1H, J = 3.2, 10.4 Hz), 3.79 (s, 3H, OMe), 3.80 (s, 3H, OMe), 3.81 (m, 1H), 4.22 (dd , 1H, J = 2.5, 7.4 Hz), 4.62 (ddd, 1H, J = 4.4, 10.4, 10.4 Hz), 5.09 (s, 1H), 6.82 (d, 2H, J = 9 Hz), 6.83 (d, 2H, J = 9 Hz), 7.18-7.65 (m, 22H), 8.01 (s, 1H), 8.03 (d, 2H, J = 7.3 Hz), 8.79 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 8) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-에톡시피페리딘-3-일}아데닌의 제조</span>(Step 8) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Preparation of oxy] -6-dimethyltrityloxymethyl-4-ethoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 7)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 7).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.01 (t, 3H, J=6.8 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.03 (d, 6H, J=6.7 Hz), 1.13 (d, 6H, J=6.7 Hz), 1.16 (d, 6H, J=6.7 Hz), 1.20 (d, 6H, J=6.7 Hz), 2.52 (m, 4H), 2.60 (d, 2H, J=11.1 Hz), 2.78 (dd, 2H, 3.7, 11.5 Hz), 2.94 (dd, 2H, J=3.6, 11.4 Hz), 3.01 (dd, 2H, J=4.7, 11.1 Hz), 3.18 - 3.80 (m, 16H), 3.83 (s, 6H, OMe), 3.84 (s, 6H, OMe), 4.28 (d, 2H, J=13.6 Hz), 4.41 (d, 2H, J=13.5 Hz), 4.72 (m, 2H), 4.76 (s, 2H), 6.82 (d, 8H, J=8.7 Hz), 7.08 - 7.66 (m, 44H), 8.07 (d, 4H, J=7.2 Hz), 8.73 (s, 1H), 8.75 (s, 1H), 9.08 (s, 1H), 9.34 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.01 (t, 3H, J = 6.8 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.03 (d, 6H, J = 6.7 Hz), 1.13 (d, 6H, J = 6.7 Hz), 1.16 (d, 6H, J = 6.7 Hz), 1.20 (d, 6H, J = 6.7 Hz), 2.52 (m, 4H), 2.60 (d, 2H, J = 11.1 Hz), 2.78 (dd, 2H, 3.7, 11.5 Hz), 2.94 (dd, 2H, J = 3.6, 11.4 Hz), 3.01 (dd, 2H, J = 4.7, 11.1 Hz), 3.18-3.80 (m, 16H), 3.83 (s, 6H, OMe), 3.84 (s, 6H, OMe), 4.28 (d, 2H, J = 13.6 Hz), 4.41 (d, 2H, J = 13.5 Hz), 4.72 (m, 2H), 4.76 (s, 2H), 6.82 (d , 8H, J = 8.7 Hz), 7.08-7.66 (m, 44H), 8.07 (d, 4H, J = 7.2 Hz), 8.73 (s, 1H), 8.75 (s, 1H), 9.08 (s, 1H) , 9.34 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ 148.85, 149.96.</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ 148.85, 149.96.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 3〉 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시에톡시피페리딘-3-일}아데닌의 제조</span>Example 3 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethyl-4-methoxyethoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) (3S,4R,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-에톡시메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 1) (3S, 4R, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-4-ethoxymethoxy-5,6-O-[(4-methoxyphenyl ) Ethylidene] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 1의 단계 5에서 얻어진 다이아스테레오머 B(혹은 다이아스테레오머 A나 A와 B의 혼합물)(200 mg, 0.61 mmol)를 무수 테트라하이드로퓨란(5 mL)에 녹였다.  여기에 무수 테트라하이드로퓨란(2 mL)에 녹인 소듐 하이드라이드(72 mg, 1.8 mmol)을 가하고 반응액의 온도를 60 ℃로 올린 다음 2-브로모에틸메틸에테르(171 μL, 1.8 mmol)을 가하여 하루동안 60 ℃에서 교반하였다.  물을 가하고 반응액을 에틸아세테이트로 추출하고, 소듐 설페이트로 물을 제거한 후 감압 농축하였다.  잔사를 실리카젤과 5 % - 10 % 에틸아세테이트/헥산 용매를 써서 컬럼 크로마토그래피로 정제하였다(215 mg, 56 %).</span>Diastereomer B (or diastereomer A or a mixture of A and B) (200 mg, 0.61 mmol) obtained in step 5 of Example 1 was dissolved in anhydrous tetrahydrofuran (5 mL). Sodium hydride (72 mg, 1.8 mmol) dissolved in anhydrous tetrahydrofuran (2 mL) was added thereto, and the reaction solution was heated to 60 ° C., followed by 2-bromoethylmethyl ether (171 μL, 1.8 mmol). Stir at 60 ° C. for 1 day. Water was added, the reaction solution was extracted with ethyl acetate, water was removed with sodium sulfate, and then concentrated under reduced pressure. The residue was purified by column chromatography using silica gel and 5%-10% ethyl acetate / hexane solvent (215 mg, 56%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.13 (s, 3H, Si-Me), 0.20 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.51 (s, 3H, Me), 1.83 (dd, 1H, J=11, 11 Hz), 2.41 (m, 1H), 2.87 (dd, 1H, J=5, 11.4 Hz), 3.03 (dd, 1H, J=4.7, 11.5 Hz), 3.23 (s, 3H, OMe), 3.26 - 3.61 (m, 4H), 3.73 (ddd, 1H, J=5, 8.7, 8.7 Hz), 3.85 (s, 3H, OMe), 3.92 (d, 1H, J=9 Hz), 3.98 (d, 1H, J=10.7 Hz), 4.42 (m, 1H), 4.95 (s, 1H), 6.93 (d, 2H, J=8.8 Hz), 7.16 - 7.40 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.13 (s, 3H, Si-Me), 0.20 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.51 (s, 3H, Me), 1.83 (dd, 1H, J = 11, 11 Hz), 2.41 (m, 1H), 2.87 (dd, 1H, J = 5, 11.4 Hz), 3.03 (dd, 1H, J = 4.7, 11.5 Hz), 3.23 (s, 3H, OMe), 3.26-3.61 (m, 4H), 3.73 (ddd, 1H, J = 5, 8.7, 8.7 Hz), 3.85 (s, 3H, OMe), 3.92 (d, 1H, J = 9 Hz), 3.98 (d, 1H, J = 10.7 Hz), 4.42 (m, 1H), 4.95 (s, 1H), 6.93 (d, 2H, J = 8.8 Hz), 7.16-7.40 (m, 12H) .</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) (3S,4R,5R,6R)-N-벤즈하이드릴-3-하이드록실-4-메톡시에톡시-5,6-O- [(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 2) (3S, 4R, 5R, 6R) -N-benzhydryl-3-hydroxyl-4-methoxyethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 7)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 7) of Example 1, using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.51 (s, 3H, Me), 1.88 (dd, 1H, J=10.8, 10.8 Hz), 2.45 (ddd, 1H, J=2.8, 9.2, 9.2 Hz), 2.76 (m, 1H), 3.02 (dd, 1H, J=5, 11.8 Hz), 3.11 (dd, 1H, J=9, 9 Hz), 3.43 (s, 3H, OMe), 3.55 - 3.68 (m, 4H), 3.86 (s, 3H, OMe), 3.90 (m, 1H), 4.26 (ddd, 1H, J=3, 5.4, 11.8 Hz), 4.44 (dd, 1H, J=4, 11 Hz), 4.93 (s, 1H), 6.97 (d, 2H, J=8.7 Hz), 7.20 - 7.40 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.51 (s, 3H, Me), 1.88 (dd, 1H, J = 10.8, 10.8 Hz), 2.45 (ddd, 1H, J = 2.8, 9.2, 9.2 Hz), 2.76 (m , 1H), 3.02 (dd, 1H, J = 5, 11.8 Hz), 3.11 (dd, 1H, J = 9, 9 Hz), 3.43 (s, 3H, OMe), 3.55-3.68 (m, 4H), 3.86 (s, 3H, OMe), 3.90 (m, 1H), 4.26 (ddd, 1H, J = 3, 5.4, 11.8 Hz), 4.44 (dd, 1H, J = 4, 11 Hz), 4.93 (s, 1H), 6.97 (d, 2H, J = 8.7 Hz), 7.20-7.40 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) (3S,4R,5R,6R)-N-벤즈하이드릴-3-메탄설포닐-4-메톡시에톡시-5,6-O- [(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 3) (3S, 4R, 5R, 6R) -N-benzhydryl-3-methanesulfonyl-4-methoxyethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] Preparation of Piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 8)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 8) of Example 1, using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.52 (s, 3H, Me), 2.04 (dd, 1H, J=11, 11 Hz), 2.46 (ddd, 1H, J=4, 10, 10 Hz), 3.15 (s, 3H, OMs), 3.33 (d, 1H, J=11 Hz), 3.41 (s, 3H, OMe), 3.61 - 3.68 (m, 2H), 3.86 (s, 3H, OMe), 3.88 (m, 1H), 4.18 (dd, 1H, J=3, 5.7 Hz), 4.22 (dd, 1H, J=3, 5.7 Hz), 4.39 (dd, 1H, J=4.5, 9.5 Hz), 4.45 (dd, 1H, J=4, 10 Hz), 4.95 (s, 1H), 6.98 (d, 2H, J=8.8 Hz), 7.14 - 7.40 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.52 (s, 3H, Me), 2.04 (dd, 1H, J = 11, 11 Hz), 2.46 (ddd, 1H, J = 4, 10, 10 Hz), 3.15 (s , 3H, OMs), 3.33 (d, 1H, J = 11 Hz), 3.41 (s, 3H, OMe), 3.61-3.68 (m, 2H), 3.86 (s, 3H, OMe), 3.88 (m, 1H ), 4.18 (dd, 1H, J = 3, 5.7 Hz), 4.22 (dd, 1H, J = 3, 5.7 Hz), 4.39 (dd, 1H, J = 4.5, 9.5 Hz), 4.45 (dd, 1H, J = 4, 10 Hz), 4.95 (s, 1H), 6.98 (d, 2H, J = 8.8 Hz), 7.14-7.40 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4)  {(3R,4R,5R,6R)-N-벤즈하이드릴-4-메톡시에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 4) {(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxyethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine-3 Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 9)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 9) of Example 1 using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.54 (s, 3H, Me), 2.75 (ddd, 1H, J=4, 10, 10 Hz), 2.95 (m, 1H), 3.12 (s, 3H, OMe), 3.14 - 3.22 (m, 2H), 3.48 (ddd, 1H, J=3, 5.8, 5.8), 3.81 (dd, 1H, J=6.2, 6.2 Hz),3.85 (m, 1H), 3.87 (s, 3H, OMe), 3.94 (ddd, 1H, J=3.2, 6, 11.4 Hz), 4.13 (dd, 1H, J=9.5, 9.5 Hz), 4.42 (dd, 1H, J=5, 10.2 Hz), 4.47 (dd, 1H, J=4, 10.5 Hz), 5.00 (s, 1H), 6.98 (d, 2H, J=8.7 Hz), 7.14 - 7.44 (m, 12H), 7.74 (s, 1H), 8.30 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.54 (s, 3H, Me), 2.75 (ddd, 1H, J = 4, 10, 10 Hz), 2.95 (m, 1H), 3.12 (s, 3H, OMe), 3.14 3.22 (m, 2H), 3.48 (ddd, 1H, J = 3, 5.8, 5.8), 3.81 (dd, 1H, J = 6.2, 6.2 Hz), 3.85 (m, 1H), 3.87 (s, 3H, OMe), 3.94 (ddd, 1H, J = 3.2, 6, 11.4 Hz), 4.13 (dd, 1H, J = 9.5, 9.5 Hz), 4.42 (dd, 1H, J = 5, 10.2 Hz), 4.47 (dd , 1H, J = 4, 10.5 Hz), 5.00 (s, 1H), 6.98 (d, 2H, J = 8.7 Hz), 7.14-7.44 (m, 12H), 7.74 (s, 1H), 8.30 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-4-메톡시에톡시-5,6-O- [(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 5) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxyethoxy-5,6-O-[(4-methoxyphenyl) ethylidene ] Piperidin-3-yl} Adenine Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 4)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 10)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 10) of Example 1 using the title compound prepared in (Step 4).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.55 (s, 3H, Me), 2.74 (ddd, 1H, J=5, 9, 9 Hz), 2.97 (dd, 1H, J=11.2, 11.2 Hz), 3.03 (m, 1H), 3.11 (s, 3H, OMe), 3.14 - 3.21 (m, 2H), 3.46 (ddd, 1H, J=3.1, 6, 11.5), 3.70 (dd, 1H, J=10.5, 10.5 Hz), 3.83 (d, 1H, J=8.9 Hz), 3.88 (s, 3H, OMe), 3.98 (ddd, 1H, J=3, 5.5, 5.5 Hz), 4.17 (dd, 1H, J=9.2, 9.2 Hz), 4.51 (m, 1H), 4.54 (ddd, 1H, J=5, 11, 11 Hz), 5.02 (s, 1H), 6.98 (d, 2H, J=8.8 Hz), 7.14 - 7.62 (m, 12H), 7.96 (s, 1H), 8.03 (d, 2H, J=7.4 Hz), 8.76 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.55 (s, 3H, Me), 2.74 (ddd, 1H, J = 5, 9, 9 Hz), 2.97 (dd, 1H, J = 11.2, 11.2 Hz), 3.03 (m , 1H), 3.11 (s, 3H, OMe), 3.14-3.21 (m, 2H), 3.46 (ddd, 1H, J = 3.1, 6, 11.5), 3.70 (dd, 1H, J = 10.5, 10.5 Hz) , 3.83 (d, 1H, J = 8.9 Hz), 3.88 (s, 3H, OMe), 3.98 (ddd, 1H, J = 3, 5.5, 5.5 Hz), 4.17 (dd, 1H, J = 9.2, 9.2 Hz ), 4.51 (m, 1H), 4.54 (ddd, 1H, J = 5, 11, 11 Hz), 5.02 (s, 1H), 6.98 (d, 2H, J = 8.8 Hz), 7.14-7.62 (m, 12H), 7.96 (s, 1H), 8.03 (d, 2H, J = 7.4 Hz), 8.76 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 6) 6-N-벤조일-{(3R,4R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-하이드록시메틸-4-메톡시에톡시피페리딘-3-일}아데닌의 제조</span>(Step 6) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-hydroxymethyl-4-methoxyethoxypiperidine-3- Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 5)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 5).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.69 (m, 1H), 2.90 (dd, 1H, J=11.5, 11.5), 3.17 (dd, 1H, J=4, 11.5 Hz), 3.31 (s, 3H, OMe), 3.24 - 3.40 (m, 4H), 3.89 (dd, 1H, J=9, 9 Hz), 4.01 (dd, 1H, J=8.7, 8.7 Hz), 4.23 (m, 2H), 4.57 (ddd, 1H, J=4, 10.7, 10.7 Hz), 5.59 (s, 1H), 7.17 - 7.38 (m, 10H), 7.51 (t, 2H, J=7.2 Hz), 7.59 (d, 1H, J=7.3 Hz), 7.90 (s, 1H), 8.05 (d, 2H, J=7.2 Hz), 8.72 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.69 (m, 1H), 2.90 (dd, 1H, J = 11.5, 11.5), 3.17 (dd, 1H, J = 4, 11.5 Hz), 3.31 (s, 3H, OMe) , 3.24-3.40 (m, 4H), 3.89 (dd, 1H, J = 9, 9 Hz), 4.01 (dd, 1H, J = 8.7, 8.7 Hz), 4.23 (m, 2H), 4.57 (ddd, 1H , J = 4, 10.7, 10.7 Hz), 5.59 (s, 1H), 7.17-7.38 (m, 10H), 7.51 (t, 2H, J = 7.2 Hz), 7.59 (d, 1H, J = 7.3 Hz) , 7.90 (s, 1 H), 8.05 (d, 2 H, J = 7.2 Hz), 8.72 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 7) 6-N-벤조일-{(3R,4R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시에톡시피페리딘-3-일}아데닌의 제조</span>(Step 7) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxyethoxypiperidine Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 6)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 6).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.60 (m, 1H), 3.02 (m, 1H), 3.16 (dd, 1H, J=4.3, 11.3), 3.36 (s, 3H, OMe), 3.26 - 3.38 (m, 4H), 3.57 (d, 1H, J=9.5 Hz), 3.79 (s, 3H, OMe), 3.86 (d, 1H, J=9.8 Hz), 3.95 (dd, 1H, J=10, 10 Hz), 4.33 (dd, 1H, J=8.8, 8.8 Hz), 4.63 (ddd, 1H, J=4.2, 10.8, 10.8 Hz), 5.02 (s, 1H), 6.79 (d, 2H, J=8.8 Hz), 6.81 (d, 2H, J=8.8 Hz), 7.22 - 7.42 (m, 12H), 7.53 (t, 2H, J=7.3 Hz), 7.61 (d, 1H, J=7.3 Hz), 7.97 (s, 1H), 8.03 (d, 2H, J=7.3 Hz), 8.78 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.60 (m, 1H), 3.02 (m, 1H), 3.16 (dd, 1H, J = 4.3, 11.3), 3.36 (s, 3H, OMe), 3.26-3.38 (m, 4H), 3.57 (d, 1H, J = 9.5 Hz), 3.79 (s, 3H, OMe), 3.86 (d, 1H, J = 9.8 Hz), 3.95 (dd, 1H, J = 10, 10 Hz), 4.33 (dd, 1H, J = 8.8, 8.8 Hz), 4.63 (ddd, 1H, J = 4.2, 10.8, 10.8 Hz), 5.02 (s, 1H), 6.79 (d, 2H, J = 8.8 Hz), 6.81 (d, 2H, J = 8.8 Hz), 7.22-7.42 (m, 12H), 7.53 (t, 2H, J = 7.3 Hz), 7.61 (d, 1H, J = 7.3 Hz), 7.97 (s, 1H) , 8.03 (d, 2H, J = 7.3 Hz), 8.78 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 8) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시에톡시피페리딘-3-일}아데닌의 제조</span>(Step 8) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Preparation of oxy] -6-dimethyltrityloxymethyl-4-methoxyethoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 7)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 7).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.01 (d, 6H, J=6.8 Hz), 1.15 (d, 6H, J=6.8 Hz), 1.19 (d, 6H, J=6.8 Hz), 1.24 (d, 6H, J=6.8 Hz), 2.49 (m, 4H), 2.60 (m, 2H), 2.77 (m, 3H), 2.94 (m, 2H), 3.21 (s, 3H, OMe), 3.23 (s, 3H, OMe), 3.27 - 3.59 (m, 18H), 3.83 (s, 12H, OMe), 4.17 (m, 1H), 4.28 (d, 2H, J=13.4 Hz), 4.40 (d, 2H, J=12.3 Hz), 4.75 (s, 2H), 4.77 (m, 2H), 6.81 (d, 8H, J=8.4 Hz), 7.06 - 7.35 (m, 38H), 7.53 (d, 4H, J=7.5 Hz), 7.61 (d, 2H, J=7.5 Hz), 8.05 (d, 4H, J=7.3 Hz), 8.75 (s, 1H), 9.02 (s, 1H), 9.13 (s, 1H), 9.29 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.01 (d, 6H, J = 6.8 Hz), 1.15 (d, 6H, J = 6.8 Hz), 1.19 (d, 6H, J = 6.8 Hz), 1.24 (d, 6H, J = 6.8 Hz), 2.49 (m, 4H), 2.60 (m, 2H), 2.77 (m, 3H), 2.94 (m, 2H), 3.21 (s, 3H, OMe), 3.23 (s, 3H, OMe ), 3.27-3.59 (m, 18H), 3.83 (s, 12H, OMe), 4.17 (m, 1H), 4.28 (d, 2H, J = 13.4 Hz), 4.40 (d, 2H, J = 12.3 Hz) , 4.75 (s, 2H), 4.77 (m, 2H), 6.81 (d, 8H, J = 8.4 Hz), 7.06-7.35 (m, 38H), 7.53 (d, 4H, J = 7.5 Hz), 7.61 ( d, 2H, J = 7.5 Hz), 8.05 (d, 4H, J = 7.3 Hz), 8.75 (s, 1H), 9.02 (s, 1H), 9.13 (s, 1H), 9.29 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 148.99, 149.77.</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 148.99, 149.77.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 4〉 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸피페리딘-3-일}아데닌의 제조</span>Example 4 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethylpiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) (3S,4R,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-(이미다졸 -1-일) -치오카르복실-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 1) (3S, 4R, 5R, 6R) -N-benzhydryl-3-tertbutyldimethylsilyloxy-4- (imidazol-1-yl) -thiocarboxy-5,6-O Preparation of-[(4-methoxyphenyl) ethylidene] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">1,1'-치오카보닐다이이미다졸(12.44 g, 69.81 mmol)을 아세트나이트릴 (200 mL)에 녹인 실시예 1의 단계 6에서 얻어진 표제화합물 다이아스테레오머 A (12.0 g, 20.84 mmol)(혹은 다이아스테레오머 B나 A와 B의 혼합물)에 가하였다.  이 반응액을 24시간동안 환류시킨 후 감압농축하였다.  여기에 메틸렌클로라이드와 물을 가하고 유기층을 추출하여 건조시키고 감압농축하였다.  잔사를 컬럼 크로마토그래피(EtOAc:Hexane = 1:4)로 정제하였다(3.33 g, 23 %).</span>The title compound diastereomer A (12.0 g, 20.84 mmol) (or 1,1'-thiocarbonyldiimidazole (12.44 g, 69.81 mmol) dissolved in acetnitrile (200 mL) was obtained in step 6 of Example 1. Diastereomer B or a mixture of A and B). The reaction solution was refluxed for 24 hours and then concentrated under reduced pressure. Methylene chloride and water were added thereto, the organic layer was extracted, dried and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc: Hexane = 1: 4) (3.33 g, 23%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ -0.18 (s, 6H, Si-Me), 0.68 (s, 9H, Si-tBu), 1.45 (s, 3H, Me), 2.12 (dd, 1H, J=11, 11 Hz), 2.65 (ddd, 1H, J=4, 10.1, 10.1 Hz), 2.94 (dd, 1H, J=5, 11.6 Hz), 3.70 (dd, 1H, J=10.6, 10.6 Hz), 3.74 (m, 1H), 3.43 (s, 1H, OMe), 3.44 (m, 1H), 4.99 (s, 1H), 5,78 (dd, 1H, J=9, 9 Hz), 6.93 (d, 2H, J=8.8 Hz), 7.16 - 7.43 (m, 12H), 7.76 (s, 1H), 8.46 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ -0.18 (s, 6H, Si-Me), 0.68 (s, 9H, Si-tBu), 1.45 (s, 3H, Me), 2.12 (dd, 1H, J = 11, 11 Hz), 2.65 (ddd, 1H, J = 4, 10.1, 10.1 Hz), 2.94 (dd, 1H, J = 5, 11.6 Hz), 3.70 (dd, 1H, J = 10.6, 10.6 Hz), 3.74 ( m, 1H), 3.43 (s, 1H, OMe), 3.44 (m, 1H), 4.99 (s, 1H), 5,78 (dd, 1H, J = 9, 9 Hz), 6.93 (d, 2H, J = 8.8 Hz), 7.16-7.43 (m, 12H), 7.76 (s, 1H), 8.46 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) (3S,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 2) Preparation of (3S, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">트리부틸틴 하이드라이드(2.22g 7.62 mmol)와 2,2'-아조비스(이소부티로나이트릴)(0.82 g, 4.97 mmol)을 톨루엔(30 mL)에 녹인 상기 (단계 1) 표제화합물 (2.62g 3.82 mmol)에 가하고 2시간 동안 교반하였다.  이를 감압농축한 후 잔사를 컬럼 크로마토그래피(10% - 20% EtOAc/Hexane)로 정제하였다 (2.0 g, 47 %)</span>Tributyltin hydride (2.22 g 7.62 mmol) and 2,2'-azobis (isobutyronitrile) (0.82 g, 4.97 mmol) dissolved in toluene (30 mL) (step 1) Title compound (2.62) g 3.82 mmol) and stirred for 2 hours. After concentration under reduced pressure, the residue was purified by column chromatography (10%-20% EtOAc / Hexane) (2.0 g, 47%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ -0.03 (s, 3H, Si-Me), 0.00 (s, 3H, Si-Me), 0.82 (s, 9H, Si-tBu), 1.55 (s, 3H, Me), 1.81 (dd, 1H, J=10.5, 10.5 Hz), 2.18 (m, 1H), 2.33 (ddd, 1H, J=4, 10.5, 10.5 Hz), 2.86 (dd, 1H, J=4, 10.3 Hz), 3.49 (ddd, 1H, J=4.4, 10.5, 10.5 Hz), 3.61 (dd, 1H, J=10.5, 10.5 Hz), 3.69 (m, 1H), 3.86 (s, 3H, OMe), 4.50 (dd, 1H, J=4, 10.5 Hz), 4.95 (s, 1H), 6.97 (d, 2H, J=8.8 Hz), 7.16 - 7.47 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ -0.03 (s, 3H, Si-Me), 0.00 (s, 3H, Si-Me), 0.82 (s, 9H, Si-tBu), 1.55 (s, 3H, Me) , 1.81 (dd, 1H, J = 10.5, 10.5 Hz), 2.18 (m, 1H), 2.33 (ddd, 1H, J = 4, 10.5, 10.5 Hz), 2.86 (dd, 1H, J = 4, 10.3 Hz ), 3.49 (ddd, 1H, J = 4.4, 10.5, 10.5 Hz), 3.61 (dd, 1H, J = 10.5, 10.5 Hz), 3.69 (m, 1H), 3.86 (s, 3H, OMe), 4.50 ( dd, 1H, J = 4, 10.5 Hz), 4.95 (s, 1H), 6.97 (d, 2H, J = 8.8 Hz), 7.16-7.47 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3)  (3S,5R,6R)-N-벤즈하이드릴-3-하이드록시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 3) Preparation of (3S, 5R, 6R) -N-benzhydryl-3-hydroxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)의 화합물을 이용하여 실시예 1의 (단계 7)의 과정과 같은 방법으로 실시하여 목적화합물을 얻었다.</span>This compound was carried out in the same manner as the procedure of (Step 7) of Example 1 using the compound of (step 2) above to obtain the target compound.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.52 (s, 3H, Me), 1.76 (dd, 1H, J=10.5, 10.5 Hz), 2.32 (m, 2H), 3.00 (dd, 1H, J=3, 10.5 Hz), 3.51 - 3.59 (m, 2H), 3.66 (m, 1H), 3.76 (m, 1H), 3.86 (s, 3H, OMe), 4.47 (dd, 1H, J=4, 10.5 Hz), 4.97 (s, 1H), 6.96 (d, 2H, J=6.8 Hz), 7.17 - 7.40 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.52 (s, 3H, Me), 1.76 (dd, 1H, J = 10.5, 10.5 Hz), 2.32 (m, 2H), 3.00 (dd, 1H, J = 3, 10.5 Hz ), 3.51-3.59 (m, 2H), 3.66 (m, 1H), 3.76 (m, 1H), 3.86 (s, 3H, OMe), 4.47 (dd, 1H, J = 4, 10.5 Hz), 4.97 ( s, 1H), 6.96 (d, 2H, J = 6.8 Hz), 7.17-7.40 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4)  (3S,5R,6R)-N-벤즈하이드릴-3-메탄설폭시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 4) Preparation of (3S, 5R, 6R) -N-benzhydryl-3-methanesulfoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 화합물은 실시예 1의 (단계 8)의 과정과 같은 방법으로 실시하여 목적화합물을 얻었다.</span>The compound was carried out in the same manner as in the (Step 8) of Example 1 to obtain the target compound.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.52 (s, 3H, Me), 2.01 (dd, 1H, J=10.5, 10.5 Hz), 2.38 (ddd, 1H, J=4, 10.2, 10.2 Hz), 2.53 (m 1H), 2.95 (s, 3H, OMs), 3.14 (dd, 1H, J=4, 11.5 Hz), 3.56 (m, 1H), 3.63 (dd, 1H, J=10.5, 10.5 Hz), 3.87 (s, 3H, OMe), 4.46 (dd, 1H, J=4, 10.5 Hz), 4.67 (m, 1H), 4.98 (s, 1H), 6.96 (d, 2H, J=8.6 Hz), 7.19 - 7.42 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.52 (s, 3H, Me), 2.01 (dd, 1H, J = 10.5, 10.5 Hz), 2.38 (ddd, 1H, J = 4, 10.2, 10.2 Hz), 2.53 (m 1H), 2.95 (s, 3H, OMs), 3.14 (dd, 1H, J = 4, 11.5 Hz), 3.56 (m, 1H), 3.63 (dd, 1H, J = 10.5, 10.5 Hz), 3.87 (s , 3H, OMe), 4.46 (dd, 1H, J = 4, 10.5 Hz), 4.67 (m, 1H), 4.98 (s, 1H), 6.96 (d, 2H, J = 8.6 Hz), 7.19-7.42 ( m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5)  {(3R,5R,6R)-N-벤즈하이드릴-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘 -3-일}아데닌의 제조</span>(Step 5) Preparation of {(3R, 5R, 6R) -N-benzhydryl-5,6-O-[(4-methoxyphenyl) ethylidene] piperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 4)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 9)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 9) using the title compound prepared in (Step 4).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.54 (s, 3H, Me), 2.24 (dd, 1H, J=10.8, 10.8 Hz), 2.55 (m, 2H), 3.20 (m, 1H), 3.72 (dd, 1H, J=10.5, 10.5 Hz), 3.86 (m 1H), 3.88 (s, 3H, OMe), 4.53 (dd, 1H, J=4, 10.5 Hz), 4.77 (m, 1H), 5.06 (s, 1H), 6.98 (d, 2H, J=8.7 Hz), 7.12 - 7.39 (m, 12H), 8.03 (s, 1H), 8.32 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.54 (s, 3H, Me), 2.24 (dd, 1H, J = 10.8, 10.8 Hz), 2.55 (m, 2H), 3.20 (m, 1H), 3.72 (dd, 1H , J = 10.5, 10.5 Hz), 3.86 (m 1H), 3.88 (s, 3H, OMe), 4.53 (dd, 1H, J = 4, 10.5 Hz), 4.77 (m, 1H), 5.06 (s, 1H ), 6.98 (d, 2H, J = 8.7 Hz), 7.12-7.39 (m, 12H), 8.03 (s, 1H), 8.32 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 6) 6-N-벤조일-{(3R,5R,6R)-N-벤즈하이드릴-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 6) 6-N-benzoyl-{(3R, 5R, 6R) -N-benzhydryl-5,6-O-[(4-methoxyphenyl) ethylidene] piperidin-3-yl} Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 5)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 10)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 10) of Example 1 using the title compound prepared in (Step 5).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.55 (s, 3H, Me), 2.27 (dd, 1H, J=11, 11 Hz), 2.55 (m, 2H), 3.21 (m, 1H), 3.74 (dd, 1H, J=10.5, 10.5 Hz), 3.78 (m, 1H), 3.88 (s, 3H, OMe), 4.54 (dd, 1H, J=4, 10.5 Hz), 4.77 (m, 1H), 5.07 (s, 1H), 6.99 (d, 2H, J=8.7 Hz), 7.14 - 7.55 (m, 15H), 7.94 (s, 1H), 8.03 (d, 2H, J=7.2 Hz), 8.75 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.55 (s, 3H, Me), 2.27 (dd, 1H, J = 11, 11 Hz), 2.55 (m, 2H), 3.21 (m, 1H), 3.74 (dd, 1H , J = 10.5, 10.5 Hz), 3.78 (m, 1H), 3.88 (s, 3H, OMe), 4.54 (dd, 1H, J = 4, 10.5 Hz), 4.77 (m, 1H), 5.07 (s, 1H), 6.99 (d, 2H, J = 8.7 Hz), 7.14-7.55 (m, 15H), 7.94 (s, 1H), 8.03 (d, 2H, J = 7.2 Hz), 8.75 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 7) 6-N-벤조일-{(3R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-하이드록시메틸피페리딘-3-일}아데닌의 제조</span>(Step 7) Preparation of 6-N-benzoyl-{(3R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-hydroxymethylpiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 6)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 6).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.07 (m, 1H), 2.54 (m, 2H), 2.68 (m, 1H), 3.25 (dd, 1H, J=3, 11.3 Hz), 4.17 - 4.24 (m, 3H), 4.85 (m, 1H), 5.43 (s, 1H), 7.18 - 7.33 (m, 10H), 7.52 (t, 2H, J=7 Hz), 7.61 (d, 1H, J=7.3 Hz), 8.05 (d, 2H, J=7.2 Hz), 8.26 (s, 1H), 8.70 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.07 (m, 1H), 2.54 (m, 2H), 2.68 (m, 1H), 3.25 (dd, 1H, J = 3, 11.3 Hz), 4.17-4.24 (m, 3H ), 4.85 (m, 1H), 5.43 (s, 1H), 7.18-7.33 (m, 10H), 7.52 (t, 2H, J = 7 Hz), 7.61 (d, 1H, J = 7.3 Hz), 8.05 (d, 2H, J = 7.2 Hz), 8.26 (s, 1 H), 8.70 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 8) 6-N-벤조일-{(3R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸피페리딘-3-일}아데닌의 제조</span>(Step 8) Preparation of 6-N-benzoyl-{(3R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethylpiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 7)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 12) of Example 1 using the title compound prepared in (Step 7).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.45 (m, 2H), 2.63 (dd, 1H, J=7, 12.4 Hz), 2.85 (m, 1H), 3.14 (dd, 1H, J=3, 12, 12 Hz), 3.52 (dd, 1H, J=6, 10 Hz), 3.74 (dd, 1H, J=3, 10 Hz), 3.823 (s, 3H, OMe), 3.829 (s, 3H, OMe), 4.25 (m, 1H), 4.84 (m, 1H), 4.92 (s, 1H), 6.85 (d, 2H, J=8.9 Hz), 6.87 (d, 2H, J=8.9 Hz), 7.15 - 7.35 (m, 12H), 7.44 (d, 2H, J=7 Hz), 7.55 (t, 2H, J=7.3 Hz), 7.61 (d, 1H, J=7.3 Hz), 8.05 (d, 2H, J=7 Hz), 8.52 (s, 1H), 8.78 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.45 (m, 2H), 2.63 (dd, 1H, J = 7, 12.4 Hz), 2.85 (m, 1H), 3.14 (dd, 1H, J = 3, 12, 12 Hz ), 3.52 (dd, 1H, J = 6, 10 Hz), 3.74 (dd, 1H, J = 3, 10 Hz), 3.823 (s, 3H, OMe), 3.829 (s, 3H, OMe), 4.25 ( m, 1H), 4.84 (m, 1H), 4.92 (s, 1H), 6.85 (d, 2H, J = 8.9 Hz), 6.87 (d, 2H, J = 8.9 Hz), 7.15-7.35 (m, 12H ), 7.44 (d, 2H, J = 7 Hz), 7.55 (t, 2H, J = 7.3 Hz), 7.61 (d, 1H, J = 7.3 Hz), 8.05 (d, 2H, J = 7 Hz), 8.52 (s, 1 H), 8.78 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 9) 6-N-벤조일-{(3R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸피페리딘-3-일}아데닌의 제조</span>(Step 9) 6-N-benzoyl-{(3R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] Preparation of -6-dimethyltrityloxymethylpiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 8)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 8).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.05 (d, 6H, J=6.7 Hz), 1.10 (d, 6H, J=6.7 Hz), 1.16 (d, 6H, J=6.7 Hz), 1.19 (d, 6H, J=6.7 Hz), 2.28 (m, 2H), 2.73 (m, 2H), 2.77 (m, 4H), 2.96 (dd, 2H, J=2, 12.8 Hz), 3.10 (dd, 2H, J=3, 13 Hz), 3.33 (dd, 2H, J=8.2, 8.7 Hz), 3.42 - 3.75 (m, 12H), 3.82 (s, 3H, OMe), 3.83 (s, 6H, OMe),  3.84 (s, 3H, OMe), 4.37 (m, 1H), 4.57 (s, 1H), 4.60 (s, 1H), 4.91 (m, 2H), 6.85 (d, 4H, J=7.2 Hz), 6.86 (d, 4H, J=7.2 Hz), 7.07 - 7.42 (m, 34H), 7.55 (d, 4H, J=7.7 Hz), 7.62 (d, 2H, J=7.2 Hz), 8.09 (d, 4H, J=7.3 Hz), 8.71 (s, 1H), 8.72 (s, 1H), 9.17 (s, 1H), 9.30 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.05 (d, 6H, J = 6.7 Hz), 1.10 (d, 6H, J = 6.7 Hz), 1.16 (d, 6H, J = 6.7 Hz), 1.19 (d, 6H, J = 6.7 Hz), 2.28 (m, 2H), 2.73 (m, 2H), 2.77 (m, 4H), 2.96 (dd, 2H, J = 2, 12.8 Hz), 3.10 (dd, 2H, J = 3 , 13 Hz), 3.33 (dd, 2H, J = 8.2, 8.7 Hz), 3.42-3.75 (m, 12H), 3.82 (s, 3H, OMe), 3.83 (s, 6H, OMe), 3.84 (s, 3H, OMe), 4.37 (m, 1H), 4.57 (s, 1H), 4.60 (s, 1H), 4.91 (m, 2H), 6.85 (d, 4H, J = 7.2 Hz), 6.86 (d, 4H , J = 7.2 Hz), 7.07-7.42 (m, 34H), 7.55 (d, 4H, J = 7.7 Hz), 7.62 (d, 2H, J = 7.2 Hz), 8.09 (d, 4H, J = 7.3 Hz ), 8.71 (s, 1H), 8.72 (s, 1H), 9.17 (s, 1H), 9.30 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 148.30, 148.59</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 148.30, 148.59</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 5〉 6-N-벤조일-{(3R,4S,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>Example 5 6-N-benzoyl-{(3R, 4S, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) (3S,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-옥소-5,6- O-[(4-메톡시페닐)에틸리덴]피페리딘 의 제조</span>(Step 1) (3S, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-4-oxo-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">-78 ℃에서 무수다이클로로메탄(40 mL)에 다이메틸설폭사이드(253 ㎕, 3.81 mmol)를 가하고, 옥사릴 클로라이드(1.8 mL, mmol)를 첨가한 후, 실시예 1의 (단계 5)에서 얻어진 다이아스테레오머 B(1 g, 1.73 mmol)(혹은 다이아스테레오머 A나 A와 B의 혼합물)를 5분 동안 첨가하였다.  15분 후 트리에틸아민 (574 ㎕, 0.87 mmol)을  -78 ℃에서 첨가하였다.  5분 후 냉각기를 제거하고 반응물이 실온이 되면, 증류수를 첨가하고 유기용매층을 분획한 다음 소듐 설페이트로 수분을 제거한 후 용매를 감압 증발시켰다.  그 잔사를 (5~10 %) 메탄올/다이클로로메탄 용매계로 실리카겔 60 컬럼 크로마토그래피로 정제하여 700 mg(71 %)을 얻었다.</span>Dimethylsulfoxide (253 μl, 3.81 mmol) was added to anhydrous dichloromethane (40 mL) at −78 ° C., and oxalyl chloride (1.8 mL, mmol) was added, followed by (step 5) in Example 1 The resulting diastereomer B (1 g, 1.73 mmol) (or diastereomer A or a mixture of A and B) was added for 5 minutes. After 15 minutes triethylamine (574 μl, 0.87 mmol) was added at -78 ° C. After 5 minutes, the cooler was removed, and when the reaction mixture reached room temperature, distilled water was added, the organic solvent layer was fractionated, water was removed with sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel 60 column chromatography with (5-10%) methanol / dichloromethane solvent system to obtain 700 mg (71%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ -0.15 (s, 3H, Si-Me), 0.08 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.59 (s, 3H, Me), 2.30 (ddd, 1H, J=11, 11 Hz), 2.75 (ddd, 1H, J=3.6, 10, 10 Hz), 3.21 (dd, 1H, J=7, 11.3 Hz), 3.80 (m, 1H), 3.89 (s, 3H, OMe), 4.16 (dd, 1H, J=1.5, 9.4 Hz), 4.26 (dd, 1H, J=5.2, 10.7 Hz), 4.46 (dd, 1H, 4, 10.6 Hz), 5.10 (s, 1H), 6.96 (d, 2H, J=8.8 Hz), 7.17 - 7.41 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ -0.15 (s, 3H, Si-Me), 0.08 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.59 (s, 3H, Me) , 2.30 (ddd, 1H, J = 11, 11 Hz), 2.75 (ddd, 1H, J = 3.6, 10, 10 Hz), 3.21 (dd, 1H, J = 7, 11.3 Hz), 3.80 (m, 1H ), 3.89 (s, 3H, OMe), 4.16 (dd, 1H, J = 1.5, 9.4 Hz), 4.26 (dd, 1H, J = 5.2, 10.7 Hz), 4.46 (dd, 1H, 4, 10.6 Hz) , 5.10 (s, 1 H), 6.96 (d, 2H, J = 8.8 Hz), 7.17-7.41 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2)   (3S,4S,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-하이드록시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 2) (3S, 4S, 5R, 6R) -N-benzhydryl-3-tertbutyldimethylsilyloxy-4-hydroxy-5,6-O-[(4-methoxyphenyl) ethyl Liden] Piperidine Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">질소하 실온에서 엘-셀렉트라이드(23.2 mL, 23.2 mmol)를 무수 테트라하이드로퓨란(tetrahydrofuran)에 녹인 상기 (단계 1) 표제화합물(3.3 g, 5.8 mmol)에 첨가한 후 17시간 동안 교반하였다.  반응이 완료되면 증류수를 첨가하고 메틸렌클로라이드를 사용하여 유기용매층을 분획한 다음, 소듐 설페이트로 수분을 제거하고 용매를 감압 증발시켰다.  그 잔사를 (5~10 %)에틸아세테이트/핵산 용매계로 실리카겔 60 컬럼크로마토그래피로 정제하여 2.2 g(66 %)을 얻었다.</span>El-selectide (23.2 mL, 23.2 mmol) dissolved in anhydrous tetrahydrofuran (step 1) was added to the title compound (3.3 g, 5.8 mmol) in anhydrous tetrahydrofuran at room temperature under nitrogen, followed by stirring for 17 hours. After the reaction was completed, distilled water was added and the organic solvent layer was partitioned using methylene chloride. Then, water was removed with sodium sulfate and the solvent was evaporated under reduced pressure. The residue was purified by silica gel 60 column chromatography with (5-10%) ethyl acetate / nucleic acid solvent to give 2.2 g (66%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ -0.36 (s, 3H), 0.03 (s, 3H), 0.84 (s, 9H), 1.58 (s, 3H), 2.29 (dd, 1H, J=10.5, 10.5 Hz), 2.54 (dd, 1H, J=4.8, 11 Hz), 2.89 (ddd, 1H, J=4.2, 10.5, 10.5 Hz), 3.55 (dd, 1H, J=2.5, 9 Hz), 3.61 (dd, 1H, J=10.5, 10.5 Hz), 3.74 (ddd, 1H, J=2.9, 4.7, 10.4 Hz), 3.87 (s, 1H), 4.45 (dd, 1H, J=4.3, 10.4 Hz), 4.95 (s, 1H), 6.97 (d, 2H, J=8.7 Hz), 7,17∼7.39 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ -0.36 (s, 3H), 0.03 (s, 3H), 0.84 (s, 9H), 1.58 (s, 3H), 2.29 (dd, 1H, J = 10.5, 10.5 Hz) , 2.54 (dd, 1H, J = 4.8, 11 Hz), 2.89 (ddd, 1H, J = 4.2, 10.5, 10.5 Hz), 3.55 (dd, 1H, J = 2.5, 9 Hz), 3.61 (dd, 1H , J = 10.5, 10.5 Hz), 3.74 (ddd, 1H, J = 2.9, 4.7, 10.4 Hz), 3.87 (s, 1H), 4.45 (dd, 1H, J = 4.3, 10.4 Hz), 4.95 (s, 1H), 6.97 (d, 2H, J = 8.7 Hz), 7,17-7.39 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) (3S,4S,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 3) (3S, 4S, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-4-methoxy-5,6-O-[(4-methoxyphenyl) ethyl Liden] Piperidine Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 6)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 6) of Example 1 using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ -0.03 (s, 3H, Si-Me), 0.03 (s, 3H, Si-Me), 0.85 (s, 9H, Si-tBu), 1.58 (s, 3H, Me), 2.33 (dd, 1H, J=11, 11 Hz), 2.51 (dd, 1H, J=4.4, 11 Hz), 2.78 (ddd, 1H, J=4.2, 10.4, 10.4 Hz), 3.47 (dd, 1H, J=2.3 9.4 Hz), 3.57 (m, 2H), 3.59 (s, 3H, OMe), 3.69 (ddd, 1H, J=2.6, 4.5, 4.5 Hz), 3.87 (s, 3H, OMe), 4.41 (dd, 1H, J=4.2 10.5 Hz), 4.93 (s, 1H), 6.96 (d, 2H, J=8.8 Hz), 7.17 - 7.38 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ -0.03 (s, 3H, Si-Me), 0.03 (s, 3H, Si-Me), 0.85 (s, 9H, Si-tBu), 1.58 (s, 3H, Me) , 2.33 (dd, 1H, J = 11, 11 Hz), 2.51 (dd, 1H, J = 4.4, 11 Hz), 2.78 (ddd, 1H, J = 4.2, 10.4, 10.4 Hz), 3.47 (dd, 1H , J = 2.3 9.4 Hz), 3.57 (m, 2H), 3.59 (s, 3H, OMe), 3.69 (ddd, 1H, J = 2.6, 4.5, 4.5 Hz), 3.87 (s, 3H, OMe), 4.41 (dd, 1H, J = 4.2 10.5 Hz), 4.93 (s, 1H), 6.96 (d, 2H, J = 8.8 Hz), 7.17-7.38 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4)  (3S,4S,5R,6R)-N-벤즈하이드릴-3-하이드록시-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 4) (3S, 4S, 5R, 6R) -N-benzhydryl-3-hydroxy-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 7)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 7) of Example 1 using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.53 (s, 3H, Me), 2.03 (dd, 1H, J=10.5, 10.5 Hz), 2.74 (ddd, 1H, J=5.4, 11, 11 Hz), 2.78 (m, 1H), 3.55 - 3.68 (m, 4H), 3.64 (s, 3H, OMe), 3.87 (s, 3H, OMe), 4.44 (dd, 1H, J=4.3, 10.4 Hz), 4.93 (s, 1H), 6.95 (d, 2H, J=8.8 Hz), 7.17 - 7.39 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.53 (s, 3H, Me), 2.03 (dd, 1H, J = 10.5, 10.5 Hz), 2.74 (ddd, 1H, J = 5.4, 11, 11 Hz), 2.78 (m , 1H), 3.55-3.68 (m, 4H), 3.64 (s, 3H, OMe), 3.87 (s, 3H, OMe), 4.44 (dd, 1H, J = 4.3, 10.4 Hz), 4.93 (s, 1H ), 6.95 (d, 2H, J = 8.8 Hz), 7.17-7.39 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5) (3S,4S,5R,6R)-N-벤즈하이드릴-3-메탄설폭시-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 5) (3S, 4S, 5R, 6R) -N-benzhydryl-3-methanesulfoxy-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperi Dean's Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 4)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 8)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 8) using the title compound prepared in (Step 4).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.57 (s, 3H, Me), 2.52 (dd, 1H, J=10.8, 10.8 Hz), 2.75 (dd, 1H, J=5, 10.7 Hz), 2.84 (ddd, 1H, J=6, 9.6, 9.6 Hz), 2.97 (s, 3H, OMs), 3.57 (d, 1H, J=10.2 Hz), 3.56 (m, 1H), 3.57 (s, 3H, OMe), 3.88 (s, 3H, OMe), 3.94 (m, 1H), 4.44 (dd, 1H, J=4.3, 10.4 Hz), 4.66 (ddd, 1H, J=2.8, 4.6, 10.9 Hz), 4.97 (s, 1H), 6.98 (d, 2H, J=8.8 Hz), 7.16 - 7.40 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.57 (s, 3H, Me), 2.52 (dd, 1H, J = 10.8, 10.8 Hz), 2.75 (dd, 1H, J = 5, 10.7 Hz), 2.84 (ddd, 1H , J = 6, 9.6, 9.6 Hz), 2.97 (s, 3H, OMs), 3.57 (d, 1H, J = 10.2 Hz), 3.56 (m, 1H), 3.57 (s, 3H, OMe), 3.88 ( s, 3H, OMe), 3.94 (m, 1H), 4.44 (dd, 1H, J = 4.3, 10.4 Hz), 4.66 (ddd, 1H, J = 2.8, 4.6, 10.9 Hz), 4.97 (s, 1H) , 6.98 (d, 2H, J = 8.8 Hz), 7.16-7.40 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 6) {(3R,4S,5R,6R)-N-벤즈하이드릴-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 6) {(3R, 4S, 5R, 6R) -N-benzhydryl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidin-3-yl } Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 5)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 9)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 9) of Example 1, using the title compound prepared in (Step 5).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.56 (s, 3H, Me), 2.72 (m, 2H), 3.03 (ddd, 1H, J=4.2, 10, 10 Hz), 3.42 (m, 1H), 3.45 (s, 3H, OMe), 3.69 (dd, 1H, J=10.6, 10.6 Hz), 3.76 (m, 1H), 3.86 (s, 3H, OMe), 4.52 (dd, 1H, J=4, 10.4 Hz), 4.90 (m, 1H), 5.04 (s, 1H), 6.98 (d, 2H, J=8.7 Hz), 7.15 - 7.43 (m, 12H), 7.94 (s, 1H), 8.37 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.56 (s, 3H, Me), 2.72 (m, 2H), 3.03 (ddd, 1H, J = 4.2, 10, 10 Hz), 3.42 (m, 1H), 3.45 (s , 3H, OMe), 3.69 (dd, 1H, J = 10.6, 10.6 Hz), 3.76 (m, 1H), 3.86 (s, 3H, OMe), 4.52 (dd, 1H, J = 4, 10.4 Hz), 4.90 (m, 1H), 5.04 (s, 1H), 6.98 (d, 2H, J = 8.7 Hz), 7.15-7.43 (m, 12H), 7.94 (s, 1H), 8.37 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 7) 6-N-벤조일-{(3R,4S,5R,6R)-N-벤즈하이드릴-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 7) 6-N-benzoyl-{(3R, 4S, 5R, 6R) -N-benzhydryl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 6)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 10)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 10) of Example 1 using the title compound prepared in (Step 6).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.56 (s, 3H, Me), 2.76 (m, 2H), 3.07 (ddd, 1H, J=4.2, 10, 10 Hz), 3.48 (s, 3H, OMe), 3.69 (dd, 1H, J=10.6, 10.6 Hz), 3.79 (m, 2H), 3.90 (s, 3H, OMe), 4.52 (m, 1H), 4.98 (m, 1H), 5.05 (s, 1H), 7.00 (d, 2H, J=8.6 Hz), 7.18 - 7.56 (m, 15H), 8.04 (d, 2H, J=8.5 Hz), 8.17 (s, 1H), 8.81 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.56 (s, 3H, Me), 2.76 (m, 2H), 3.07 (ddd, 1H, J = 4.2, 10, 10 Hz), 3.48 (s, 3H, OMe), 3.69 (dd, 1H, J = 10.6, 10.6 Hz), 3.79 (m, 2H), 3.90 (s, 3H, OMe), 4.52 (m, 1H), 4.98 (m, 1H), 5.05 (s, 1H), 7.00 (d, 2H, J = 8.6 Hz), 7.18-7.56 (m, 15H), 8.04 (d, 2H, J = 8.5 Hz), 8.17 (s, 1H), 8.81 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 8) 6-N-벤조일-{(3R,4S,5R,6R)-N-벤즈하이드릴-5-하이드록시-6-하이드록시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 8) 6-N-benzoyl-{(3R, 4S, 5R, 6R) -N-benzhydryl-5-hydroxy-6-hydroxymethyl-4-methoxypiperidin-3-yl} adenine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 7)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 7).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.93 (d, 1H, J=9.6 Hz), 2.99 (dd, 1H, J=3.9, 10.9 Hz), 3.20 (s, 3H, OMe), 3.88 (dd, 1H, 3.4, 3.4 Hz), 4.16 (dd, 1H, J=10.7, 10.7 Hz), 4.26 (dd, 1H, J=3.8, 12.2 Hz), 5.08 (dd, 1H, J=4, 9.5 Hz), 5.48 (s, 1H), 7.18 - 7.40 (m, 10H), 7.53 (t, 2H, J=7 Hz), 7.61 (d, 1H, J=7.1 Hz), 8.06 (d, 2H, J=7.3 Hz), 8.03 (s, 1H), 8.80 (s, 1H)).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.93 (d, 1H, J = 9.6 Hz), 2.99 (dd, 1H, J = 3.9, 10.9 Hz), 3.20 (s, 3H, OMe), 3.88 (dd, 1H, 3.4 , 3.4 Hz), 4.16 (dd, 1H, J = 10.7, 10.7 Hz), 4.26 (dd, 1H, J = 3.8, 12.2 Hz), 5.08 (dd, 1H, J = 4, 9.5 Hz), 5.48 (s , 1H), 7.18-7.40 (m, 10H), 7.53 (t, 2H, J = 7 Hz), 7.61 (d, 1H, J = 7.1 Hz), 8.06 (d, 2H, J = 7.3 Hz), 8.03 (s, 1 H), 8.80 (s, 1 H)).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 9) 6-N-벤조일-{(3R,4S,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 9) 6-N-benzoyl-{(3R, 4S, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidine-3- Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 8)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 8).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.89 (m, 1H), 3.01 (m, 1H), 3.18 (m, 2H), 3,23 (s, 3H, OMe), 3.58 - 3.66 (m 2H), 3.82 (s, 6H, OMe), 4.36 (m 1H), 4.85 (m, 1H), 5.14 (m, 1H), 6.85 (d, 2H, J=8.9 Hz), 6.86 (d, 2H, J=8.8 Hz), 7.11 - 7.47 (m, 20H), 7.54 (t, 2H, J=7.5 Hz), 7.61 (d, 1H, J=7.3 Hz), 8.07 (d, 3H, J=7.9 Hz), 8.80 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.89 (m, 1H), 3.01 (m, 1H), 3.18 (m, 2H), 3,23 (s, 3H, OMe), 3.58-3.66 (m 2H), 3.82 ( s, 6H, OMe), 4.36 (m 1H), 4.85 (m, 1H), 5.14 (m, 1H), 6.85 (d, 2H, J = 8.9 Hz), 6.86 (d, 2H, J = 8.8 Hz) , 7.11-7.47 (m, 20H), 7.54 (t, 2H, J = 7.5 Hz), 7.61 (d, 1H, J = 7.3 Hz), 8.07 (d, 3H, J = 7.9 Hz), 8.80 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 10) 6-N-벤조일-{(3R,4S,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 10) 6-N-benzoyl-{(3R, 4S, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Preparation of oxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 9)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 13) using the title compound prepared in (Step 9).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.99 (d, 6H, J=6.6 Hz), 1.22 (d, 6H, J=6.6 Hz), 1.28 (d, 6H, J=6.8 Hz), 1.29 (d, 6H, J=6.8 Hz), 2.57 (m, 2H), 2.77 (dd, 2H, J=6.4, 6.8 Hz), 2.84 (m, 1H), 3.00 (m, 1H), 3.36 (s, 3H, OMe), 3.44 - 3.66 (m, 4H), 3.75 (m, 1H), 3.83 (s, 6H, OMe), 3.84 (s, 6H, OMe), 4.13 - 4.17 (m, 2H), 4.45 (m, 1H), 4.55 (d, 1H, J=10 Hz), 5.16 (m, 1H), 6.87 (d, 4H, J=7.4 Hz), 7.13 - 7.43 (m, 21H), 7.55 (t, 2H, J=7 Hz), 7.62 (d, 1H, J=7 Hz), 8.10 (d, 2H, J=7.3 Hz), 8.73 (s, 1H), 9.18 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.99 (d, 6H, J = 6.6 Hz), 1.22 (d, 6H, J = 6.6 Hz), 1.28 (d, 6H, J = 6.8 Hz), 1.29 (d, 6H, J = 6.8 Hz), 2.57 (m, 2H), 2.77 (dd, 2H, J = 6.4, 6.8 Hz), 2.84 (m, 1H), 3.00 (m, 1H), 3.36 (s, 3H, OMe), 3.44-3.66 (m, 4H), 3.75 (m, 1H), 3.83 (s, 6H, OMe), 3.84 (s, 6H, OMe), 4.13-4.17 (m, 2H), 4.45 (m, 1H), 4.55 (d, 1H, J = 10 Hz), 5.16 (m, 1H), 6.87 (d, 4H, J = 7.4 Hz), 7.13-7.43 (m, 21H), 7.55 (t, 2H, J = 7 Hz ), 7.62 (d, 1H, J = 7 Hz), 8.10 (d, 2H, J = 7.3 Hz), 8.73 (s, 1H), 9.18 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 153.08</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 153.08</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 6〉 6-N-벤조일-{(3S,4S,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-에톡시피페리딘-3-일}아데닌의 제조</span>Example 6 6-N-benzoyl-{(3S, 4S, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethyl-4-ethoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) (3S,4S,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘 의 제조</span>(Step 1) (3S, 4S, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethyl Preparation of Liden] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 실시예 5의 단계 2에서 얻어진 화합물을 이용하여 실시예 1의 (단계 6)과 같은 과정으로 아이오도에탄(EtI)을 사용하여 제조하였다.</span>This compound was prepared using iodoethane (EtI) in the same manner as in (Step 6) of Example 1, using the compound obtained in Step 2 of Example 5.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ -0.05 (s, 3H, Si-Me), 0.01 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.18 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.51 (s, 3H, Me), 2.34 (dd, 1H, J=11.2, 11.2 Hz), 2.50 (dd, 1H, J=5, 10 Hz), 2.84 (ddd, 1H, J=4, 10, 10 Hz), 3.46 (dd, 1H, J=9.3 Hz), 3.56 (dd, 1H, J=10.4, 10.4 Hz), 3.67 (m 2H), 3.81 (q, 2H, J=7 Hz), 3.87 (s, 3H, OMe), 4.40 (dd, 1H, J=4, 10.4 Hz), 4.91 (s, 1H), 6.98 (d, 2H, J=8.7 Hz), 7.17 - 7.38 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ -0.05 (s, 3H, Si-Me), 0.01 (s, 3H, Si-Me), 0.83 (s, 9H, Si-tBu), 1.18 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.51 (s, 3H, Me), 2.34 (dd, 1H, J = 11.2, 11.2 Hz), 2.50 (dd, 1H, J = 5, 10 Hz), 2.84 (ddd, 1H, J = 4, 10, 10 Hz), 3.46 (dd, 1H, J = 9.3 Hz), 3.56 (dd, 1H, J = 10.4, 10.4 Hz), 3.67 (m 2H), 3.81 (q, 2H, J = 7 Hz), 3.87 (s, 3H, OMe), 4.40 (dd, 1H, J = 4, 10.4 Hz), 4.91 (s, 1H), 6.98 (d, 2H, J = 8.7 Hz), 7.17- 7.38 (m, 12 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2)   (3S,4S,5R,6R)-N-벤즈하이드릴-3-하이드록시-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 2) (3S, 4S, 5R, 6R) -N-benzhydryl-3-hydroxy-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 7)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 7) of Example 1, using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.18 (t, 3H, J=7.2 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.52 (s, 3H, Me), 2.04 (dd, 1H, J=11, 11 Hz), 2.72 (dd, 1H, J=5, 11 Hz), 2.80 (m, 1H), 3.53∼3.77 (m, 3H), 3.77 (dd, 1H, J=3, 3 Hz), 3.87 (s, 3H), 4.10 (m, 2H), 4.43 (dd, 1H, J=4, 10 Hz), 4.92 (s, 1H), 6.96 (d, 2H, J=8.8 Hz), 7.17∼7.39 (m, 12H)</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.18 (t, 3H, J = 7.2 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.52 (s, 3H, Me), 2.04 (dd, 1H, J = 11, 11 Hz), 2.72 ( dd, 1H, J = 5, 11 Hz), 2.80 (m, 1H), 3.53-3.77 (m, 3H), 3.77 (dd, 1H, J = 3, 3 Hz), 3.87 (s, 3H), 4.10 (m, 2H), 4.43 (dd, 1H, J = 4, 10 Hz), 4.92 (s, 1H), 6.96 (d, 2H, J = 8.8 Hz), 7.17-7.39 (m, 12H)</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) (3S,4S,5R,6R)-N-벤즈하이드릴-3-메탄설포닐-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 3) (3S, 4S, 5R, 6R) -N-benzhydryl-3-methanesulfonyl-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperi Dean's Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 8)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 8) of Example 1, using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.17 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.62 (s, 3H, Me), 2.56 (dd, 1H, J=11, 11 Hz), 2.76 (dd, 1H, J=5, 10 Hz), 2.91 (m, 1H), 2.95 (s, 3H, OMs), 3.58 (m, 1H), 3.59 (dd, 1H, J=11, 11 Hz), 3.74 (dq, 1H, J=3, 7Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.87 (s, 3H, OMe), 3.93 (dq, 1H, J=3, 7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 4.03 (m, 1H), 4.39 (m, 1H), 4.65 (m, 1H), 4.96 (s, 1H), 6.97 (d, 2H, J=12.7 Hz), 7.18∼7.41 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.17 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.62 (s, 3H, Me), 2.56 (dd, 1H, J = 11, 11 Hz), 2.76 ( dd, 1H, J = 5, 10 Hz), 2.91 (m, 1H), 2.95 (s, 3H, OMs), 3.58 (m, 1H), 3.59 (dd, 1H, J = 11, 11 Hz), 3.74 (dq, 1H, J = 3, 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.87 (s, 3H, OMe), 3.93 (dq, 1H, J = 3, 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 4.03 (m, 1H ), 4.39 (m, 1H), 4.65 (m, 1H), 4.96 (s, 1H), 6.97 (d, 2H, J = 12.7 Hz), 7.18-7.41 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4)  {(3R,4S,5R,6R)-N-벤즈하이드릴-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 4) {(3R, 4S, 5R, 6R) -N-benzhydryl-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidin-3-yl } Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 9)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 9) of Example 1 using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.02 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.53 (s, 3H, Me),  2.73 (m, 1H), 2.77 (d, 1H, J=12.4 Hz), 3.06 (ddd, 1H, J=4, 9, 9 Hz), 3.33 (dq, 1H, J=7, 11.8 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.68 (dd, 1H, J=11, 11 Hz), 3.84∼3.93 (m, 3H), 3.86 (s, 3H, OMe), 4.49 (dd, 1H, J=4.2, 10.5 Hz), 4.89 (ddd, 1H, J=2.4, 5, 11.3 Hz), 5.03 (s, 1H), 6.99 (d, 2H, J=8.7 Hz), 7.15∼7.43 (m, 12H), 7.96 (s, 1H), 8.38 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.02 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.53 (s, 3H, Me), 2.73 (m, 1H), 2.77 (d, 1H, J = 12.4 Hz), 3.06 (ddd, 1H, J = 4, 9, 9 Hz), 3.33 (dq, 1H, J = 7, 11.8 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.68 (dd, 1H, J = 11, 11 Hz ), 3.84 to 3.93 (m, 3H), 3.86 (s, 3H, OMe), 4.49 (dd, 1H, J = 4.2, 10.5 Hz), 4.89 (ddd, 1H, J = 2.4, 5, 11.3 Hz), 5.03 (s, 1H), 6.99 (d, 2H, J = 8.7 Hz), 7.15-7.43 (m, 12H), 7.96 (s, 1H), 8.38 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5) 6-N-벤조일-{(3R,4S,5R,6R)-N-벤즈하이드릴-4-에톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 5) 6-N-benzoyl-{(3R, 4S, 5R, 6R) -N-benzhydryl-4-ethoxy-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 4)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 10)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 10) of Example 1 using the title compound prepared in (Step 4).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.04 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.55 (s, 3H, Me), 2.77 (m, 2H), 3.04 (m, 1H), 3.39 (dd, 1H, J=7, 10 Hz), 3.70 (dd, 1H, J=10.5, 10.5 Hz), 3.87 (m, 2H), 3.90 (s, 3H, OMe), 3.96 (dd, 1H, J=7.2, 9.5 Hz), 4.50 (dd, 1H, J=4.2, 10.5 Hz), 4.99 (m, 1H), 5.05 (s, 1H), 6.99 (d, 2H, J=8.7 Hz), 7.17∼7.56 (m, 15H), 8.03 (d, 2H, J=7 Hz), 8.19 (s, 1H), 8.82 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.04 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 1.55 (s, 3H, Me), 2.77 (m, 2H), 3.04 (m, 1H), 3.39 ( dd, 1H, J = 7, 10 Hz), 3.70 (dd, 1H, J = 10.5, 10.5 Hz), 3.87 (m, 2H), 3.90 (s, 3H, OMe), 3.96 (dd, 1H, J = 7.2, 9.5 Hz), 4.50 (dd, 1H, J = 4.2, 10.5 Hz), 4.99 (m, 1H), 5.05 (s, 1H), 6.99 (d, 2H, J = 8.7 Hz), 7.17 to 7.56 ( m, 15H), 8.03 (d, 2H, J = 7 Hz), 8.19 (s, 1H), 8.82 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 6) 6-N-벤조일-{(3R,4S,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-하이드록시메틸-4-에톡시피페리딘-3-일}아데닌의 제조</span>(Step 6) 6-N-benzoyl-{(3R, 4S, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-hydroxymethyl-4-ethoxypiperidin-3-yl} adenine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 5)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 5).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.96 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 2.91 - 3.18 (m, 3H), 3.19 (dq, 1H, J=7, 7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.38 (dq, 1H, J=7, 9.3 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.98 (m, 1H), 4.14 (d, 1H, J=11.7 Hz), 4.16 (m, 1H), 4.25 (dd, 1H, J=3.7, 11.9 Hz), 5.08 (m, 1H), 5.48 (s, 1H), 7.8 - 7.63 (m, 13H), 8.06 (d, 2H, J=7 Hz), 8.40 (s, 1H), 8.80 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.96 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 2.91-3.18 (m, 3H), 3.19 (dq, 1H, J = 7, 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.38 (dq, 1H, J = 7, 9.3 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 3.98 (m, 1H), 4.14 (d, 1H, J = 11.7 Hz), 4.16 (m, 1H), 4.25 ( dd, 1H, J = 3.7, 11.9 Hz), 5.08 (m, 1H), 5.48 (s, 1H), 7.8-7.63 (m, 13H), 8.06 (d, 2H, J = 7 Hz), 8.40 (s , 1H), 8.80 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 7) 6-N-벤조일-{(3R,4S,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸-4-에톡시피페리딘-3-일}아데닌의 제조</span>(Step 7) 6-N-benzoyl-{(3R, 4S, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethyl-4-ethoxypiperidine-3- Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 6)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 6).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.95 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 2.91 (dd, 1H, J=7, 11.7 Hz), 3.04 (m, 1H), 3.15 (m, 1H), 3.25 (m, 1H), 3.38 (m, 1H), 3.56 (m, 1H), 3.62 (m, 1H), 3.82 (s, 6H, OMe), 3.95 (dd, 1H, J=4, 4 Hz), 4.33 (m, 1H), 4.83 (s, 1H), 5.12 (m, 1H), 6.84 (d, 2H, J=9 Hz), 6.87 (d, 2H, J=9 Hz), 7.08 - 7.58 (m, 18H), 7.47 (d, 2H, J=7 Hz), 7.55 (t, 2H, J=7 Hz), 7.62 (d, 1H, J=7.2 Hz), 8.06 (d, 2H, J=7.4 Hz), 8.81 (s, 1H), 9.06 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.95 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ), 2.91 (dd, 1H, J = 7, 11.7 Hz), 3.04 (m, 1H), 3.15 (m, 1H), 3.25 (m, 1H), 3.38 (m, 1H), 3.56 (m, 1H), 3.62 (m, 1H), 3.82 (s, 6H, OMe), 3.95 (dd, 1H, J = 4, 4 Hz), 4.33 (m, 1H), 4.83 (s, 1H), 5.12 (m, 1H), 6.84 (d, 2H, J = 9 Hz), 6.87 (d, 2H, J = 9 Hz), 7.08 7.58 (m, 18H), 7.47 (d, 2H, J = 7 Hz), 7.55 (t, 2H, J = 7 Hz), 7.62 (d, 1H, J = 7.2 Hz), 8.06 (d, 2H, J = 7.4 Hz), 8.81 (s, 1 H), 9.06 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 8) 6-N-벤조일-{(3R,4S,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-에톡시피페리딘-3-일}아데닌의 제조</span>(Step 8) 6-N-benzoyl-{(3R, 4S, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Preparation of oxy] -6-dimethyltrityloxymethyl-4-ethoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 7)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 7).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.88 (t, 3H, J=7 Hz, OCH<sub>2</sub>CH<sub>3</sub>) 0.96 (d, 3H, J=7 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.20 (d, 3H, J=7 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.22∼1.30 (m, 6H, OMe), 1.97 (m, 1H), 2.29 (m, 1H), 2.53 (t, 1H), 2.84 (m, 1H), 2.90 (m, 1H), 3.02 (m, 1H), 3.50∼3.59 (m, 7H), 8.84 (s, 6H), 4.08 (m, 1H), 4.38 (m, 1H), 4.51 (m, 1H), 5.13 (m, 1H), 6.87 (d, 4H, J=7 Hz), 7.03∼7.40 (m, 19H), 7.56 (t, 2H, J=7.6 Hz), 7.62 (d, 1H, J=7.3 Hz), 8.10 (d, 2H, J=7 Hz), 8.81 (s, 1H), 9.14 (s, 1H)</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.88 (t, 3H, J = 7 Hz, OCH <sub>2</sub> CH <sub>3</sub> ) 0.96 (d, 3H, J = 7 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.20 (d, 3H, J = 7 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.22 to 1.30 (m, 6H, OMe), 1.97 (m, 1H), 2.29 (m, 1H), 2.53 (t, 1H), 2.84 (m, 1H) , 2.90 (m, 1H), 3.02 (m, 1H), 3.50 to 3.59 (m, 7H), 8.84 (s, 6H), 4.08 (m, 1H), 4.38 (m, 1H), 4.51 (m, 1H ), 5.13 (m, 1H), 6.87 (d, 4H, J = 7 Hz), 7.03-7.40 (m, 19H), 7.56 (t, 2H, J = 7.6 Hz), 7.62 (d, 1H, J = 7.3 Hz), 8.10 (d, 2H, J = 7 Hz), 8.81 (s, 1H), 9.14 (s, 1H)</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 153.32</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 153.32</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 7〉 6-N-벤조일-{(3R,4R,5R,6R)-N-메틸-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>Example 7 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-methyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy ] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) 6-N-벤조일-{(3R,4R,5R,6R)-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 1) Preparation of 6-N-benzoyl-{(3R, 4R, 5R, 6R) -6-hydroxymethyl-5-hydroxy-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 2의 (단계 10)에서 얻은 화합물(508 mg, 0.76 mmol)에 메틸렌클로라이드(15 mL) 트라이플루오르아세틱 산(15 mL)을 가하여 상온에서 4시간 동안 교반하였다.  반응물을 감압하에서 완전히 고체화시킨 후 이를 10 % - 25 % 메탄올/메틸렌클로라이드 용매를 써서 컬럼크로마티그래피로 정제하여 268 mg을 얻었다(수율 95 %).</span>Methylene chloride (15 mL) trifluoroacetic acid (15 mL) was added to the compound (508 mg, 0.76 mmol) obtained in Example 10 (step 10), and the mixture was stirred at room temperature for 4 hours. The reaction was completely solidified under reduced pressure and then purified by column chromatography using 10% -25% methanol / methylene chloride solvent to give 268 mg (yield 95%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 3.03 (s, 3H), 3.22 (m, 1H), 3.61 (dd. 1H, J=4.9, 12 Hz), 3.75 (dd, 1H, J= 9.3, 9.3 Hz), 3.77 (dd, 1H, J=12, 12 Hz), 3.88 (m, 2H), 4.07 (dd, 1H, J= 9, 9 Hz), 4.75 (m, 1H), 7.50 (t, 1H, J=7.3 Hz), 7.61 (d, 1H, J=7 Hz), 8.48 (s, 1H), 8.68 (s, 1H).</span> <sup>1</sup> H NMR (CD <sub>3</sub> OD) δ 3.03 (s, 3H), 3.22 (m, 1H), 3.61 (dd. 1H, J = 4.9, 12 Hz), 3.75 (dd, 1H, J = 9.3, 9.3 Hz) , 3.77 (dd, 1H, J = 12, 12 Hz), 3.88 (m, 2H), 4.07 (dd, 1H, J = 9, 9 Hz), 4.75 (m, 1H), 7.50 (t, 1H, J = 7.3 Hz), 7.61 (d, 1H, J = 7 Hz), 8.48 (s, 1H), 8.68 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 6-N-벤조일-{(3R,4R,5R,6R)-N-메틸-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 2) Preparation of 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-methyl-6-hydroxymethyl-5-hydroxy-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물(140 mg, 0.35 mmol)에 메틸아이오다이드(42 μL, 0.7 mmol)와 4-다이메틸아미노피리딘(촉매량), 트라이에틸아민(273 μL, 1.75 mmol)을 가하였다.  반응물을 상온에서 15시간 동안 교반한 후 감압 농축하였다.  잔사를 메틸렌클로라이드에 녹이고 불용성물질을 여과 제거한 후 감압 농축하였다. 잔사를 실리카젤 컬럼 크로마토그래피로 10 % - 25 % 메탄올/메틸렌클로라이드를 사용하여 정제하였다(69 mg, 48 %).</span>To the title compound (140 mg, 0.35 mmol) prepared in the above (Step 1), methyl iodide (42 μL, 0.7 mmol), 4-dimethylaminopyridine (catalyst amount), triethylamine (273 μL, 1.75 mmol) was added. The reaction was stirred at room temperature for 15 hours and then concentrated under reduced pressure. The residue was dissolved in methylene chloride, the insoluble substance was filtered off, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography using 10% -25% methanol / methylenechloride (69 mg, 48%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 2.13 (m, 1H), 2.47 (s, 3H, N-Me), 3.10 (dd, 1H, J=5, 11 Hz), 3.17 (s, 3H, OMe), 3.22 (m, 1H), 3.72 (dd, 1H, J=9.5, 9.5 Hz), 3.95 (m, 2H), 3.99 (dd, 1H, J=9, 9 Hz), 4.67 (ddd, 1H, J=4.5, 11, 11 Hz), 7.59 (t, 2H, J=7.1 Hz), 7.67 (d, 1H, J=7.3 Hz), 8.11 (d, 2H, J=7.2 Hz), 8.54 (s, 1H), 8.74 (s, 1H).</span> <sup>1</sup> H NMR (CD <sub>3</sub> OD) δ 2.13 (m, 1H), 2.47 (s, 3H, N-Me), 3.10 (dd, 1H, J = 5, 11 Hz), 3.17 (s, 3H, OMe), 3.22 (m, 1H), 3.72 (dd, 1H, J = 9.5, 9.5 Hz), 3.95 (m, 2H), 3.99 (dd, 1H, J = 9, 9 Hz), 4.67 (ddd, 1H, J = 4.5, 11, 11 Hz), 7.59 (t, 2H, J = 7.1 Hz), 7.67 (d, 1H, J = 7.3 Hz), 8.11 (d, 2H, J = 7.2 Hz), 8.54 (s, 1H) , 8.74 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 6-N-벤조일-{(3R,4R,5R,6R)-N-메틸-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 3) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-methyl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.22 (s, 3H, N-Me), 2.36 (m, 1H), 2.96 (d, 1H, J=2.5 Hz), 3.02 (dd, 1H, J=4.4, 11.2 Hz), 3.11 (s, 3H, OMe), 3.22 (dd, 1H, J=11.4, 11.5 Hz), 3.45 (dd, 1H, J=4.1, 10.1 Hz), 3.55 (dd, 1H, J=2.3, 8.7 Hz), 3.80 (s, 3H, OMe), 3.81 (s, 3H, OMe),3.97 (dd, 1H, J=8.6, 10.3 Hz), 4.56 (ddd, 1H, J=4.7, 11.3, 11.3 Hz), 6.88 (d, 4H, J=8.7 Hz), 7.17 - 7.65 (m, 12H), 8.00 (s, 1H), 8.05 (d, 2H, J=7.4 Hz), 8.84 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.22 (s, 3H, N-Me), 2.36 (m, 1H), 2.96 (d, 1H, J = 2.5 Hz), 3.02 (dd, 1H, J = 4.4, 11.2 Hz ), 3.11 (s, 3H, OMe), 3.22 (dd, 1H, J = 11.4, 11.5 Hz), 3.45 (dd, 1H, J = 4.1, 10.1 Hz), 3.55 (dd, 1H, J = 2.3, 8.7 Hz), 3.80 (s, 3H, OMe), 3.81 (s, 3H, OMe), 3.97 (dd, 1H, J = 8.6, 10.3 Hz), 4.56 (ddd, 1H, J = 4.7, 11.3, 11.3 Hz) , 6.88 (d, 4H, J = 8.7 Hz), 7.17-7.65 (m, 12H), 8.00 (s, 1H), 8.05 (d, 2H, J = 7.4 Hz), 8.84 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4) 6-N-벤조일-{(3R,4R,5R,6R)-N-메틸-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 4) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-methyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] Preparation of -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1, using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.04 (d, 3H, J=6.8 Hz), 1.08 (d, 3H, J=6.8 Hz), 2.32 (t, 2H, J=6.8 Hz), 2.76 (m, 1H), 2.91 (m, 1H), 3.00 (s, 3H, N-Me), 3.04 (m 1H), 3.15 (dd, 1H, J=7.3, 10.1 Hz), 3.30 - 3.70 (m, 5H), 3.81 (s, 6H, OMe), 3.83  (m, 1H), 4,23 (dd, 1H, J=3.8, 5.7 Hz), 4.55 (ddd, 1H, J=4, 9.2, 9.2 Hz), 6.84 (d, 2H, J=8.8 Hz), 6.87 (d, 2H, J=8.8 Hz), 7.21 - 7.62 (m, 12H), 8.05 (d, 2H, J=7.3 Hz), 8.18 (s, 1H), 8.86 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.04 (d, 3H, J = 6.8 Hz), 1.08 (d, 3H, J = 6.8 Hz), 2.32 (t, 2H, J = 6.8 Hz), 2.76 (m, 1H) , 2.91 (m, 1H), 3.00 (s, 3H, N-Me), 3.04 (m 1H), 3.15 (dd, 1H, J = 7.3, 10.1 Hz), 3.30-3.70 (m, 5H), 3.81 ( s, 6H, OMe), 3.83 (m, 1H), 4,23 (dd, 1H, J = 3.8, 5.7 Hz), 4.55 (ddd, 1H, J = 4, 9.2, 9.2 Hz), 6.84 (d, 2H, J = 8.8 Hz), 6.87 (d, 2H, J = 8.8 Hz), 7.21-7.62 (m, 12H), 8.05 (d, 2H, J = 7.3 Hz), 8.18 (s, 1H), 8.86 ( s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 151.14, 151.84 (major)</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 151.14, 151.84 (major)</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 8〉 6-N-벤조일-{(3R,4R,5R,6R)-N-프로필-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>Example 8 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-propyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy ] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) 6-N-벤조일-{(3R,4R,5R,6R)-N-프로필-5-하이드록시-6-하이드록시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 1) Preparation of 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-propyl-5-hydroxy-6-hydroxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">질소 하에서 실시예 7의 (단계 1)의 표제화합물(240 mg, 0.6 mmol)을 무수 아세트나이트릴(10 mL)에 녹인 후, 4-다이메틸아미노피리딘(소량), 트리에틸아민(0.83 mL, 6 mmol)과 n-프로필아이오다이드(300 ㎕, 3 mmol)를 첨가하였다.  이 반응물을 4시간 동안 가열환류시킨 후, 용매를 감압 하에서 증발시켰다.  그 잔사를 7 ~ 25 % 메탄올/다이클로로메탄 용매계를 사용하여 실리카겔 60 컬럼크로마토그래피 (CH<sub>2</sub>Cl<sub>2</sub>:MeOH =10:1)로 정제하여 트리에틸아민염과 함께 200 mg (45 %)을 얻었다.</span>The title compound of Example 7 (step 1) (240 mg, 0.6 mmol) was dissolved in anhydrous acetnitrile (10 mL) under nitrogen, and then 4-dimethylaminopyridine (small amount), triethylamine (0.83 mL, 6 mmol) and n-propyliodide (300 μl, 3 mmol) were added. After the reaction was heated to reflux for 4 hours, the solvent was evaporated under reduced pressure. The residue was purified by silica gel 60 column chromatography (CH <sub>2</sub> Cl <sub>2</sub> : MeOH = 10: 1) using a 7-25% methanol / dichloromethane solvent system to give 200 mg (45%) with triethylamine salt. Got it.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.90 (t, 3H, J=7.2 Hz, N-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.52 (m, 2H, N-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 2.54 (m, 2H), 2.75 (m, 1H), 3.05 (s, 3H, OMe), 3.17 (m, 1H), 3.33 (dd, 1H, J=11.4, 11.5 Hz), 3.83 (dd, 1H, J=9, 9 Hz), 3.90 - 4.10 (m, 3H), 4.50 (ddd, 1H, J=4.3, 10.6, 10.6 Hz) 7.54 (t, 2H, J=7.6 Hz), 7.62 (d, 1H, J=6.9 Hz), 8.05 (d, 2H, J=7.6 Hz), 8.06 (s, 1H), 8.82 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.90 (t, 3H, J = 7.2 Hz, N-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub> ), 1.52 (m, 2H, N-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub> ), 2.54 (m, 2H ), 2.75 (m, 1H), 3.05 (s, 3H, OMe), 3.17 (m, 1H), 3.33 (dd, 1H, J = 11.4, 11.5 Hz), 3.83 (dd, 1H, J = 9, 9 Hz), 3.90-4.10 (m, 3H), 4.50 (ddd, 1H, J = 4.3, 10.6, 10.6 Hz) 7.54 (t, 2H, J = 7.6 Hz), 7.62 (d, 1H, J = 6.9 Hz) , 8.05 (d, 2H, J = 7.6 Hz), 8.06 (s, 1H), 8.82 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 6-N-벤조일-{(3R,4R,5R,6R)-N-프로필-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 2) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-propyl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 12) of Example 1 using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.67 (t, 3H, J=7.3 Hz, N-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 1.32 (m, 2H, N-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 2.30 (m, 1H), 2.48 (m, 1H), 2.64 (m, 1H), 3.05 (m, 1H), 3.10 (s, 3H, OMe), 3.23 (dd, 1H, J=11.3, 11.3 Hz), 3.45 (dd, 1H, 3.7, 10.1 Hz), 3.53 (dd, 1H, J=3.3, 10.1 Hz), 3.80 (s, 6H, OMe), 3.82 (m, 1H), 3.93 (dd, 1H, J=8.6, 10 Hz), 4.52 (ddd, 1H, J=4.3, 10.7, 10.7 Hz) 6.86 (d, 4H, J=8.7 Hz), 7.21 - 7.64 (m, 15H), 8.03 (s, 1H), 8.04 (d, 2H, J=8.5 Hz), 8.82 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.67 (t, 3H, J = 7.3 Hz, N-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub> ), 1.32 (m, 2H, N-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub> ), 2.30 (m, 1H ), 2.48 (m, 1H), 2.64 (m, 1H), 3.05 (m, 1H), 3.10 (s, 3H, OMe), 3.23 (dd, 1H, J = 11.3, 11.3 Hz), 3.45 (dd, 1H, 3.7, 10.1 Hz), 3.53 (dd, 1H, J = 3.3, 10.1 Hz), 3.80 (s, 6H, OMe), 3.82 (m, 1H), 3.93 (dd, 1H, J = 8.6, 10 Hz ), 4.52 (ddd, 1H, J = 4.3, 10.7, 10.7 Hz) 6.86 (d, 4H, J = 8.7 Hz), 7.21-7.64 (m, 15H), 8.03 (s, 1H), 8.04 (d, 2H , J = 8.5 Hz), 8.82 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 6-N-벤조일-{(3R,4R,5R,6R)-N-프로필-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 3) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-propyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] Preparation of -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.85 (t, 3H, J=7 Hz, N-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 0.88 (t, 3H, J=7 Hz, N-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 0.94 (d, 6H, J=6.7 Hz, NCH(CH<sub>3</sub>)<sub>2</sub>), 1.07 (d, 6H, J=6.7 Hz, NCH(CH<sub>3</sub>)<sub>2</sub>), 1.14 (d, 6H, J=6.8 Hz, NCH(CH<sub>3</sub>)<sub>2</sub>), 1.18 (d, 6H, J=6.8 Hz, NCH(CH<sub>3</sub>)<sub>2</sub>), 2.33 (t, 4H, J=6.3 Hz), 2.40 - 2.57 (m, 4H), 2.75 (t, 2H, J=6 Hz), 2.82 (m, 1H), 2.87 (m, 1H), 3.08 (m, 1H), 3.13 (m, 1H), 3.22 (s, 3H, OMe), 3.26 - 3.69 (m, 14H), 3.31 (s, 3H, OMe), 3.81 (s, 6H, OMe), 4.23 (m, 3H),  4.29 (m, 1H), 4.33 (m, 1H), 4.63 (m, 1H), 4.74 (m, 2H), 6.84 (d, 4H, J=8.8 Hz), 6.85 (d, 4H, J=8.8 Hz), 7.21 - 7.64 (m, 24H), 8.05 (d, 2H, J=8.6 Hz), 8.64 (s, 1H), 8.80 (s, 1H), 8.81 (s, 1H), 8.92 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.85 (t, 3H, J = 7 Hz, N-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub> ), 0.88 (t, 3H, J = 7 Hz, N-CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub> ), 0.94 (d, 6H, J = 6.7 Hz, NCH (CH <sub>3</sub> ) <sub>2</sub> ), 1.07 (d, 6H, J = 6.7 Hz, NCH (CH <sub>3</sub> ) <sub>2</sub> ), 1.14 (d, 6H, J = 6.8 Hz, NCH (CH <sub>3</sub> ) <sub>2</sub> ), 1.18 (d, 6H, J = 6.8 Hz, NCH (CH <sub>3</sub> ) <sub>2</sub> ), 2.33 (t, 4H, J = 6.3 Hz), 2.40-2.57 (m, 4H), 2.75 (t , 2H, J = 6 Hz), 2.82 (m, 1H), 2.87 (m, 1H), 3.08 (m, 1H), 3.13 (m, 1H), 3.22 (s, 3H, OMe), 3.26-3.69 ( m, 14H), 3.31 (s, 3H, OMe), 3.81 (s, 6H, OMe), 4.23 (m, 3H), 4.29 (m, 1H), 4.33 (m, 1H), 4.63 (m, 1H) , 4.74 (m, 2H), 6.84 (d, 4H, J = 8.8 Hz), 6.85 (d, 4H, J = 8.8 Hz), 7.21-7.64 (m, 24H), 8.05 (d, 2H, J = 8.6 Hz), 8.64 (s, 1 H), 8.80 (s, 1 H), 8.81 (s, 1 H), 8.92 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 149.94, 150.64</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 149.94, 150.64</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 9〉 6-N-벤조일-{(3R,4R,5R,6R)-N-벤질-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>Example 9 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy ] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤질-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 1) Preparation of 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzyl-6-hydroxymethyl-5-hydroxy-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">질소 하에서 실시예 7의 (단계 1)의 표제화합물(300 mg, 0.78 mmol)을 무수 아세트나이트릴(10 mL)에 녹인 후, 여기에 4-다이메틸아미노피리딘(소량), 트리에틸아민(1.08 mL, 7.8 mmol) 및 벤질브로마이드(468 ㎕, 3.9 mmol)를 첨가하였다.  이 반응물을 4시간 동안 가열환류시킨 다음, 용매를 감압 하에서 증발시켰다.  잔사를 7 ~ 25 % 메탄올/다이클로로메탄 용매계를 사용하여 실리카겔 60 컬럼크로마토그래피(CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 15:1 ∼ 4:1)로 정제하여 66 mg(18 %)을 얻었다.</span>The title compound (300 mg, 0.78 mmol) of Example 7 (Step 1) under nitrogen was dissolved in anhydrous acetnitrile (10 mL), and then 4-dimethylaminopyridine (small amount) and triethylamine (1.08) were added. mL, 7.8 mmol) and benzylbromide (468 μl, 3.9 mmol) were added. The reaction was heated to reflux for 4 hours and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel 60 column chromatography (CH <sub>2</sub> Cl <sub>2</sub> : MeOH = 15: 1 to 4: 1) using a 7-25% methanol / dichloromethane solvent system to obtain 66 mg (18%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.84 - 2.97 (m 2H), 3.19 (dd, 1H, J=11.2, 11.2 Hz), 3.36 (m, 1H), 3.51 (s, 3H, OMe), 3.73 (d, 1H, J=9 Hz), 3.85 (ddd, 1H, 5, 9.2, 9.2 Hz), 3.99 (dd, 1H, J=9, 9 Hz), 4.09 (m, 2H), 4.32 (dd, 1H, J=6.7, 6.7 Hz) 7.23 - 7.45 (m, 8H), 7.94 (d, 2H, J=7.1 Hz), 8.04 (s, 1H), 8.41 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.84-2.97 (m 2 H), 3.19 (dd, 1H, J = 11.2, 11.2 Hz), 3.36 (m, 1H), 3.51 (s, 3H, OMe), 3.73 (d, 1H, J = 9 Hz), 3.85 (ddd, 1H, 5, 9.2, 9.2 Hz), 3.99 (dd, 1H, J = 9, 9 Hz), 4.09 (m, 2H), 4.32 (dd, 1H, J = 6.7, 6.7 Hz) 7.23-7.45 (m, 8H), 7.94 (d, 2H, J = 7.1 Hz), 8.04 (s, 1H), 8.41 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤질-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 2) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzyl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 12) of Example 1 using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.70 (m, 1H), 2.98 (dd, 1H, J=4.6, 11.6 Hz), 3.07 (s, 3H, OMe), 3.15 (m, 2H), 3.61 (m, 2H), 3.803 (s, 3H, OMe), 3.807 (s, 3H, OMe), 3.89 - 4.02 (m, 3H),  4.44 (ddd, 1H, J=4, 10, 10 Hz), 6.84 (d, 2H, J=8.9 Hz), 6.85 (d, 2H, J=8.9 Hz), 7.18 - 7.56 (m, 16H), 7.61 (d, 2H, J=7.2 Hz), 7.96 (s, 1H), 8.03 (d, 2H, J=7.2 Hz), 8.81 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.70 (m, 1H), 2.98 (dd, 1H, J = 4.6, 11.6 Hz), 3.07 (s, 3H, OMe), 3.15 (m, 2H), 3.61 (m, 2H ), 3.803 (s, 3H, OMe), 3.807 (s, 3H, OMe), 3.89-4.02 (m, 3H), 4.44 (ddd, 1H, J = 4, 10, 10 Hz), 6.84 (d, 2H) , J = 8.9 Hz), 6.85 (d, 2H, J = 8.9 Hz), 7.18-7.56 (m, 16H), 7.61 (d, 2H, J = 7.2 Hz), 7.96 (s, 1H), 8.03 (d , 2H, J = 7.2 Hz), 8.81 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤질-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 3) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] Preparation of -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.96 (d, 3H, J=6.7 Hz), 1.08 (d, 3H, J=6.7 Hz), 1.12 (d, 3H, J=7 Hz), 1.14 (d, 3H, J=7 Hz), 2.37 (t, 1H, J=6.3 Hz), 2.43 (t, 1H, J=6.4 Hz), 2.80 (m, 1H), 3.34 (s, 3H, OMe), 3.10 - 3.79 (m, 10H), 3.81 (s, 3H, OMe), 3.82 (s, 3H, OMe), 4.32 (m, 1H), 4.58 (m, 1H), 4.73 (m, 1H), 6.84 (d, 4H, J=8.9 Hz), 7.21 - 7.64 (m, 18H), 8.04 (d, 2H, J=7.4 Hz), 8.42 (s, 1H), 8.82 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.96 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz), 1.12 (d, 3H, J = 7 Hz), 1.14 (d, 3H, J = 7 Hz), 2.37 (t, 1H, J = 6.3 Hz), 2.43 (t, 1H, J = 6.4 Hz), 2.80 (m, 1H), 3.34 (s, 3H, OMe), 3.10-3.79 ( m, 10H), 3.81 (s, 3H, OMe), 3.82 (s, 3H, OMe), 4.32 (m, 1H), 4.58 (m, 1H), 4.73 (m, 1H), 6.84 (d, 4H, J = 8.9 Hz), 7.21-7.64 (m, 18H), 8.04 (d, 2H, J = 7.4 Hz), 8.42 (s, 1H), 8.82 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 150.53</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 150.53</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 10〉  6-N-벤조일-{(3R,4R,5R,6R)-N-(4-시아노벤질)-5-[(2-아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3 -일}아데닌의 제조</span>Example 10 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-cyanobenzyl) -5-[(2-anoethoxy) (N, N-diisopropyl Preparation of Amino) phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-시아노벤질)-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 1) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-cyanobenzyl) -6-hydroxymethyl-5-hydroxy-4-methoxypiperidine-3 Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 7의 (단계 1)의 표제화합물(450 mg, 1.17 mmol)을 무수 아세트나이트릴(40 mL)에 녹이고, α-브로모-p-톨루나이트라일(1 g, 5.85 mmol), 트라이에틸아민(1.62 mL, 10.7 mmol), 및 다이메틸아미노피리딘(소량)을 가하였다.  반응물을 상온에서 14시간동안 교반시킨 후 감압응축하고 잔사를 실리카젤로 컬럼크로마티그래피하여 (5 - 25 % 메탄올/메틸렌클로라이드) 200 mg의 화합물을 얻었다(32 %).</span>The title compound (450 mg, 1.17 mmol) of (step 1) of Example 7 was dissolved in anhydrous acetnitrile (40 mL), and α-bromo-p-tolunatriyl (1 g, 5.85 mmol), triethyl Amine (1.62 mL, 10.7 mmol), and dimethylaminopyridine (small amount) were added. The reaction was stirred at room temperature for 14 hours, and then condensed under reduced pressure, and the residue was purified by column chromatography with silica gel (5-25% methanol / methylene chloride) to obtain 200 mg of the compound (32%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.63 (m, 1H), 2.92 (dd, 1H, J=4.2, 11.3 Hz), 3.07 (s, 3H, OMe), 3.23 (m, 1H), 3.43 (d, 1H, J=14.2 Hz), 3.90 (dd, 1H, J=9, 9 Hz), 3.97 - 4.16 (m, 4H), 4.33 (d, 1H, J=14.3 Hz), 4.44 (ddd, 1H, J=4, 10.6, 10.6 Hz), 7.46  (m, 2H), 7.52 (d, 2H, J=7.7 Hz), 7.59 (d, 3H, J=8.3 Hz), 8.01 (d, 2H, J=9.8 Hz), 8.03 (s, 1H), 8.76 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.63 (m, 1H), 2.92 (dd, 1H, J = 4.2, 11.3 Hz), 3.07 (s, 3H, OMe), 3.23 (m, 1H), 3.43 (d, 1H , J = 14.2 Hz), 3.90 (dd, 1H, J = 9, 9 Hz), 3.97-4.16 (m, 4H), 4.33 (d, 1H, J = 14.3 Hz), 4.44 (ddd, 1H, J = 4, 10.6, 10.6 Hz), 7.46 (m, 2H), 7.52 (d, 2H, J = 7.7 Hz), 7.59 (d, 3H, J = 8.3 Hz), 8.01 (d, 2H, J = 9.8 Hz) , 8.03 (s, 1 H), 8.76 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-시아노벤질)-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 2) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-cyanobenzyl) -5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperi Din-3-yl} adenine preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.75 (m, 1H), 2.86 (dd, 1H, J=4.5, 11.2 Hz), 3.07 (s, 3H, OMe), 3.20 (dd, 1H, J=5.4, 11 Hz), 3.30 (dd, 1H, J=5.7, 8 Hz), 3.57 (m, 2H), 3.788 (s, 3H, OMe), 3.794 (s, 3H, OMe), 3.88 (dd, 1H, J=9, 9 Hz), 3.97 (m, 2H),  4.39 (ddd, 1H, J=4, 10, 10 Hz), 6.80 (d, 2H, J=8.7 Hz), 6.81 (d, 2H, J=8.7 Hz), 7.25 - 7.54 (m, 16H), 7.97 (s, 1H), 8.03 (d, 2H, J=7.2 Hz), 8.80 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.75 (m, 1H), 2.86 (dd, 1H, J = 4.5, 11.2 Hz), 3.07 (s, 3H, OMe), 3.20 (dd, 1H, J = 5.4, 11 Hz ), 3.30 (dd, 1H, J = 5.7, 8 Hz), 3.57 (m, 2H), 3.788 (s, 3H, OMe), 3.794 (s, 3H, OMe), 3.88 (dd, 1H, J = 9 , 9 Hz), 3.97 (m, 2H), 4.39 (ddd, 1H, J = 4, 10, 10 Hz), 6.80 (d, 2H, J = 8.7 Hz), 6.81 (d, 2H, J = 8.7 Hz ), 7.25-7.54 (m, 16H), 7.97 (s, 1H), 8.03 (d, 2H, J = 7.2 Hz), 8.80 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-시아노벤질)-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 3) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-cyanobenzyl) -5-[(2-cyanoethoxy) (N, N-diisopropyl Preparation of amino) phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 13) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.05 (d, 6H, J=6.7 Hz), 1.09 (d, 6H, J=6.2 Hz), 1.11 (d, 6H, J=5.6 Hz), 1.15 (d, 6H, J=6.7 Hz), 2.02 - 2.06 (m, 1H), 2.21 - 2.40 (m, 2H), 2.44 (t, 2H, J=6.1 Hz), 2.95 (m, 2H), 3.07 (s, 3H, OMe), 3.31 (s, 3H, OMe), 3.31 - 3.82 (m, 13H), 3.80 (s, 6H, OMe), 3.81 (s, 6H, OMe), 3.88 - 3.99 (m, 4H), 4.13 (m, 2H), 4.50 (m, 2H), 4.73 (m, 2H), 5.38 (m, 2H), 6.82 (d, 4H, J=8.6 Hz), 6.83 (d, 4H, J=8.1 Hz), 7.16 - 7.46 (m, 23H), 7.54 (t, 4H, J=8 Hz), 7.61 (d, 2H, J=8.9 Hz), 8.04 (m, 5H), 8.19 (s, 1H), 8.65 (s, 1H) 8.81 (s, 1H),  8.84 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.05 (d, 6H, J = 6.7 Hz), 1.09 (d, 6H, J = 6.2 Hz), 1.11 (d, 6H, J = 5.6 Hz), 1.15 (d, 6H, J = 6.7 Hz), 2.02-2.06 (m, 1H), 2.21-2.40 (m, 2H), 2.44 (t, 2H, J = 6.1 Hz), 2.95 (m, 2H), 3.07 (s, 3H, OMe ), 3.31 (s, 3H, OMe), 3.31-3.82 (m, 13H), 3.80 (s, 6H, OMe), 3.81 (s, 6H, OMe), 3.88-3.99 (m, 4H), 4.13 (m , 2H), 4.50 (m, 2H), 4.73 (m, 2H), 5.38 (m, 2H), 6.82 (d, 4H, J = 8.6 Hz), 6.83 (d, 4H, J = 8.1 Hz), 7.16 7.46 (m, 23H), 7.54 (t, 4H, J = 8 Hz), 7.61 (d, 2H, J = 8.9 Hz), 8.04 (m, 5H), 8.19 (s, 1H), 8.65 (s, 1H) 8.81 (s, 1 H), 8.84 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 150.69, 151.45</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 150.69, 151.45</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 11〉  6-N-벤조일-{(3R,4R,5R,6R)-N-(4-플로로벤질)-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>Example 11 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-fluorobenzyl) -5-[(2-cyanoethoxy) (N, N-diiso Preparation of propylamino) phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-플로로벤질)-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 1) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-fluorobenzyl) -6-hydroxymethyl-5-hydroxy-4-methoxypiperidine-3 Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 실시예 7의 1 단계의 표제화합물과 4-플루우로벤질브로마이드를 사용하여 실시예 10의 (단계 1)과 같은 방법을 이용하여 제조하였다.</span>This compound was prepared in the same manner as in Example 10 (Step 1) using the title compound of Step 1 of Example 7 and 4-fluurobenzylbromide.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.53 (m, 1H), 2.94 (dd, 1H, J=4.6 Hz), 3.2 (m, 2H), 3.94 (m, 2H), 4.02 (m, 2H), 4.15 (m, 2H), 4.42 (ddd, 1H, J=4.6, 10.4, 10.4 Hz), 7.46 (t, 2H, J=7.1 Hz), 7.52 (d, 2H, J=9.2 Hz), 7.64 - 7.54 (m, 3H), 7.97 (d, 2H, J=7.4 Hz), 8.01 (s, 1H), 8.72 (s, 1H)</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.53 (m, 1H), 2.94 (dd, 1H, J = 4.6 Hz), 3.2 (m, 2H), 3.94 (m, 2H), 4.02 (m, 2H), 4.15 ( m, 2H), 4.42 (ddd, 1H, J = 4.6, 10.4, 10.4 Hz), 7.46 (t, 2H, J = 7.1 Hz), 7.52 (d, 2H, J = 9.2 Hz), 7.64-7.54 (m , 3H), 7.97 (d, 2H, J = 7.4 Hz), 8.01 (s, 1H), 8.72 (s, 1H)</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-플로로벤질)-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 2) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-fluorobenzyl) -5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperi Din-3-yl} adenine preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.69 (m, 1H), 2.93 (dd, 1H, J=4.5, 11.4 Hz), 3.06 (s, 3H, OMe), 3.14 (m, 1H), 3.35 - 3.28 (m, 2H),  3.59 (m, 2H), 3.80 (s, 6H, OMe), 3.98 - 3.87 (m, 2H), 4.42 (ddd, 1H, J=4.6, 11.1, 11.1 Hz), 6.83 (d, 2H, J=6.5 Hz), 6.84 (d, 2H, J=7.1 Hz),  7.39-7.17 (m, 14H), 7.51 (t, 1H, J=7.0 Hz), 7.61 (d, 1H, J=7.5 Hz), 7.96 (s, 1H), 8.03 (d, 2H, J=7.2 Hz), 8.81 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.69 (m, 1H), 2.93 (dd, 1H, J = 4.5, 11.4 Hz), 3.06 (s, 3H, OMe), 3.14 (m, 1H), 3.35-3.28 (m , 2H), 3.59 (m, 2H), 3.80 (s, 6H, OMe), 3.98-3.87 (m, 2H), 4.42 (ddd, 1H, J = 4.6, 11.1, 11.1 Hz), 6.83 (d, 2H , J = 6.5 Hz), 6.84 (d, 2H, J = 7.1 Hz), 7.39-7.17 (m, 14H), 7.51 (t, 1H, J = 7.0 Hz), 7.61 (d, 1H, J = 7.5 Hz ), 7.96 (s, 1H), 8.03 (d, 2H, J = 7.2 Hz), 8.81 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-플로로벤질)-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 3) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-fluorobenzyl) -5-[(2-cyanoethoxy) (N, N-diisopropyl Preparation of amino) phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 13) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.99 (d, 6H, J=6.8 Hz), 1.06 (d, 6H, J=6.0 Hz)), 1.09 (d, 6H, J=6.1 Hz)), 1.14 (d, 6H, J=6.8 Hz)), 2.40 (m, 4H), 2.78 (m, 2H), 2.92 (m, 2H), 3.15 (s, 3H, OMe), 3.35 (s, 3H, OMe), 3.79 - 3.21 (m, 16H), 3.81 (s, 6H), 3.82 (s, 6H, OMe),  4.19 - 4.05 (m, 4H), 4.30 (m, 2H), 4.55 (m, 2H), 4.72 (m, 2H), 6.85 (d, 8H, J=8.8 Hz)), 7.63 - 6.96 (m, 35H), 8.04 (d, 4H, J=8.2 Hz)), 8.34 (s, 1H) 8.74 (s, 1H), 8.80 (s, 1H), 8.83 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.99 (d, 6H, J = 6.8 Hz), 1.06 (d, 6H, J = 6.0 Hz)), 1.09 (d, 6H, J = 6.1 Hz)), 1.14 (d, 6H, J = 6.8 Hz)), 2.40 (m, 4H), 2.78 (m, 2H), 2.92 (m, 2H), 3.15 (s, 3H, OMe), 3.35 (s, 3H, OMe), 3.79- 3.21 (m, 16H), 3.81 (s, 6H), 3.82 (s, 6H, OMe), 4.19-4.05 (m, 4H), 4.30 (m, 2H), 4.55 (m, 2H), 4.72 (m, 2H), 6.85 (d, 8H, J = 8.8 Hz)), 7.63-6.96 (m, 35H), 8.04 (d, 4H, J = 8.2 Hz)), 8.34 (s, 1H) 8.74 (s, 1H) , 8.80 (s, 1 H), 8.83 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 12〉 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-메톡시벤질)-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>Example 12 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-methoxybenzyl) -5-[(2-cyanoethoxy) (N, N-diiso Preparation of propylamino) phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-메톡시벤질)-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 1) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-methoxybenzyl) -6-hydroxymethyl-5-hydroxy-4-methoxypiperidine-3 Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 7의 (단계 1)의 표제화합물(200 mg, 0.5 mmol)을 무수 아세트나이트릴(5 mL)에 녹이고, 4-메톡시벤질크로라이드(339 mg, 2.5 mmol), 트라이에틸아민 (0.69 mL, 5 mmol), 및 다이메틸아미노피리딘(소량)을 가하였다.  반응물을 상온에서 2시간 동안 가열 환류시킨 후, 감압농축하고 잔사를 컬럼 크로마토그래피(10 - 20 % 메탄올/메틸렌클로라이드)하여 104 mg의 화합물을 얻었다(40 %).</span>The title compound (200 mg, 0.5 mmol) of (step 1) of Example 7 was dissolved in anhydrous acetnitrile (5 mL), 4-methoxybenzyl chloride (339 mg, 2.5 mmol), triethylamine (0.69 mL, 5 mmol), and dimethylaminopyridine (small amount) were added. The reaction was heated to reflux at room temperature for 2 hours, concentrated under reduced pressure and the residue was column chromatographed (10-20% methanol / methylene chloride) to give 104 mg of a compound (40%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.60 (d, 1H, J=9 Hz), 3.03 (s, 3H, OMe), 3.07 (m, 1H), 3.19 (dd, 1H, J=11.5, 11.5 Hz), 3.35 (d, 1H, J=13.4 Hz), 3.79 (s, 3H, OMe), 3.88 (dd, 1H, J=9, 9 Hz), 3.99 (dd, 1H, J=9, 9 Hz), 4.12 (m, 3H), 4.42 (ddd, 1H, J=4, 10.5, 10.5 Hz), 6.86 (d, 2H, J=8.6 Hz), 7.20 (d, 2H, J=8.6 Hz), 7.54 (t, 2H, J=7 Hz), 7.62 (d, 1H, J=7 Hz), 7.96 (s, 1H), 8.04 (d, 2H, J=7 Hz), 8.81 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.60 (d, 1H, J = 9 Hz), 3.03 (s, 3H, OMe), 3.07 (m, 1H), 3.19 (dd, 1H, J = 11.5, 11.5 Hz), 3.35 (d, 1H, J = 13.4 Hz), 3.79 (s, 3H, OMe), 3.88 (dd, 1H, J = 9, 9 Hz), 3.99 (dd, 1H, J = 9, 9 Hz), 4.12 (m, 3H), 4.42 (ddd, 1H, J = 4, 10.5, 10.5 Hz), 6.86 (d, 2H, J = 8.6 Hz), 7.20 (d, 2H, J = 8.6 Hz), 7.54 (t, 2H, J = 7 Hz), 7.62 (d, 1H, J = 7 Hz), 7.96 (s, 1H), 8.04 (d, 2H, J = 7 Hz), 8.81 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-메톡시벤질)-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 2) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-methoxybenzyl) -5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperi Din-3-yl} adenine preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.67 (m, 1H), 2.79 (m, 1H), 2.99 (dd, 1H, J=3, 9 Hz), 3.04 (m, 1H), 3.07 (s, 3H, OMe), 3.12 (m, 1H), 3.61 (m, 2H), 3.77 (s, 3H, OMe), 3.81 (s, 6H, OMe), 3.89 (d, 1H, J=9 Hz), 3.94 (m, 1H), 4.43 (ddd, 1H, J=4.7, 10, 10), 6.78 (d, 2H, J=8.7 Hz), 6.86 (d, 2H, J=8.6 Hz), 6.87 (d, 2H, J=8.7 Hz), 7.08 (d, 2H, J=8.5 Hz), 7.22∼7.62 (m, 22H), 7.95 (s, 1H), 8.04 (d, 2H, J=7.4 Hz), 8.81 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.67 (m, 1H), 2.79 (m, 1H), 2.99 (dd, 1H, J = 3, 9 Hz), 3.04 (m, 1H), 3.07 (s, 3H, OMe ), 3.12 (m, 1H), 3.61 (m, 2H), 3.77 (s, 3H, OMe), 3.81 (s, 6H, OMe), 3.89 (d, 1H, J = 9 Hz), 3.94 (m, 1H), 4.43 (ddd, 1H, J = 4.7, 10, 10), 6.78 (d, 2H, J = 8.7 Hz), 6.86 (d, 2H, J = 8.6 Hz), 6.87 (d, 2H, J = 8.7 Hz), 7.08 (d, 2H, J = 8.5 Hz), 7.22 to 7.82 (m, 22H), 7.95 (s, 1H), 8.04 (d, 2H, J = 7.4 Hz), 8.81 (s, 1H) .</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 6-N-벤조일-{(3R,4R,5R,6R)-N-(4-메톡시벤질)-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌의 제조</span>(Step 3) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-methoxybenzyl) -5-[(2-cyanoethoxy) (N, N-diisopropyl Preparation of amino) phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 13) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.96 (d, 6H, J=6.7 Hz), 1.08 (d, 6H, J=6.7 Hz), 1.13 (d, 6H, J=6.7 Hz), 1.15 (d, 6H, J=6.7 Hz), 2.36 (t, 2H, J=6 Hz), 2.44 (t, 2H, J=6 Hz), 2.87 (dd, 2H, J= 4, 13 Hz), 3.10 (m, 4H), 3.19 (s, 3H, OMe), 3.34 (s, 3H, OMe), 3.77∼3.36 (m, 12H), 3.79 (s, 3H, OMe), 3.81 (s, 3H, OMe), 3.82 (s, 6H, OMe), 4.33 (m, 1H), 4.58 (m, 1H), 4.72 (m, 1H), 6.85 (d, 4H, J=8.6 Hz), 6.88 (d, 4H, J=8.8 Hz), 7.50 - 7.11 (m, 13H), 7.53 (t, 2H, J=7.8 Hz), 7.61 (d, 1H, J=7.1 Hz), 8.05 (d, 2H, J=7.5 Hz), 8.45 (s, 2H), 8.77 (s, 2H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.96 (d, 6H, J = 6.7 Hz), 1.08 (d, 6H, J = 6.7 Hz), 1.13 (d, 6H, J = 6.7 Hz), 1.15 (d, 6H, J = 6.7 Hz), 2.36 (t, 2H, J = 6 Hz), 2.44 (t, 2H, J = 6 Hz), 2.87 (dd, 2H, J = 4, 13 Hz), 3.10 (m, 4H) , 3.19 (s, 3H, OMe), 3.34 (s, 3H, OMe), 3.77-3.36 (m, 12H), 3.79 (s, 3H, OMe), 3.81 (s, 3H, OMe), 3.82 (s, 6H, OMe), 4.33 (m, 1H), 4.58 (m, 1H), 4.72 (m, 1H), 6.85 (d, 4H, J = 8.6 Hz), 6.88 (d, 4H, J = 8.8 Hz), 7.50-7.11 (m, 13H), 7.53 (t, 2H, J = 7.8 Hz), 7.61 (d, 1H, J = 7.1 Hz), 8.05 (d, 2H, J = 7.5 Hz), 8.45 (s, 2H ), 8.77 (s, 2 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 150.41, 150.60</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 150.41, 150.60</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 13〉 4-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}시토신의 제조</span>Example 13 4-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} cytosine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1)  4-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}시토신의 제조</span>(Step 1) 4-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridin-3-yl} cytosine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">N<sup>3</sup>-벤조일시토신(600 mg, 1.26 mmol)과 트리페닐포스핀(1.5 g, 5.76 mmol) 혼합액을 무수 다이옥산(30 mL)에 녹인 실시예 1의 (단계 7)의 표제화합물(600 mg, 1.26 mmol)에 첨가한 후, 무수 테트라하이드로퓨란(12 mL)에 녹인 다이에틸 아조다이카르복실레이트(1 mL, 1 mmol)를 처리하였다.  이 반응액을 실온에서 하루 밤 교반시켰다.  이 반응액에 에틸아세테이트를 첨가하고 증류수(50 mL)로 2번 씻은 후 유기 용매층을 분획하여 소듐 설페이트로 수분을 제거한 후 용매를 감압 증발시켰다.  그 잔사를(50 % ~ 75 %) 에틸아세테이트/핵산 용매계로 실리카겔 60 컬럼크로마토그래피 (30% - 50% EtOAc/Hexane)로 정제하여 200 mg (24 %) 을 얻었다 .<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.55 (s, 3H, Me), 2.64 (m, 1H), 3.00 (dd, 1H, J=4.0, 11.2 Hz), 3.59 (s, 3H, OMe), 3.70 (m, 2H), 3.82 (m, 2H), 3.88 (s, 3H, OMe), 4.23 (m, 1H), 4.46 (dd, 1H, J=3.8, 10.5 Hz), 5.01 (s, 1H), 6.98 (d, 2H, J=8.8 Hz), 7.69 - 7.12 (m, 17H), 7.92 (d, 2H, J=7.6 Hz)</span>The title compound (600 mg, 1.26) of Example 1 (600 mg, 1.26) in which a mixture of N <sup>3</sup> -benzoylcytosine (600 mg, 1.26 mmol) and triphenylphosphine (1.5 g, 5.76 mmol) was dissolved in anhydrous dioxane (30 mL) mmol), followed by treatment with diethyl azodicarboxylate (1 mL, 1 mmol) dissolved in anhydrous tetrahydrofuran (12 mL). The reaction solution was stirred overnight at room temperature. Ethyl acetate was added to the reaction solution, washed twice with distilled water (50 mL), the organic solvent layer was separated, water was removed with sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel 60 column chromatography (30%-50% EtOAc / Hexane) with ethyl acetate / nucleic acid solvent to give 200 mg (24%). <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.55 (s, 3H, Me), 2.64 (m, 1H), 3.00 (dd, 1H, J = 4.0, 11.2 Hz), 3.59 (s, 3H, OMe), 3.70 (m , 2H), 3.82 (m, 2H), 3.88 (s, 3H, OMe), 4.23 (m, 1H), 4.46 (dd, 1H, J = 3.8, 10.5 Hz), 5.01 (s, 1H), 6.98 ( d, 2H, J = 8.8 Hz), 7.69-7.12 (m, 17H), 7.92 (d, 2H, J = 7.6 Hz)</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 4-N-벤조일-{(3R,4R,5R,6R)-N-(4-메톡시벤질)-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}시토신의 제조</span>(Step 2) 4-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-methoxybenzyl) -6-hydroxymethyl-5-hydroxy-4-methoxypiperidine-3 Preparation of Cytosine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.03 (m, 1H), 2.49 (m, 1H), 2.72 (m, 1H), 3.22 (dd, 1H, J=4,2, 12.0 Hz), 3.44 (s, 3H, OMe), 3.63 (m, 1H),  4.07 (m, 2H), 4.23 (dd, 1H, J=3.7, 12.3 Hz), 5.46 (s, 1H), 7.93 - 7.24 (m, 19H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.03 (m, 1H), 2.49 (m, 1H), 2.72 (m, 1H), 3.22 (dd, 1H, J = 4,2, 12.0 Hz), 3.44 (s, 3H , OMe), 3.63 (m, 1H), 4.07 (m, 2H), 4.23 (dd, 1H, J = 3.7, 12.3 Hz), 5.46 (s, 1H), 7.93-7.24 (m, 19H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 4-N-벤조일-{(3R,4R,5R,6R)-N-(4-메톡시벤질)-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}시토신의 제조</span>(Step 3) 4-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-methoxybenzyl) -5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperi Din-3-yl} cytosine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.52 (m, 1H), 2.58 (m, 1H), 3.09 (dd, 1H, J=3.8, 11.5 Hz), 3.41 (s, 3H, OMe), 3.62 (m, 1H), 3.77 (m, 2H), 3.79 (s, 3H, OMe), 3.80 (s, 3H, OMe), 4.17 (m, 2H), 5.04 (s, 1H), 6.80 (d, 2H, J=8.7 Hz), 6.81 (d, 2H, J=8.8 Hz), 7.72 - 7.13 (m, 24H), 7.90 (d, 2H, J=7.4 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 2.52 (m, 1H), 2.58 (m, 1H), 3.09 (dd, 1H, J = 3.8, 11.5 Hz), 3.41 (s, 3H, OMe), 3.62 (m, 1H ), 3.77 (m, 2H), 3.79 (s, 3H, OMe), 3.80 (s, 3H, OMe), 4.17 (m, 2H), 5.04 (s, 1H), 6.80 (d, 2H, J = 8.7 Hz), 6.81 (d, 2H, J = 8.8 Hz), 7.72-7.13 (m, 24H), 7.90 (d, 2H, J = 7.4 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4) 4-N-벤조일-{(3R,4R,5R,6R)-N-(4-메톡시벤질)-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}시토신의 제조</span>(Step 4) 4-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-methoxybenzyl) -5-[(2-cyanoethoxy) (N, N-diisopropyl Preparation of amino) phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} cytosine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1, using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.17 (d, 3H, J=6.8 Hz), 1.21 (d, 3H, J=6.7 Hz), 2.64 - 2.42 (m, 4H), 2.91 (dd, 1H, J=4.8, 13.3 Hz), 3.09 (m, 1H, OMe), 3.35 (s, 3H OMe), 3.64 - 3.48 (m, 5H), 3.829 (s, 3H OMe), 3.832 (s, 3H OMe), 4.19 (m, 1H), 4.48 (d, 1H, J=12.8 Hz), 4.64 (s, 1H), 4.68 (m, 1H), 5.04 (s, 1H), 6.82 (m, 4H), 7.71 - 7.14 (m, 2H), 7.91 (d, 2H, J=8.3 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.17 (d, 3H, J = 6.8 Hz), 1.21 (d, 3H, J = 6.7 Hz), 2.64-2.42 (m, 4H), 2.91 (dd, 1H, J = 4.8 , 13.3 Hz), 3.09 (m, 1H, OMe), 3.35 (s, 3H OMe), 3.64-3.48 (m, 5H), 3.829 (s, 3H OMe), 3.832 (s, 3H OMe), 4.19 (m , 1H), 4.48 (d, 1H, J = 12.8 Hz), 4.64 (s, 1H), 4.68 (m, 1H), 5.04 (s, 1H), 6.82 (m, 4H), 7.71-7.14 (m, 2H), 7.91 (d, 2H, J = 8.3 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 149.72, 150.59</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 149.72, 150.59</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 14〉 2-N-이소부티릴-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}구아닌의 제조</span>Example 14 2-N-isobutyryl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino Preparation of phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} guanine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1)  2-N-이소부티릴-6-O-[2-(p-나이트로페닐)에틸]-{(3R,4R, 5R,6R)- N-벤즈하이드릴-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}구아닌의 제조</span>(Step 1) 2-N-isobutyryl-6-O- [2- (p-nitrophenyl) ethyl]-{(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxy Preparation of -5,6-O-[(4-methoxyphenyl) ethylidene] piperidin-3-yl} guanine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 1의 (단계 7)의 표제화합물(1.5 g, 3.15 mmol)을 무수 자일렌(70 mL)에 녹이고 N<sup>2</sup>-이소부티릴-O<sup>6</sup>-[2-(p-나이트로페닐)에틸]구아닌(2.3 g, 6.2 mmol), 트라이페닐포스핀(1.74 g, 6.6 mmol)을 가한 후 상온에서 한시간 동안 교반하였다. 무수 자일렌(10 mL)에 녹인 다이에틸디카르복실레이트(DEAD, 1.04 mL, 6.6 mmol)를 이 반응액에 20분간 천천히 가하고 120 ℃에서 6시간동안 교반시켰다.  반응액을 상온으로 천천히 식힌 후, 여과하고 용액을 감압농축하였다.  잔사를 실리카젤을 사용하여 컬럼 크로마토그래피로 정제하였다(1:1 에틸아세테이트/헥산, 560 mg, 22 %).</span>The title compound of Example 1 (step 7) (1.5 g, 3.15 mmol) was dissolved in anhydrous xylene (70 mL) and N <sup>2</sup> -isobutyryl-O <sup>6-</sup> [2- (p-nitrophenyl) ethyl] Guanine (2.3 g, 6.2 mmol) and triphenylphosphine (1.74 g, 6.6 mmol) were added and stirred at room temperature for 1 hour. Diethyldicarboxylate (DEAD, 1.04 mL, 6.6 mmol) dissolved in anhydrous xylene (10 mL) was slowly added to the reaction solution for 20 minutes and stirred at 120 ° C. for 6 hours. The reaction solution was slowly cooled to room temperature, filtered and the solution was concentrated under reduced pressure. The residue was purified by column chromatography using silica gel (1: 1 ethyl acetate / hexanes, 560 mg, 22%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.28 (d, 3H, J=4.9 Hz), 1.29 (d, 3H, J=5.3 Hz), 1.30 (d, 3H, J=4.6 Hz), 1.31 (d, 3H, J=5.3 Hz), 1.55 (s, 3H, Me), 1.81 (s, 3H, Me), 2.58 (m, 2H), 2.72 (dd, 2H, J=11.2, 11.3 Hz), 3.00 (dd, 1H, J=4.5, 11.2 Hz), 3.08 (m, 1H),  3.34 (t, 2H, J=6.9 Hz), 3.35 (s, 3H, OMe),3.38 (s, 3H, OMe), 3.70 (d, 2H, J=9.5 Hz), 3.80 (d, 2H, J=9 Hz), 3.82 (s, 3H, OMe), 3.88 (s, 3H, OMe), 4.06 - 4.39 (m, 6H), 4.53 (m, 2H), 4.80 (m, 2H), 5.02 (s, 1H), 5.14 (s, 1H), 6.90 (d, 2H, J=8.9 Hz), 6.99 (d, 2H, J=8.8 Hz), 7.72 - 7.15 (m, 30H), 8.18 (d, 4H, J=8.7 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.28 (d, 3H, J = 4.9 Hz), 1.29 (d, 3H, J = 5.3 Hz), 1.30 (d, 3H, J = 4.6 Hz), 1.31 (d, 3H, J = 5.3 Hz), 1.55 (s, 3H, Me), 1.81 (s, 3H, Me), 2.58 (m, 2H), 2.72 (dd, 2H, J = 11.2, 11.3 Hz), 3.00 (dd, 1H , J = 4.5, 11.2 Hz), 3.08 (m, 1H), 3.34 (t, 2H, J = 6.9 Hz), 3.35 (s, 3H, OMe), 3.38 (s, 3H, OMe), 3.70 (d, 2H, J = 9.5 Hz), 3.80 (d, 2H, J = 9 Hz), 3.82 (s, 3H, OMe), 3.88 (s, 3H, OMe), 4.06-4.39 (m, 6H), 4.53 (m , 2H), 4.80 (m, 2H), 5.02 (s, 1H), 5.14 (s, 1H), 6.90 (d, 2H, J = 8.9 Hz), 6.99 (d, 2H, J = 8.8 Hz), 7.72 7.15 (m, 30H), 8.18 (d, 4H, J = 8.7 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2)  2-N-이소부티릴-{(3R,4R,5R,6R)-N-벤즈하이드릴-4-메톡시-5,6-O- [(4-메톡시페닐)에틸리덴]피페리딘-3-일}구아닌의 제조</span>(Step 2) 2-N-isobutyryl-{(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene ] Piperidin-3-yl} guanine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 (단계 1)에서 제조된 표제화합물을 무수 피리딘(12 mL)에 녹이고 1,8-다이아자바이사이클로[5.4.0]운덱-7-엔(DBU, 203 mL, 1.35 mmol)을 가하였다.  이를 상온에서 10시간 동안 교반시키고 감압농축하였다.  잔사를 실리카젤을 사용하여 컬럼크로마토그래피로 정제하였다(5 - 10 % 메탄올/메틸렌클로라이드, 375 mg, 83 %).</span>The title compound prepared in (Step 1) was dissolved in anhydrous pyridine (12 mL) and 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU, 203 mL, 1.35 mmol) was added. It was stirred for 10 hours at room temperature and concentrated under reduced pressure. The residue was purified by column chromatography using silica gel (5-10% methanol / methylene chloride, 375 mg, 83%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.310 (d, 3H, J=4.1 Hz), 1.32 (d, 3H, J=4 Hz), 1.33 (d, 3H, J=4.7 Hz), 1.34 (d, 3H, J=4.1 Hz), 1.56 (s, 3H, Me), 1.80 (s, 3H, Me), 2.51 (dd, 1H, J=11.2, 11.3 Hz), 2.62 (m, 3H), 3.02 (dd, 1H, J=4.5, 11.2 Hz), 3.08 (m, 1H),  3.40 (s, 3H, OMe), 3.45 (s, 3H, OMe), 3.69 (d, 2H, J=9.5 Hz), 3.77 (d, 2H, J=9 Hz), 3.82 (s, 3H, OMe), 3.88 (s, 3H, OMe), 4.27 - 4.05 (m, 6H), 4.58 - 4.45 (m, 2H), 5.02 (s, 1H), 5.13 (s, 1H), 6.90 (d, 2H, J=8.7 Hz), 6.99 (d, 2H, J=8.9 Hz), 7.72 - 7.15 (m, 26H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.310 (d, 3H, J = 4.1 Hz), 1.32 (d, 3H, J = 4 Hz), 1.33 (d, 3H, J = 4.7 Hz), 1.34 (d, 3H, J = 4.1 Hz), 1.56 (s, 3H, Me), 1.80 (s, 3H, Me), 2.51 (dd, 1H, J = 11.2, 11.3 Hz), 2.62 (m, 3H), 3.02 (dd, 1H , J = 4.5, 11.2 Hz), 3.08 (m, 1H), 3.40 (s, 3H, OMe), 3.45 (s, 3H, OMe), 3.69 (d, 2H, J = 9.5 Hz), 3.77 (d, 2H, J = 9 Hz), 3.82 (s, 3H, OMe), 3.88 (s, 3H, OMe), 4.27-4.05 (m, 6H), 4.58-4.45 (m, 2H), 5.02 (s, 1H) , 5.13 (s, 1H), 6.90 (d, 2H, J = 8.7 Hz), 6.99 (d, 2H, J = 8.9 Hz), 7.72-7.15 (m, 26H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 2-N-이소부티릴-{(3R,4R,5R,6R)-N-벤즈하이드릴-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}구아닌의 제조</span>(Step 3) 2-N-isobutyryl-{(3R, 4R, 5R, 6R) -N-benzhydryl-6-hydroxymethyl-5-hydroxy-4-methoxypiperidin-3-yl } Preparation of Guanine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.25 (d, 3H, J=7 Hz), 1.28 (d, 3H, J=7 Hz), 2.59 (d, 1H, J=8.5 Hz), 2.71 (dd, 1H, J=10.5, 10.5 Hz), 2.87 (dq,  1H, J=7.7 Hz), 3.07 (m, 1H),  3.16 (s, 3H, OMe), 3.65 (dd, 1H, J=9, 9 Hz), 4.06 (dd, 1H, J=8.6, 8.6 Hz), 4.21 (m, 2H), 4.41 (m, 1H), 5.56 (s, 1H), 7.30 - 7.12 (m, 10H), 7.86 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.25 (d, 3H, J = 7 Hz), 1.28 (d, 3H, J = 7 Hz), 2.59 (d, 1H, J = 8.5 Hz), 2.71 (dd, 1H, J = 10.5, 10.5 Hz), 2.87 (dq, 1H, J = 7.7 Hz), 3.07 (m, 1H), 3.16 (s, 3H, OMe), 3.65 (dd, 1H, J = 9, 9 Hz), 4.06 (dd, 1H, J = 8.6, 8.6 Hz), 4.21 (m, 2H), 4.41 (m, 1H), 5.56 (s, 1H), 7.30-7.12 (m, 10H), 7.86 (s, 1H) .</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4) 2-N-이소부티릴-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}구아닌의 제조</span>(Step 4) 2-N-isobutyryl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidine- Preparation of 3-yl} guanine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 12) of Example 1 using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.26 (d, 3H, J=7.2 Hz), 1.30 (d, 3H, J=6.8 Hz), 2.56 (d, 1H, J=8.7 Hz), 2.66 (m, 2H), 3.08 (dd, 1H, J=4.2, 11.4 Hz),  3.15 (s, 3H, OMe), 3.29 (dq, 1H, J=1.5, 5.7 Hz), 3.57 (dd, 1H, J=8.9, 8.9 Hz), 3.67 (m, 1H), 3.77 (s, 3H, OMe), 3.78 (s, 3H, OMe), 3.81 (m, 1H), 4.39 (ddd, 1H, J=4, 11.6, 11.6 Hz), 5.06 (s, 1H), 6.80 (d, 2H, J=8.9 Hz), 6.81 (d, 2H, J=8.8 Hz), 7.48 - 7.22 (m, 15H), 7.65 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.26 (d, 3H, J = 7.2 Hz), 1.30 (d, 3H, J = 6.8 Hz), 2.56 (d, 1H, J = 8.7 Hz), 2.66 (m, 2H) , 3.08 (dd, 1H, J = 4.2, 11.4 Hz), 3.15 (s, 3H, OMe), 3.29 (dq, 1H, J = 1.5, 5.7 Hz), 3.57 (dd, 1H, J = 8.9, 8.9 Hz ), 3.67 (m, 1H), 3.77 (s, 3H, OMe), 3.78 (s, 3H, OMe), 3.81 (m, 1H), 4.39 (ddd, 1H, J = 4, 11.6, 11.6 Hz), 5.06 (s, 1H), 6.80 (d, 2H, J = 8.9 Hz), 6.81 (d, 2H, J = 8.8 Hz), 7.48-7.22 (m, 15H), 7.65 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5) 2-N-이소부티릴-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}구아닌의 제조</span>(Step 5) 2-N-isobutyryl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) Preparation of Phospinoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} guanine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 4)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 13) using the title compound prepared in (Step 4).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.15 (d, 6H, J=6.7 Hz), 1.16 (d, 6H, J=7.3 Hz), 1.19 (d, 6H, J=6.5 Hz), 1.21 (d, 6H, J=6.7 Hz), 1.26 (d, 6H, J=6.8 Hz), 1.27 (d, 6H, J=6.8 Hz), 2.38 (t, 4H, J=7 Hz), 2.94 - 2.42 (m, 10H), 3.18 (s, 3H, OMe),  3.24 (s, 3H, OMe), 3.30 (dd, 1H, J=5.7, 7 Hz), 3.40 (m, 1H), 3.80 - 3.53 (m, 10H), 3.812 (s, 3H, OMe), 3.818 (s, 3H, OMe), 4.17 (m, 1H), 4.53 - 4.37 (m, 3H), 4.67 (s, 1H), 4.72 (s, 1H), 6.81 (d, 2H, J=8.8 Hz), 6.83 (d, 2H, J=8.9 Hz), 7.13 - 7.35 (m), 8.32 (s, 1H), 8.63 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.15 (d, 6H, J = 6.7 Hz), 1.16 (d, 6H, J = 7.3 Hz), 1.19 (d, 6H, J = 6.5 Hz), 1.21 (d, 6H, J = 6.7 Hz), 1.26 (d, 6H, J = 6.8 Hz), 1.27 (d, 6H, J = 6.8 Hz), 2.38 (t, 4H, J = 7 Hz), 2.94-2.42 (m, 10H) , 3.18 (s, 3H, OMe), 3.24 (s, 3H, OMe), 3.30 (dd, 1H, J = 5.7, 7 Hz), 3.40 (m, 1H), 3.80-3.53 (m, 10H), 3.812 (s, 3H, OMe), 3.818 (s, 3H, OMe), 4.17 (m, 1H), 4.53-4.37 (m, 3H), 4.67 (s, 1H), 4.72 (s, 1H), 6.81 (d , 2H, J = 8.8 Hz), 6.83 (d, 2H, J = 8.9 Hz), 7.13-7.35 (m), 8.32 (s, 1H), 8.63 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 149.32, 150.08</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 149.32, 150.08</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 15〉 {(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>Example 15 {(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6- Preparation of Dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1)  {(3R,4R,5R,6R)-N-벤즈하이드릴-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}티민의 제조</span>(Step 1) {(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidin-3-yl } Preparation of Thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 1의 (단계 7)의 표제화합물(2.2 g, 4.63 mmol)을 무수 다이옥산(100 mL)에 녹이고 N<sup>3</sup>-벤조일티민(2.7 g, 20.73 mmol) 및 트라이페닐포스핀(3.3 g, 12.58 mmol)을 가하여 교반한 후, 무수 테트라하이드로퓨란(15 mL)에 녹인 다이에틸 아조다이카르복실레이트(DEAD, 2.1 mL, 11.87 mmol)를 이 용액에 가하여 상온에서 12시간 동안 교반시켰다.  반응액을 감압 농축하고 잔사를 메탄올(90 mL)에 녹인 다음,  암모니아 가스로 30분간 포화시켰다.  톨루엔을 가하면서 이를 감압농축하고, 잔사를 실리카젤을 사용하여 컬럼 크로마토그래피로 정제하였다(30 - 50 % 에틸아세테이트/헥산, 2.45 g, 91 %).</span>The title compound (2.2 g, 4.63 mmol) of (step 7) of Example 1 was dissolved in anhydrous dioxane (100 mL), N <sup>3</sup> -benzoylthymine (2.7 g, 20.73 mmol) and triphenylphosphine (3.3 g, 12.58 mmol) ) Was added and stirred, and then diethyl azodicarboxylate (DEAD, 2.1 mL, 11.87 mmol) dissolved in anhydrous tetrahydrofuran (15 mL) was added to the solution, followed by stirring at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in methanol (90 mL), and then saturated with ammonia gas for 30 minutes. It was concentrated under reduced pressure with toluene, and the residue was purified by column chromatography using silica gel (30-50% ethyl acetate / hexane, 2.45 g, 91%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.79 (s, 3H, Me), 1.89 (s, 3H, Me), 2.54 (ddd, 1H, J=4, 10, 10 Hz), 3.01 (dd, 1H, J=4.3, 11.1 Hz), 3.56 (s, 3H, OMe), 3.45 (s, 3H, OMe), 3.62 (m, 1H), 3.82 (s, 3H, OMe), 4.12 (dd, 1H, J=7.1, 7.2 Hz), 4.15 (m, 3H), 4.52 (dd, 1H, J=4.2, 10.7 Hz), 5.09 (s, 1H), 6.86 (s, 1H, vinyl H), 6.89 (d, 2H, J=8.9 Hz), 7.12 - 7.47 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.79 (s, 3H, Me), 1.89 (s, 3H, Me), 2.54 (ddd, 1H, J = 4, 10, 10 Hz), 3.01 (dd, 1H, J = 4.3, 11.1 Hz), 3.56 (s, 3H, OMe), 3.45 (s, 3H, OMe), 3.62 (m, 1H), 3.82 (s, 3H, OMe), 4.12 (dd, 1H, J = 7.1, 7.2 Hz), 4.15 (m, 3H), 4.52 (dd, 1H, J = 4.2, 10.7 Hz), 5.09 (s, 1H), 6.86 (s, 1H, vinyl H), 6.89 (d, 2H, J = 8.9 Hz), 7.12-7.47 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) {(3R,4R,5R,6R)-N-벤즈하이드릴-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 2) Preparation of {(3R, 4R, 5R, 6R) -N-benzhydryl-6-hydroxymethyl-5-hydroxy-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.35 (s, 3H, OMe), 1.89 (s, 3H, Me), 2.53 (dd, 1H, J=8.3, 12.5 Hz), 3.08 (dd, 1H, J=4, 11.4 Hz), 3.33 (m, 1H),  3.35 (s, 3H, OMe), 3.54 (s, 3H, OMe), 3.77 (dd, 1H, J=8.4, 8.4 Hz), 3.97 (dd, 1H, J=8.2, 8.3 Hz), 4.10 (d, 1H, J=10.5 Hz), 4.22 (m, 2H), 5.46 (s, 1H), 7.05 (s, 1H, vinyl H), 7.20 - 7.41 (m, 10H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 3.35 (s, 3H, OMe), 1.89 (s, 3H, Me), 2.53 (dd, 1H, J = 8.3, 12.5 Hz), 3.08 (dd, 1H, J = 4, 11.4 Hz), 3.33 (m, 1H), 3.35 (s, 3H, OMe), 3.54 (s, 3H, OMe), 3.77 (dd, 1H, J = 8.4, 8.4 Hz), 3.97 (dd, 1H, J = 8.2, 8.3 Hz), 4.10 (d, 1H, J = 10.5 Hz), 4.22 (m, 2H), 5.46 (s, 1H), 7.05 (s, 1H, vinyl H), 7.20-7.41 (m, 10H ).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) {(3R,4R,5R,6R)-N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 3) Preparation of {(3R, 4R, 5R, 6R) -N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.91 (s, 3H, Me), 2.47 (d, 1H, J=9 Hz), 2.48 (m, 1H), 3.03 (dd, 1H, J=4, 10.5 Hz), 3.44 (s, 3H, OMe), 3.53 - 3.79 (m, 5H), 3.791 (s, 3H, OMe), 3.797 (s, 3H, OMe), 5.05 (s, 1H), 6.80 (d, 4H, J=8.8 Hz), 6.81 (d, 4H, J=8.8 Hz), 6.83 (s, 1H, vinyl H), 7.22 - 7.37 (m, 15H), 7.47 (d, 2H, J=6.8 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.91 (s, 3H, Me), 2.47 (d, 1H, J = 9 Hz), 2.48 (m, 1H), 3.03 (dd, 1H, J = 4, 10.5 Hz), 3.44 (s, 3H, OMe), 3.53-3.79 (m, 5H), 3.791 (s, 3H, OMe), 3.797 (s, 3H, OMe), 5.05 (s, 1H), 6.80 (d, 4H, J = 8.8 Hz), 6.81 (d, 4H, J = 8.8 Hz), 6.83 (s, 1H, vinyl H), 7.22-7.37 (m, 15H), 7.47 (d, 2H, J = 6.8 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4) {(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 4) {(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-di Preparation of Methyltrityloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.27 (d, 6H, J=6.7 Hz), 1.29 (d, 6H, J=6.8 Hz), 1.91 (s, 3H, Me), 2.49 (d, 1H, J=8.5 Hz), 2.57 (d, 1H, J=3.1 Hz), 2.77 (t, 2H, J=6.2 Hz),  3.03 (dd, 1H, J=4.2, 11.4 Hz), 3.44 (s, 3H, OMe), 3.46 - 3.73 (m, 6H), 3.76 (m, 1H), 3.790 (s, 3H, OMe), 3.796 (s, 3H, OMe), 4.13 (m, 2H), 5.05 (s, 1H), 6.80 (d, 2H, J=8.8 Hz), 6.81 (d, 2H, J=8.9 Hz), 7.00 (s, 1H, vinyl H), 7.20 - 7.37 (m, 15H), 7.46 (d, 2H, J=7 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.27 (d, 6H, J = 6.7 Hz), 1.29 (d, 6H, J = 6.8 Hz), 1.91 (s, 3H, Me), 2.49 (d, 1H, J = 8.5 Hz), 2.57 (d, 1H, J = 3.1 Hz), 2.77 (t, 2H, J = 6.2 Hz), 3.03 (dd, 1H, J = 4.2, 11.4 Hz), 3.44 (s, 3H, OMe), 3.46-3.73 (m, 6H), 3.76 (m, 1H), 3.790 (s, 3H, OMe), 3.796 (s, 3H, OMe), 4.13 (m, 2H), 5.05 (s, 1H), 6.80 ( d, 2H, J = 8.8 Hz), 6.81 (d, 2H, J = 8.9 Hz), 7.00 (s, 1H, vinyl H), 7.20-7.37 (m, 15H), 7.46 (d, 2H, J = 7 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 16〉 3-N-메틸-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>Example 16 3-N-methyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1)  3-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-4-메톡시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}티민의 제조</span>(Step 1) 3-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-4-methoxy-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 1의 (단계 7)의 표제화합물(1.4 g, 2.94 mmol)을 무수 다이옥산(65 mL)에 녹이고 N<sup>3</sup>-벤조일티민(1.7 g, 13.1 mmol)과 트라이페닐포스핀(2.1 g, 8 mmol)을 가하여 교반한 후, 무수 테트라하이드로퓨란(10 mL)에 녹인 다이에틸 아조다이카르복실레이트(DEAD, 1.34 mL, 1.8 mmol)를 이 용액에 가하고, 상온에서 12 시간동안 교반시켰다.  반응액을 감압 농축하고, 잔사를 실리카젤을 사용하여 컬럼 크로마토그래피로 정제하였다(30 % 에틸아세테이트/헥산, 1.9 g, 94 %).</span>The title compound of Example 1 (step 7) (1.4 g, 2.94 mmol) was dissolved in anhydrous dioxane (65 mL), N <sup>3</sup> -benzoylthymine (1.7 g, 13.1 mmol) and triphenylphosphine (2.1 g, 8 mmol) ) Was added and stirred, and diethyl azodicarboxylate (DEAD, 1.34 mL, 1.8 mmol) dissolved in anhydrous tetrahydrofuran (10 mL) was added to the solution, and the mixture was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by column chromatography using silica gel (30% ethyl acetate / hexane, 1.9 g, 94%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.78 (s, 3H, Me), 1.94 (s, 3H, Me), 2.54 (m, 1H), 3.04 (dd, 1H, J=3.3, 10 Hz), 3.62 (s, 3H, OMe), 3.68 (m, 1H), 3.82 (s, 3H, OMe), 4.01 (dd, 1H, J=10, 10 Hz), 4.13 - 4.32 (m, 3H), 4.51 (dd, 1H, J=7, 10.5 Hz), 5.08 (s, 1H), 6.89 (s, 2H, J=8.8 Hz), 6.96 (s, 1H, vinyl H), 7.13 - 7.51 (m, 12H), 7.64 (d, 1H, J=7.4 Hz), 7.91 (d, 2H, J=7.2 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.78 (s, 3H, Me), 1.94 (s, 3H, Me), 2.54 (m, 1H), 3.04 (dd, 1H, J = 3.3, 10 Hz), 3.62 (s , 3H, OMe), 3.68 (m, 1H), 3.82 (s, 3H, OMe), 4.01 (dd, 1H, J = 10, 10 Hz), 4.13-4.32 (m, 3H), 4.51 (dd, 1H , J = 7, 10.5 Hz), 5.08 (s, 1H), 6.89 (s, 2H, J = 8.8 Hz), 6.96 (s, 1H, vinyl H), 7.13-7.51 (m, 12H), 7.64 (d , 1H, J = 7.4 Hz), 7.91 (d, 2H, J = 7.2 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2) 3-N-벤조일-{(3R,4R,5R,6R)-6-하이드록시메틸-5-하이드록시-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 2) Preparation of 3-N-benzoyl-{(3R, 4R, 5R, 6R) -6-hydroxymethyl-5-hydroxy-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 7의 (단계 1)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 1) of Example 7 using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 1.99 (s, 3H, Me), 3.19 (ddd, 1H, J=4.2, 4, 10.3 Hz), 3.32 (m, 2H), 3.58 (m, 1H), 3.60 (s, 3H, OMe), 3.74 (dd, 1H, J=10.4, 10.4 Hz), 3.89 (m, 1H), 3.91 (m, 2H), 7.50 (t, 1H, J=7.6 Hz), 7.74 (s, 1H), 7.75 (d, 1H, J=7.5 Hz), 7.96 (d, 2H, J=7.2 Hz).</span> <sup>1</sup> H NMR (CD <sub>3</sub> OD) δ 1.99 (s, 3H, Me), 3.19 (ddd, 1H, J = 4.2, 4, 10.3 Hz), 3.32 (m, 2H), 3.58 (m, 1H), 3.60 ( s, 3H, OMe), 3.74 (dd, 1H, J = 10.4, 10.4 Hz), 3.89 (m, 1H), 3.91 (m, 2H), 7.50 (t, 1H, J = 7.6 Hz), 7.74 (s , 1H), 7.75 (d, 1H, J = 7.5 Hz), 7.96 (d, 2H, J = 7.2 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) 3-N-벤조일-{{(3R,4R,5R,6R)-N-메틸-5-하이드록시-6-하이드록시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 3) 3-N-benzoyl-{{(3R, 4R, 5R, 6R) -N-methyl-5-hydroxy-6-hydroxymethyl-4-methoxypiperidin-3-yl} thymine Produce</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 7의 (단계 2)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 2) of Example 7 using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.98 (s, 3H, Me), 2.02 (m, 1H), 2.36 (s, 3H, NMe), 2.80 (m, 1H), 2.99 (dd, 1H, J=4, 4, 10.8 Hz), 3.51 (s, 3H, OMe), 3.85 - 3.72 (m, 4H), 3.96 (d, 1H, J=11 Hz), 7.13 (s, 1H, vinyl H), 7.50 (t, 1H, J=7.5 Hz), 7.65 (d, 1H, J=7.4 Hz), 7.92 (d, 2H, J=7.2 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.98 (s, 3H, Me), 2.02 (m, 1H), 2.36 (s, 3H, NMe), 2.80 (m, 1H), 2.99 (dd, 1H, J = 4, 4, 10.8 Hz), 3.51 (s, 3H, OMe), 3.85-3.72 (m, 4H), 3.96 (d, 1H, J = 11 Hz), 7.13 (s, 1H, vinyl H), 7.50 (t, 1H, J = 7.5 Hz), 7.65 (d, 1H, J = 7.4 Hz), 7.92 (d, 2H, J = 7.2 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4) {(3R,4R,5R,6R)-N-메틸-5-하이드록시-6-하이드록시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 4) Preparation of {(3R, 4R, 5R, 6R) -N-methyl-5-hydroxy-6-hydroxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 (단계 3)에서 제조된 표제화합물(50 mg, 0.12 mmol)을 메탄올(5 mL)에 녹이고 0 ℃에서 암모니아가스를 10분간 포화시킨 후 상온에서 10분간 교반시켰다. 반응기의 마개를 열고 교반시켜 과포화된 암모니아 가스를 제거한 후, 감압 농축한 다음 잔사를 컬럼 그로마토그래피(실리카젤, 10 - 25 % 메탄올/메틸렌클로라이드) 하여 26 mg의 화합물을 얻었다(73 %).</span>The title compound (50 mg, 0.12 mmol) prepared in (Step 3) was dissolved in methanol (5 mL), saturated ammonia gas at 0 ° C. for 10 minutes, and stirred at room temperature for 10 minutes. The reactor was capped and stirred to remove supersaturated ammonia gas, and then concentrated under reduced pressure, and the residue was then subjected to column chromatography (silica gel, 10-25% methanol / methylene chloride) to give 26 mg of the compound (73%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 1.91 (s, 3H, Me), 1.95 (m, 1H), 2.40 (s, 3H, NMe), 2.60 (m, 1H), 2.88 (dd, 1H, J=4.4, 11 Hz), 3.44 (m, 1H), 3.46 (s, 3H, OMe), 3.61 (m, 2H), 3.89 (d, 2H, J=2.5 Hz), 7.59 (s, 1H, vinyl H).</span> <sup>1</sup> H NMR (CD <sub>3</sub> OD) δ 1.91 (s, 3H, Me), 1.95 (m, 1H), 2.40 (s, 3H, NMe), 2.60 (m, 1H), 2.88 (dd, 1H, J = 4.4 , 11 Hz), 3.44 (m, 1H), 3.46 (s, 3H, OMe), 3.61 (m, 2H), 3.89 (d, 2H, J = 2.5 Hz), 7.59 (s, 1H, vinyl H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5) {(3R,4R,5R,6R)-N-메틸-5-하이드록시-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 5) Preparation of {(3R, 4R, 5R, 6R) -N-methyl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 4)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 12) of Example 1 using the title compound prepared in (Step 4).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.94 (s, 3H, Me), 2.14 (s, 3H, NMe), 2.17 (m, 1H), 2.65 (m, 1H), 2.86 (dd, 1H, J=4.2, 11 Hz), 3.42 (m, 1H), 3.45 (s, 3H, OMe), 3.48 (m, 1H), 3.65 (m, 1H), 3.77 (m, 1H), 3.80 (s, 6H, OMe), 4.23 (dd, 1H, J=3.8, 5.8 Hz), 6.49 (d, 2H, J=5.1 Hz), 6.50 (d, 2H, J=5 Hz), 7.01 (s, 1H, vinyl H), 7.48 - 7.22 (m, 9H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.94 (s, 3H, Me), 2.14 (s, 3H, NMe), 2.17 (m, 1H), 2.65 (m, 1H), 2.86 (dd, 1H, J = 4.2, 11 Hz), 3.42 (m, 1H), 3.45 (s, 3H, OMe), 3.48 (m, 1H), 3.65 (m, 1H), 3.77 (m, 1H), 3.80 (s, 6H, OMe), 4.23 (dd, 1H, J = 3.8, 5.8 Hz), 6.49 (d, 2H, J = 5.1 Hz), 6.50 (d, 2H, J = 5 Hz), 7.01 (s, 1H, vinyl H), 7.48- 7.22 (m, 9 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 6) {(3R,4R,5R,6R)-N-메틸-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 6) {(3R, 4R, 5R, 6R) -N-methyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-dimethyltri Preparation of Tyloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 5)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 5).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.11 (d, 6H, J=6.5 Hz), 1.12 (d, 12H, J=6.7 Hz), 1.16 (d, 6H, J=6.8 Hz), 1.93 (s, 6H, Me), 2.30 (s, 3H, NMe), 2.34 (s, 3H, NMe), 2.55 (t, 4H, J=6 Hz), 2.79 - 2.63 (m, 3H), 2.86 (m, 3H), 3.11 (dd, 1H, J=7, 10 Hz), 3.23 (dd, 1H, J=5.6, 10 Hz), 3.33 (s, 3H, OMe), 3.34 (s, 3H, OMe), 3.74 - 3.38 (m, 15H), 3.81 (s, 12H, OMe), 4.15 (m, 2H), 4.20 (m, 2H), 4.38 (m, 1H), 6.86 - 6.82 (m, 8H), 7.47 - 7.28 (m, 20H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.11 (d, 6H, J = 6.5 Hz), 1.12 (d, 12H, J = 6.7 Hz), 1.16 (d, 6H, J = 6.8 Hz), 1.93 (s, 6H, Me), 2.30 (s, 3H, NMe), 2.34 (s, 3H, NMe), 2.55 (t, 4H, J = 6 Hz), 2.79-2.63 (m, 3H), 2.86 (m, 3H), 3.11 (dd, 1H, J = 7, 10 Hz), 3.23 (dd, 1H, J = 5.6, 10 Hz), 3.33 (s, 3H, OMe), 3.34 (s, 3H, OMe), 3.74-3.38 (m , 15H), 3.81 (s, 12H, OMe), 4.15 (m, 2H), 4.20 (m, 2H), 4.38 (m, 1H), 6.86-6.82 (m, 8H), 7.47-7.28 (m, 20H ).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 151.73, 151.90</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 151.73, 151.90</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 17〉 {(3R,4R,5R,6R)-N-플루오레닐-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>Example 17 {(3R, 4R, 5R, 6R) -N-fluorenyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6- Preparation of Dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1)  {(3R,4R,5R,6R)-5-하이드록시-6-하이드록시메틸-4-메톡시피페리딘-3 -일}티민의 제조</span>(Step 1) Preparation of {(3R, 4R, 5R, 6R) -5-hydroxy-6-hydroxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 15의 단계 1의 표제화합물을 사용하여 실시예 7의 (단계 1)과 같은 방법을 사용하여 제조하였다.</span>Prepared using the same method as (Step 1) of Example 7 using the title compound of Step 1 of Example 15.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (DMSO) δ 1.80 (s, 3H, Me), 3.16 (m, 1H), 3.28 (m, 2H) 3.33 (s, 3H, OMe), 3.53 - 3.66 (m, 4H), 3.78 (m, 1H), 5.47 (s, 1H), 7.74 (s, 1H, vinyl H).</span> <sup>1</sup> H NMR (DMSO) δ 1.80 (s, 3H, Me), 3.16 (m, 1H), 3.28 (m, 2H) 3.33 (s, 3H, OMe), 3.53-3.66 (m, 4H), 3.78 (m , 1H), 5.47 (s, 1H), 7.74 (s, 1H, vinyl H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2)  {(3R,4R,5R,6R)-N-플루오레닐-5-하이드록시-6-다이메틸트리틸옥시메틸하이드록시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 2) {(3R, 4R, 5R, 6R) -N-fluorenyl-5-hydroxy-6-dimethyltrityloxymethylhydroxymethyl-4-methoxypiperidin-3-yl} thymine Manufacture</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">상기 단계 1의 표제화합물(800 mg, 2.8 mmol)을 다이옥산(18 mL)에 녹이고, 여기에 9-풀루오레닐메톡시카르보닐 클로라이드(9-fluorenylmethoxycarbonyl chloride, 1.04 g, 2.32 mmol)와 10 % 소듐카보네이드 수용액(35 mL)을  0 ℃에서 가하였다.  반응액을 0 ℃에서 1시간 동안 교반한 후 감압 농축하였다.  잔사를 실리카젤로 컬럼 크로마토그래피 (50 % 에틸아세테이트/헥산 - 100 % 에틸아세테이트)로 정제하여 600 mg을 얻었다(42 %).</span>The title compound of Step 1 (800 mg, 2.8 mmol) was dissolved in dioxane (18 mL), and 9-fluoroenylmethoxycarbonyl chloride (1.04 g, 2.32 mmol) and 10% sodium carbo were added thereto. An aqueous solution of amide (35 mL) was added at 0 ° C. The reaction solution was stirred at 0 ° C. for 1 hour and then concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (50% ethyl acetate / hexane-100% ethyl acetate) to obtain 600 mg (42%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.92 (s, 3H, Me), 3.37 (m, 1H), 3.46 (s, 3H, OMe), 3.50 (m, 5H), 3.89 (m, 2H), 4.25 (dd, 1H, J=5.4, 5.4 Hz), 4.55 (dd, 1H, J=5.3, 10.5 Hz), 4.70 (dd, 1H, J=5.5, 10.5 Hz), 6.85 (s, 1H, vinyl H), 7.33 (t, 2H, J=7.3 Hz), 7.42 (t, 2H, J=7.3 Hz), 7.57 (dd, 2H, J=4, 7.3 Hz), 7.77 (d, 2H, J=7.5 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.92 (s, 3H, Me), 3.37 (m, 1H), 3.46 (s, 3H, OMe), 3.50 (m, 5H), 3.89 (m, 2H), 4.25 (dd , 1H, J = 5.4, 5.4 Hz), 4.55 (dd, 1H, J = 5.3, 10.5 Hz), 4.70 (dd, 1H, J = 5.5, 10.5 Hz), 6.85 (s, 1H, vinyl H), 7.33 (t, 2H, J = 7.3 Hz), 7.42 (t, 2H, J = 7.3 Hz), 7.57 (dd, 2H, J = 4, 7.3 Hz), 7.77 (d, 2H, J = 7.5 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3)  {(3R,4R,5R,6R)-N-플루오레닐-5-하이드록시-6-다이메틸트리틸옥시메틸 -4-메톡시피페리딘-3-일}티민의 제조</span>(Step 3) Preparation of {(3R, 4R, 5R, 6R) -N-fluorenyl-5-hydroxy-6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.81 (s, 3H, Me), 3.40 (m, 2H), 3.41 (s, 3H, OMe), 3.58 (m, 1H), 3.761 (s, 3H, OMe), 3.763 (s, 3H, OMe), 3.94 - 4.17 (m, 4H), 4.26 (dd, 1H, J=6.3, 10.5 Hz), 4.63 (m, 2H), 6.89 (d, 4H, J=9 Hz),  7.03 (s, 1H, vinyl H), 7.22 - 7.77 (m, 15H), 8.24 (dd, 2H, J=1.5, 5 Hz).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.81 (s, 3H, Me), 3.40 (m, 2H), 3.41 (s, 3H, OMe), 3.58 (m, 1H), 3.761 (s, 3H, OMe), 3.763 (s, 3H, OMe), 3.94-4.17 (m, 4H), 4.26 (dd, 1H, J = 6.3, 10.5 Hz), 4.63 (m, 2H), 6.89 (d, 4H, J = 9 Hz), 7.03 (s, 1 H, vinyl H), 7.22-7.77 (m, 15 H), 8.24 (dd, 2H, J = 1.5, 5 Hz).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4) {(3R,4R,5R,6R)-N-플루오레닐-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민의 제조</span>(Step 4) {(3R, 4R, 5R, 6R) -N-fluorenyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-di Preparation of Methyltrityloxymethyl-4-methoxypiperidin-3-yl} thymine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1, using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.04 (d, 6H, J=6.5 Hz), 1.09 (d, 6H, J=6.7 Hz), 1.15 (d, 12H, J=6.3 Hz), 1.79 (s, 3H, Me), 1.81 (s, 3H, Me), 2.31 (t, 4H, J=6 Hz), 2.64 (m, 2H), 1.93 (dd, 1H, J=5, 15 Hz), 3.26 (s, 3H, OMe), 3.43 (s, 3H, OMe), 3.37 - 3.54 (m, 8H), 3.58 - 3.65 (m, 4H), 3.71 (s, 3H, OMe), 3.73 (s, 3H, OMe), 3.78 (s, 6H, OMe), 4.11 - 4.32 (m, 9H), 4.43 (m, 2H), 4.62 (m, 1H), 4.74 (m, 3H), 6.78 (m, 8H), 7.22 - 7.48 (m, 26H), 7.55 (d, 2H, J=7.9 Hz), 7.64 (d, 2H, J=8.3 Hz), 7.70 - 7.83 (m, 5H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.04 (d, 6H, J = 6.5 Hz), 1.09 (d, 6H, J = 6.7 Hz), 1.15 (d, 12H, J = 6.3 Hz), 1.79 (s, 3H, Me), 1.81 (s, 3H, Me), 2.31 (t, 4H, J = 6 Hz), 2.64 (m, 2H), 1.93 (dd, 1H, J = 5, 15 Hz), 3.26 (s, 3H , OMe), 3.43 (s, 3H, OMe), 3.37-3.54 (m, 8H), 3.58-3.65 (m, 4H), 3.71 (s, 3H, OMe), 3.73 (s, 3H, OMe), 3.78 (s, 6H, OMe), 4.11-4.32 (m, 9H), 4.43 (m, 2H), 4.62 (m, 1H), 4.74 (m, 3H), 6.78 (m, 8H), 7.22-7.48 (m , 26H), 7.55 (d, 2H, J = 7.9 Hz), 7.64 (d, 2H, J = 8.3 Hz), 7.70-7.83 (m, 5H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ: 150.02, 150.84</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ: 150.02, 150.84</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 18〉 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-이소부티릴옥시피페리딘-3-일}아데닌의 제조</span>Example 18 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) force Preparation of Finoxy] -6-dimethyltrityloxymethyl-4-isobutyryloxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 1) (3S,4R,5R,6R)-N-벤즈하이드릴-3-3차부틸다이메틸실릴옥시-4-이소부티릴옥시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 1) (3S, 4R, 5R, 6R) -N-benzhydryl-3-tert-butyldimethylsilyloxy-4-isobutyryloxy-5,6-O-[(4-methoxyphenyl ) Ethylidene] piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">실시예 1의 (단계 5)에서 얻어진 다이아스테레오머 B(또는 다이아스테레오머 A 또는 A와 B의 혼합물)를 출발물질 (4 g, 6.947 mmol)로 하여 무수 피리딘 (100 mL)에 녹이고, 여기에 트라이에틸아민 (2.2 mL, 20. 74 mmol)과 이소부티릴언하이드라이드 (isobutyric anhydride, 5.8 mL, 26.62 mmol)를 가하였다.  이 용액을 60 ℃에서 하루동안 교반한 후 상온으로 식히고 메탄올 (7 mL)을 가하여 30분동안 교반하였다.  용매를 감압하에서 증발시키고 잔사를 에틸아세테이트에 희석하여 소듐바이카보네이트 포화용액으로 씻었다.  유기층을 모아서 소듐설페이트로 건조시킨 후 감압농축하였다.  잔사를 컬럼크로마토그래피(헥산:에틸아세테이트=10:1 용매)로 정제하여 2.45 g의 화합물을 얻었다(수율 55%).</span>The diastereomer B (or diastereomer A or a mixture of A and B) obtained in Example 1 (step 5) was dissolved in anhydrous pyridine (100 mL) as starting material (4 g, 6.947 mmol) and Triethylamine (2.2 mL, 20. 74 mmol) and isobutyric anhydride (5.8 mL, 26.62 mmol) were added. The solution was stirred at 60 ° C. for one day, cooled to room temperature and methanol (7 mL) was added and stirred for 30 minutes. The solvent was evaporated under reduced pressure, and the residue was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution. The organic layers were combined, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (hexane: ethyl acetate = 10: 1 solvent) to obtain 2.45 g of a compound (yield 55%).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ -0.14 (s, 3H, Si-Me), -0.04 (s, 3H, Si-Me), 0.76 (s, 9H, Si-tBu), 1.27 (d, 3H, J=6.9 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.35 (d, 3H, J=7 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.54 (s, 3H, Me), 2.01 (dd, 1H, J=10.8, 10.8 Hz), 2.56 (ddd, 1H, J=4, 10.4, 10.4 Hz), 2.68 (m, 1H), 2.87 (dd, 1H, J=4.9, 11.4 Hz), 3.56 (d, 1H, J=8.4 Hz), 3.61 (d, 1H, J=6.9 Hz), 3.67 (dd, 1H, J=4.8, 10 Hz), 3.81 (s, 3H, OMe), 4.38 (dd, 1H, J=4, 10.4 Hz), 4.90 (dd, 1H, J=9.4, 9.4 Hz), 4.94 (s, 1H), 6.95 (d, 2H, J=8.7 Hz), 7.14 - 7.40 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ -0.14 (s, 3H, Si-Me), -0.04 (s, 3H, Si-Me), 0.76 (s, 9H, Si-tBu), 1.27 (d, 3H, J = 6.9 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.35 (d, 3H, J = 7 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.54 (s, 3H, Me), 2.01 (dd, 1H, J = 10.8, 10.8 Hz), 2.56 (ddd, 1H, J = 4, 10.4, 10.4 Hz), 2.68 (m, 1H), 2.87 (dd, 1H, J = 4.9, 11.4 Hz), 3.56 (d, 1H, J = 8.4 Hz), 3.61 (d, 1H, J = 6.9 Hz), 3.67 (dd, 1H, J = 4.8, 10 Hz), 3.81 (s, 3H, OMe), 4.38 (dd, 1H, J = 4, 10.4 Hz ), 4.90 (dd, 1H, J = 9.4, 9.4 Hz), 4.94 (s, 1H), 6.95 (d, 2H, J = 8.7 Hz), 7.14-7.40 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 2)   (3S,4R,5R,6R)-N-벤즈하이드릴-3-하이드록실-4-이소부티릴옥시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 2) (3S, 4R, 5R, 6R) -N-benzhydryl-3-hydroxyl-4-isobutyryloxy-5,6-O-[(4-methoxyphenyl) ethylidene] py Preparation of Ferridine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 1)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 7)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 7) of Example 1, using the title compound prepared in (Step 1).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.32 (d, 3H, J=6.4 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.34 (d, 3H, J=6.6 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.49 (s, 3H, Me), 1.96 (dd, 1H, J=10.9, 11 Hz), 2.55 (m, 1H), 2.77 (m, 1H), 3.08 (dd, 1H, J=5.1, 11.5 Hz), 3.52 - 3.80 (m, 3H), 3.87 (s, 3H, OMe), 4.47 (dd, 1H, J=4.1, 10.4 Hz), 4.67 (dd, 1H, J=9.2, 9.2 Hz), 4.97 (m, 1H), 6.97 (d, 2H, J=8.7 Hz), 7.14 - 7.44 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.32 (d, 3H, J = 6.4 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.34 (d, 3H, J = 6.6 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.49 (s, 3H, Me), 1.96 (dd, 1H, J = 10.9, 11 Hz), 2.55 (m, 1H), 2.77 (m, 1H), 3.08 (dd, 1H, J = 5.1, 11.5 Hz), 3.52-3.80 (m, 3H), 3.87 (s, 3H, OMe), 4.47 (dd, 1H, J = 4.1, 10.4 Hz), 4.67 (dd, 1H, J = 9.2, 9.2 Hz), 4.97 (m, 1H), 6.97 (d, 2H, J = 8.7 Hz), 7.14-7.44 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 3) (3S,4R,5R,6R)-N-벤즈하이드릴-3-메탄설포닐-4-이소부티릴옥시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘의 제조</span>(Step 3) (3S, 4R, 5R, 6R) -N-benzhydryl-3-methanesulfonyl-4-isobutyryloxy-5,6-O-[(4-methoxyphenyl) ethylidene] Preparation of Piperidine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 2)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 8)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 8) of Example 1, using the title compound prepared in (Step 2).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ  1.30 (d, 3H, J=6.9 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.35 (d, 3H, J=7 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.48 (s, 3H, Me), 2.17 (dd, 1H, J=10.8, 10.8 Hz), 2.57 (ddd, 1H, J=4, 10.2, 10.2 Hz), 2.74 (m, 1H), 2.90 (s, 3H, OSO<sub>2</sub>CH<sub>3</sub>), 3.22 (dd, 1H, J=5.2, 11.1 Hz), 3.62 (dd, 1H, J=10.4, 10.5 Hz), 3.68 (dd, 1H, J=9.2, 9.3 Hz), 3.87 (s, 3H, OMe), 4.45 (dd, 1H, J=4.2, 10.6 Hz), 4.68 (ddd, 1H, J=5.2, 5.3, 10.5 Hz), 4.98 (s, 1H), 5.06 (dd, 1H, J=9.4, 9.6 Hz), 6.96 (d, 2H, J=8.9 Hz), 7.15 - 7.42 (m, 12H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 1.30 (d, 3H, J = 6.9 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.35 (d, 3H, J = 7 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.48 (s, 3H, Me), 2.17 (dd, 1H, J = 10.8, 10.8 Hz), 2.57 (ddd, 1H, J = 4, 10.2, 10.2 Hz), 2.74 (m, 1H), 2.90 (s, 3H, OSO <sub>2</sub> CH <sub>3</sub> ), 3.22 (dd, 1H, J = 5.2, 11.1 Hz), 3.62 (dd, 1H, J = 10.4, 10.5 Hz), 3.68 (dd, 1H, J = 9.2, 9.3 Hz), 3.87 (s, 3H, OMe), 4.45 (dd, 1H, J = 4.2, 10.6 Hz), 4.68 (ddd, 1H, J = 5.2, 5.3, 10.5 Hz), 4.98 (s, 1H), 5.06 (dd, 1H, J = 9.4, 9.6 Hz), 6.96 (d, 2H, J = 8.9 Hz), 7.15-7.42 (m, 12H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 4)  {(3R,4R,5R,6R)-N-벤즈하이드릴-4-이소부티릴옥시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 4) {(3R, 4R, 5R, 6R) -N-benzhydryl-4-isobutyryloxy-5,6-O-[(4-methoxyphenyl) ethylidene] piperidine-3 Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 3)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 9)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 9) of Example 1 using the title compound prepared in (Step 3).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.89 (d, 3H, J=7 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 0.97 (d, 3H, J=7 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.50 (s, 3H, Me), 2.40 (m, 1H), 2.57 (dd, 1H, J=11.4, 11.6 Hz), 2.77 (m, 1H), 3.11 (dd, 1H, J=4.4, 11.3 Hz), 3.72 (dd, 1H, J=10.4, 10.4 Hz), 3.89 (s, 3H, OMe), 3.92 (m, 1H), 4.53 (dd, 1H, J=4, 10.5 Hz), 4.82 (ddd, 1H, J=4.3, 11.2, 11.3 Hz), 5.06 (s, 1H), 5.42 (dd, 1H, J=9.7, 10.4 Hz), 6.97 (d, 2H, J=8.7 Hz), 7.13 - 7.75 (m, 12H), 7.75 (s, 1H), 8.33 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.89 (d, 3H, J = 7 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 0.97 (d, 3H, J = 7 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.50 (s, 3H, Me), 2.40 (m, 1H), 2.57 (dd, 1H, J = 11.4, 11.6 Hz), 2.77 (m, 1H), 3.11 (dd, 1H, J = 4.4, 11.3 Hz), 3.72 (dd , 1H, J = 10.4, 10.4 Hz), 3.89 (s, 3H, OMe), 3.92 (m, 1H), 4.53 (dd, 1H, J = 4, 10.5 Hz), 4.82 (ddd, 1H, J = 4.3 , 11.2, 11.3 Hz), 5.06 (s, 1H), 5.42 (dd, 1H, J = 9.7, 10.4 Hz), 6.97 (d, 2H, J = 8.7 Hz), 7.13-7.75 (m, 12H), 7.75 (s, 1 H), 8.33 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 5) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-4-이소부티릴옥시-5,6-O-[(4-메톡시페닐)에틸리덴]피페리딘-3-일}아데닌의 제조</span>(Step 5) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-4-isobutyryloxy-5,6-O-[(4-methoxyphenyl) ethylidene ] Piperidin-3-yl} Adenine Preparation</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 4)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 10)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 10) of Example 1 using the title compound prepared in (Step 4).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.89 (d, 3H, J=7 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 0.97 (d, 3H, J=6.9 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 1.51 (s, 3H, Me), 2.40 (m, 1H), 2.62 (dd, 1H, J=11.3, 11.4 Hz), 2.80 (m, 1H), 3.15 (dd, 1H, J=4.4, 11.3 Hz), 3.74 (dd, 1H, J=10.4, 10.5 Hz), 3.89 (s, 3H, OMe), 3.94 (dd, 1H, J=9.2, 9.2 Hz), 4.54 (dd, 1H, J=4, 10.5 Hz), 4.91 (m, 1H), 5.08 (s, 1H), 5.48 (dd, 1H, J=10, 10 Hz), 6.97 (d, 2H, J=8.8 Hz), 7.13 - 7.61 (m, 15H), 7.97 (s, 1H), 8.02 (d, 1H, J=7.3 Hz), 8.79 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.89 (d, 3H, J = 7 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 0.97 (d, 3H, J = 6.9 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 1.51 (s, 3H, Me), 2.40 (m, 1H), 2.62 (dd, 1H, J = 11.3, 11.4 Hz), 2.80 (m, 1H), 3.15 (dd, 1H, J = 4.4, 11.3 Hz), 3.74 (dd , 1H, J = 10.4, 10.5 Hz), 3.89 (s, 3H, OMe), 3.94 (dd, 1H, J = 9.2, 9.2 Hz), 4.54 (dd, 1H, J = 4, 10.5 Hz), 4.91 ( m, 1H), 5.08 (s, 1H), 5.48 (dd, 1H, J = 10, 10 Hz), 6.97 (d, 2H, J = 8.8 Hz), 7.13-7.61 (m, 15H), 7.97 (s , 1H), 8.02 (d, 1H, J = 7.3 Hz), 8.79 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 6) 6-N-벤조일-{(3R,4R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-하이드록시메틸-4-이소부티릴옥시피페리딘-3-일}아데닌의 제조</span>(Step 6) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-hydroxymethyl-4-isobutyryloxypiperidine-3- Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 5)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 11)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 11) of Example 1 using the title compound prepared in (Step 5).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.75 (d, 3H, J=7 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 0.90 (d, 3H, J=6.9 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 2.33 (m, 1H), 2.71 - 2.76 (m, 2H), 3.26 (dd, 1H, J=4.1, 11.6 Hz), 4.14 - 4.23 (m, 2H), 4.34 (m, 1H), 4.91 (ddd, 1H, J=3.8, 11, 11 Hz), 5.37 (dd, 1H, J=9.2, 10.6 Hz), 5.62 (s, 1H), 7.17 - 7.40 (m, 10H), 7.52 (t, 2H, J=7.2 Hz), 7.60 (d, 1H, J=7.2 Hz), 7.90 (s, 1H), 8.02 (d, 1H, J=7.7 Hz), 8.79 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.75 (d, 3H, J = 7 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 0.90 (d, 3H, J = 6.9 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 2.33 (m, 1H), 2.71-2.76 (m, 2H), 3.26 (dd, 1H, J = 4.1, 11.6 Hz), 4.14-4.23 (m, 2H), 4.34 (m, 1H), 4.91 (ddd, 1H, J = 3.8, 11, 11 Hz), 5.37 (dd, 1H, J = 9.2, 10.6 Hz), 5.62 (s, 1H), 7.17-7.40 (m, 10H), 7.52 (t, 2H, J = 7.2 Hz), 7.60 (d, 1H, J = 7.2 Hz), 7.90 (s, 1H), 8.02 (d, 1H, J = 7.7 Hz), 8.79 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 7) 6-N-벤조일-{(3R,4R,5R,6R)-1N-벤즈하이드릴-5-하이드록시-6-다이메틸트리틸옥시메틸-4-이소부티릴옥시피페리딘-3-일}아데닌의 제조</span>(Step 7) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -1N-benzhydryl-5-hydroxy-6-dimethyltrityloxymethyl-4-isobutyryloxypiperidine Preparation of Adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 6)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 12)와 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in Example 1 (Step 12) using the title compound prepared in (Step 6).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.74 (d, 3H, J=7.1 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 0.91 (d, 3H, J=6.9 Hz, CH(CH<sub>3</sub>)<sub>2</sub>), 2.34 (m, 1H), 2.63 (d, 1H, J=8.9 Hz), 2.75 (dd, 1H, J=11.3, 11.3 Hz), 3.25 (dd, 1H, J=4.2, 11.4 Hz), 3.79 (s, 6H, OMe), 4.23 (ddd, 1H, J=4.1, 10.8, 10.8 Hz), 5.20 (s, 1H), 5.33 (dd, 1H, J=9.5, 10.2 Hz), 6.81 (d, 2H, J=8.9 Hz), 6.83 (d, 2H, J=9 Hz), 7.22 - 7.41 (m, 19H), 7.52 (t, 2H, J=6.9 Hz), 7.59 (d, 1H, J=7.1 Hz), 7.98 (s, 1H), 8.02 (d, 1H, J=7.5 Hz), 8.81 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.74 (d, 3H, J = 7.1 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 0.91 (d, 3H, J = 6.9 Hz, CH (CH <sub>3</sub> ) <sub>2</sub> ), 2.34 (m, 1H), 2.63 (d, 1H, J = 8.9 Hz), 2.75 (dd, 1H, J = 11.3, 11.3 Hz), 3.25 (dd, 1H, J = 4.2, 11.4 Hz), 3.79 (s, 6H, OMe ), 4.23 (ddd, 1H, J = 4.1, 10.8, 10.8 Hz), 5.20 (s, 1H), 5.33 (dd, 1H, J = 9.5, 10.2 Hz), 6.81 (d, 2H, J = 8.9 Hz) , 6.83 (d, 2H, J = 9 Hz), 7.22-7.41 (m, 19H), 7.52 (t, 2H, J = 6.9 Hz), 7.59 (d, 1H, J = 7.1 Hz), 7.98 (s, 1H), 8.02 (d, 1H, J = 7.5 Hz), 8.81 (s, 1H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">(단계 8) 6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-이소부티릴옥시피페리딘-3-일}아데닌의 제조</span>(Step 8) 6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Preparation of oxy] -6-dimethyltrityloxymethyl-4-isobutyryloxypiperidin-3-yl} adenine</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이 화합물은 상기 (단계 7)에서 제조된 표제화합물을 이용하여 실시예 1의 (단계 13)과 같은 과정으로 제조하였다.</span>This compound was prepared in the same manner as in (Step 13) of Example 1 using the title compound prepared in (Step 7).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.83 (d, 3H, J=7.3 Hz, COCH(CH<sub>3</sub>)<sub>2</sub>), 0.92 (d, 3H, J=6.9 Hz, COCH(CH<sub>3</sub>)<sub>2</sub>), 1.09 (d, 6H, J=6.7 Hz, NCH(CH<sub>3</sub>)<sub>2</sub>), 1.17 (d, 6H, J=6.9 Hz, NCH(CH<sub>3</sub>)<sub>2</sub>), 2.22 (m, 1H), 2.44 (t, 2H, J=6.5 Hz), 2.78 (dd, 1H, J=6.5, 12.5 Hz), 3.06 (dd, 1H, J=4.1, 12.6 Hz), 3.45 - 3.60 (m, 3H), 3.62 - 3.88 (m, 4H), 3.80 (s, 3H, OMe), 3.81 (s, 3H, OMe), 4.48 (m, 1H), 4.77 (s, 1H), 4.82 (m, 1H), 5.40 (t, 1H, J=5.4 Hz), 6.79 (d, 2H, J=8.8 Hz), 6.80 (d, 2H, J=8.8 Hz), 7.11 - 7.56 (m, 22H),8.05 (d, 2H, J=7.2 Hz), 8.71 (s, 1H), 8.76 (s, 1H).</span> <sup>1</sup> H NMR (CDCl <sub>3</sub> ) δ 0.83 (d, 3H, J = 7.3 Hz, COCH (CH <sub>3</sub> ) <sub>2</sub> ), 0.92 (d, 3H, J = 6.9 Hz, COCH (CH <sub>3</sub> ) <sub>2</sub> ), 1.09 (d, 6H, J = 6.7 Hz, NCH (CH <sub>3</sub> ) <sub>2</sub> ), 1.17 (d, 6H, J = 6.9 Hz, NCH (CH <sub>3</sub> ) <sub>2</sub> ), 2.22 (m, 1H), 2.44 (t, 2H, J = 6.5 Hz), 2.78 (dd, 1H, J = 6.5, 12.5 Hz), 3.06 (dd, 1H, J = 4.1, 12.6 Hz), 3.45-3.60 (m, 3H), 3.62-3.88 (m, 4H), 3.80 (s, 3H, OMe), 3.81 (s, 3H, OMe), 4.48 (m, 1H), 4.77 (s, 1H), 4.82 (m, 1H), 5.40 (t, 1H, J = 5.4 Hz), 6.79 (d, 2H, J = 8.8 Hz), 6.80 (d, 2H, J = 8.8 Hz), 7.11-7.56 (m, 22H), 8.05 (d, 2H, J = 7.2 Hz), 8.71 (s, 1H ), 8.76 (s, 1 H).</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text"> <sup>31</sup>P NMR (CDCl<sub>3</sub>) δ 150.56, 150.83.</span> <sup>31</sup> P NMR (CDCl <sub>3</sub> ) δ 150.56, 150.83.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 19〉 올리고머의 합성</span>Example 19 Synthesis of Oligomer</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">모든 올리고머는 어플라이드 바이오시스템 392(DNA/RNA Synthesizer)를 이용하여 1 마이크로몰 스케일로 트리틸-온(trityl-on) 상태로 합성되었다.  일반적인 축합시간이 1분인데 반하여, 아자슈거의 4위치에 수소외의 기가 있는 뉴클레오타이드 축합의 경우에는 축합시간이 10분이었다.  고체지지물과 보호기는 암모니아수를 사용하여 55 ℃에서 17시간 동안의 가열에 의해 제거 되었고, 이 용액은 디메톡시트리틸(DMT) 보호기의 분리를 막기 위해 1시간마다 트리에틸아민 5방울을 가하면서 동결 건조되었다.  잔사를 1 mL의  산도 7의 100 mM 트리에틸암모니움 아세테이트(triethylammonium acetate, 이 후 TEAA) 용액에 녹이고 이를 역상 고성능 액체크로마토그래피 (Hamilton PRP-1, 300 mm x 7 mm, 18 - 28 % 아세토나이트릴/100 mM TEAA, 산도 7, 260 nm에서 UV로 모니터)로 정제하였다.  원하는 분획을 동결건조하고, 1 mL의 증류수를 두 번 가하여 다시 동결 건조함으로써, 잔류하는 TEAA 염을 완전히 제거하였다.  남은 고체를 0.3 mL의 80 % 초산을 가하여 볼텍스(votex)로 완전히 녹인 다음 20분간 상온에서 방치하여 디메톡시트리틸기를 분리하였다.  0.3 mL의 에탄올을 가하여 과량의 초산을 제거하고 이를 동결 건조하였다.  잔사에 1 mL의 증류수를 가하여 볼텍스로 잘 녹이고, 1 mL의 에테르를 가하여 볼텍스로 잘 교반시켰다.  상층의 에테르를 피펫으로 제거하고 다시 1 mL의 에테르를 가한 후, 같은 과정을 두 번 반복하였다.  물층을 동결 건조한 후 잔사에 1 mL의 증류수를 가한 다음, 이 용액을 70 ℃에서 UV 흡광도를 측정하여 정량하였다.  농도 계산을 위한 자연 뉴클레오타이드의 흡광 계수는 dAMP, 15200; dCMP, 7700; TMP, 8830; dGMP, 11500;이다.  아자 슈가를 가진 뉴클레오타이드의 흡광 계수도 자연 뉴클레오타이드와 같은 값으로 계산되었다.  올리고머의 구성은 효소분해 후 고성능 액체 크로마토그래피(HPLC)(Hewlett Packard, ODS hypersil, C-18; 20 mM K<sub>2</sub>HPO<sub>4</sub>, pH 5.6 (A), MeOH (B), 100 % A to 40% B, 20 min)와 레이져 탈착(Laser Desorption) 질량 분석으로 확인되었다.</span>All oligomers were synthesized in trityl-on state at 1 micromolar scale using Applied Biosystem 392 (DNA / RNA Synthesizer). While the general condensation time was 1 minute, the condensation time was 10 minutes in the case of nucleotide condensation having a group other than hydrogen at the 4 position of Azasugar. The solid support and protecting group were removed by heating at 55 ° C. for 17 hours using ammonia water and the solution was frozen by adding 5 drops of triethylamine every hour to prevent separation of the dimethoxytrityl (DMT) protecting group. Dried. The residue was dissolved in 1 mL of pH 7 solution of 100 mM triethylammonium acetate (TEAA) and reverse phase high performance liquid chromatography (Hamilton PRP-1, 300 mm x 7 mm, 18-28% acetonite). Reel / 100 mM TEAA, monitored with UV at pH 7, 260 nm). The desired fractions were lyophilized and 1 mL of distilled water was added twice and lyophilized to completely remove the remaining TEAA salt. 0.3 mL of 80% acetic acid was added to completely dissolve in vortex and left at room temperature for 20 minutes to separate the dimethoxytrityl group. 0.3 mL of ethanol was added to remove excess acetic acid and it was lyophilized. 1 mL of distilled water was added to the residue to dissolve it well with vortex, and 1 mL of ether was added thereto and stirred well with vortex. The upper ether was pipetted off and 1 mL of ether was added again, and the same procedure was repeated twice. The water layer was lyophilized, 1 mL of distilled water was added to the residue, and the solution was quantified by measuring UV absorbance at 70 ° C. The extinction coefficient of the natural nucleotide for the concentration calculation was dAMP, 15200; dCMP, 7700; TMP, 8830; dGMP, 11500; The extinction coefficients of nucleotides with aza sugars were also calculated to be the same values as natural nucleotides. The oligomer consists of high performance liquid chromatography (HPLC) after enzymatic degradation (Hewlett Packard, ODS hypersil, C-18; 20 mM K <sub>2</sub> HPO <sub>4</sub> , pH 5.6 (A), MeOH (B), 100% A to 40% B , 20 min) and laser desorption mass spectrometry.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 20〉 올리고머의 하이브리디제이션 : Melting Studies</span>Example 20 Hybridization of Oligomers: Melting Studies</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">온도 변화에 따른 올리고머의 UV 흡광도 변화는 베크만 분광기(Beckmann DU 650 Spectrometer)와 베크만 고성능 온도제어기(Beckmann High Performance Temperature Controller)를 사용하여 측정되었다.  상온 이하의 저온에서 흡광도를 측정할 때는 질소가스를 약하게 UV 셀에 불어줌으로써 셀 표면의 습기 응축현상을 방지하였다.  온도는 1분에 1 ℃씩 증가시켜 5 ℃에서 90 ℃까지 측정하였으며, 안티센스 올리고머 및 RNA의 농도는 각 2.5 μM을 사용하고, 완충용액은 100 mM NaCl, 10 mM 소듐 포스페이트(sodium phosphate), 0.1 mM EDTA, pH 7을 사용하였다.  Tm(melting temperature)은 온도곡선에 대한 흡광도의 1차 도함수(first derivative)로 산출되었다.  고온에서 저온으로의 Tm 곡선(Reverse melting temperature, 90 ℃에서 5 ℃까지, 1분에 1 ℃ 감소)도 측정하였으며, 이 때의 Tm 값은 포워드(Foward) 실험의 Tm 값과 ±1 ℃ 이내의 차이를 보였다.</span>Changes in UV absorbance of oligomers with temperature changes were measured using a Beckmann DU 650 Spectrometer and a Beckmann High Performance Temperature Controller. When measuring the absorbance at low temperature below room temperature, nitrogen condensation was weakly blown into the UV cell to prevent moisture condensation on the cell surface. The temperature was increased by 1 ° C. per minute and measured from 5 ° C. to 90 ° C., and the concentration of the antisense oligomer and RNA was 2.5 μM, and the buffer solution was 100 mM NaCl, 10 mM sodium phosphate, 0.1 mM EDTA, pH 7 was used. Melting temperature (Tm) was calculated as the first derivative of absorbance over a temperature curve. The Tm curve from high temperature to low temperature (reverse melting temperature, 90 ° C to 5 ° C, decreased by 1 ° C per minute) was also measured. Showed a difference.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">아자슈가를 가진 안티센스 올리고머의 상보적 서열을 갖는 RNA에 대한 Tm 값을 DNA-RNA Tm 값과 비교하였다.  높은 Tm 값은 높은 결합력을 나타낸다.</span>The Tm values for RNAs with complementary sequences of antisense oligomers with azasugars were compared to DNA-RNA Tm values. High Tm values indicate high binding forces.</span>
</div>
<div class="description-paragraph">
<tables num="1">
<patent-tables>
<span class="notranslate"> <span class="google-src-text">안티센스 올리고머의 Tm값 측정</span>Tm value measurement of antisense oligomer</span>
<table class="description-table" cols="6" width="100%">
<tbody><tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1"> </td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">R<sup>1</sup> </span>R <sup>1</sup> </span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">R<sup>2</sup> </span>R <sup>2</sup> </span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">Sequence</span>Sequence</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">Tm (RNA)</span>Tm (RNA)</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">ΔTm</span>ΔTm</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1">
<span class="notranslate"> <span class="google-src-text">대조군</span>Control</span>
</td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">-</span>-</span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">-</span>-</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-dAGG GAG AGA AAG-3'5'-rCTT TCT CTC CCT-3'</span>5'-dAGG GAG AGA AAG-3'5'-rCTT TCT CTC CCT-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">34<sup>o</sup>C</span>34 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-</span>-</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="2" nameend="1" namest="1" rowspan="3">
<span class="notranslate"> <span class="google-src-text">실시예 1</span>Example 1</span>
</td>
<td class="description-td" morerows="2" nameend="2" namest="2" rowspan="3">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="2" nameend="3" namest="3" rowspan="3">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">36<sup>o</sup>C</span>36 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">+2<sup>o</sup>C</span>+2 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">39<sup>o</sup>C</span>39 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">+5<sup>o</sup>C</span>+5 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">40<sup>o</sup>C</span>40 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">+6<sup>o</sup>C</span>+6 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 2</span>Example 2</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">β-OEt</span>β-OEt</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">36<sup>o</sup>C</span>36 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">+2<sup>o</sup>C</span>+2 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">38<sup>o</sup>C</span>38 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">+4<sup>o</sup>C</span>+4 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1">
<span class="notranslate"> <span class="google-src-text">실시예 3</span>Example 3</span>
</td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">β-OEtOMe</span>β-OEtOMe</span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">37<sup>o</sup>C</span>37 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">+1<sup>o</sup>C</span>+1 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 4</span>Example 4</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">H</span>H</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">34<sup>o</sup>C</span>34 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">0<sup>o</sup>C</span>0 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">34<sup>o</sup>C</span>34 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">0<sup>o</sup>C</span>0 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 5</span>Example 5</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">α-OMe</span>α-OMe</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">36<sup>o</sup>C</span>36 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">+2<sup>o</sup>C</span>+2 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">37<sup>o</sup>C</span>37 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">3<sup>o</sup>C</span>3 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 6</span>Example 6</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">α-OEt</span>α-OEt</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">33<sup>o</sup>C</span>33 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-1<sup>o</sup>C</span>-1 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">34<sup>o</sup>C</span>34 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">0<sup>o</sup>C</span>0 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 7</span>Example 7</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">Me</span>Me</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">28<sup>o</sup>C</span>28 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-6<sup>o</sup>C</span>-6 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">20<sup>o</sup>C</span>20 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-14<sup>o</sup>C</span>-14 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 8</span>Example 8</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">n-propyl</span>n-propyl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">31<sup>o</sup>C</span>31 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-3<sup>o</sup>C</span>-3 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">26<sup>o</sup>C</span>26 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-8<sup>o</sup>C</span>-8 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 9</span>Example 9</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">benzyl</span>benzyl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">33<sup>o</sup>C</span>33 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-1<sup>o</sup>C</span>-1 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">33<sup>o</sup>C</span>33 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-1<sup>o</sup>C</span>-1 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 10</span>Example 10</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">4-cyanobenzyl</span>4-cyanobenzyl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">32<sup>o</sup>C</span>32 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-2<sup>o</sup>C</span>-2 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">31<sup>o</sup>C</span>31 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-3<sup>o</sup>C</span>-3 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 11</span>Example 11</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">4-fluorobenzyl</span>4-fluorobenzyl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">33<sup>o</sup>C</span>33 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-1<sup>o</sup>C</span>-1 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">33<sup>o</sup>C</span>33 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-1<sup>o</sup>C</span>-1 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 12</span>Example 12</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">4-methoxybenzyl</span>4-methoxybenzyl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">31<sup>o</sup>C</span>31 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-3<sup>o</sup>C</span>-3 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">31<sup>o</sup>C</span>31 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-3<sup>o</sup>C</span>-3 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="1" nameend="1" namest="1" rowspan="2">
<span class="notranslate"> <span class="google-src-text">실시예 14</span>Example 14</span>
</td>
<td class="description-td" morerows="1" nameend="2" namest="2" rowspan="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="1" nameend="3" namest="3" rowspan="2">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">25<sup>o</sup>C</span>25 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-9<sup>o</sup>C</span>-9 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">20<sup>o</sup>C</span>20 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-14<sup>o</sup>C</span>-14 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1">
<span class="notranslate"> <span class="google-src-text">실시예 18</span>Example 18</span>
</td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">β-OH</span>β-OH</span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-AGG GAG AGA AAG-3'</span>5'-AGG GAG AGA AAG-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">31<sup>o</sup>C</span>31 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-3<sup>o</sup>C</span>-3 <sup>o</sup> C</span>
</td>
</tr>
</tbody></table>
</patent-tables>
</tables>
</div>
<div class="description-paragraph">
<tables num="2">
<patent-tables>
<span class="notranslate"> <span class="google-src-text">안티센스 올리고머의 Tm값 측정</span>Tm value measurement of antisense oligomer</span>
<table class="description-table" cols="6" width="100%">
<tbody><tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1"> </td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">R<sup>1</sup> </span>R <sup>1</sup> </span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">R<sup>2</sup> </span>R <sup>2</sup> </span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">Sequence</span>Sequence</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">Tm(RNA)</span>Tm (RNA)</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">ΔTm</span>ΔTm</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1">
<span class="notranslate"> <span class="google-src-text">대조군</span>Control</span>
</td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">-</span>-</span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">-</span>-</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-rAGG GAG AGA AAG-3'5'-dCTT TCT CTC CCT-3'</span>5'-rAGG GAG AGA AAG-3'5'-dCTT TCT CTC CCT-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">54 ℃</span>54 ℃</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-</span>-</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1">
<span class="notranslate"> <span class="google-src-text">실시예 13</span>Example 13</span>
</td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-CTT TCT CTC CCT-3'</span>5'-CTT TCT CTC CCT-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">34<sup>o</sup>C</span>34 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-20<sup>o</sup>C</span>-20 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1">
<span class="notranslate"> <span class="google-src-text">실시예 15</span>Example 15</span>
</td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">benzhydryl</span>benzhydryl</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-CTT TCT CTC CCT-3'</span>5'-CTT TCT CTC CCT-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">46<sup>o</sup>C</span>46 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-8<sup>o</sup>C</span>-8 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1">
<span class="notranslate"> <span class="google-src-text">실시예 16</span>Example 16</span>
</td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">Me</span>Me</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-CTT TCT CTC CCT-3'</span>5'-CTT TCT CTC CCT-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">42<sup>o</sup>C</span>42 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-12<sup>o</sup>C</span>-12 <sup>o</sup> C</span>
</td>
</tr>
<tr class="description-tr">
<td class="description-td" morerows="0" nameend="1" namest="1">
<span class="notranslate"> <span class="google-src-text">실시예 17</span>Example 17</span>
</td>
<td class="description-td" morerows="0" nameend="2" namest="2">
<span class="notranslate"> <span class="google-src-text">β-OMe</span>β-OMe</span>
</td>
<td class="description-td" morerows="0" nameend="3" namest="3">
<span class="notranslate"> <span class="google-src-text">H(Fmoc 보호기)</span>H (Fmoc Protector)</span>
</td>
<td class="description-td" morerows="0" nameend="4" namest="4">
<span class="notranslate"> <span class="google-src-text">5'-CTT TCT CTC CCT-3'</span>5'-CTT TCT CTC CCT-3 '</span>
</td>
<td class="description-td" morerows="0" nameend="5" namest="5">
<span class="notranslate"> <span class="google-src-text">40<sup>o</sup>C</span>40 <sup>o</sup> C</span>
</td>
<td class="description-td" morerows="0" nameend="6" namest="6">
<span class="notranslate"> <span class="google-src-text">-14<sup>o</sup>C</span>-14 <sup>o</sup> C</span>
</td>
</tr>
</tbody></table>
</patent-tables>
</tables>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">표 1 및 표 2의 결과를 살펴보면, 모든 올리고머가 자연형의 DNA 나선보다 RNA에 대한 강한 결합을 나타내는데, 특히 그 중에서도 실시예 1, 실시예 2, 실시예 3 및 실시예 5의 모노머를 가지는 올리고머는 Tm 값이 1 - 6 ℃까지 상승하는 것으로 보아 상보적 서열을 갖는 RNA에 대해 가장 높은 결합력을 보임을 알 수 있다.</span>Looking at the results of Table 1 and Table 2, all oligomers show stronger binding to RNA than natural DNA helix, in particular the oligomers having monomers of Examples 1, 2, 3 and 5, among others. It can be seen that the Tm value rises to 1-6 ° C., which shows the highest binding force to the RNA having the complementary sequence.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">따라서, 본 발명의 올리고머는 RNA에 대한 결합력이 높은 우수한 안티센스로서 이용될 수 있다.</span>Therefore, the oligomer of the present invention can be used as an excellent antisense having high binding ability to RNA.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 21〉 올리고머의 뉴클리아제(Nuclease)에 대한 안정성</span>&lt;Example 21&gt; Stability of the oligomer to Nuclease</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">에펜돌프 튜브에 각 올리고머 (실시예 1의 모노머를 이용한 3개의 올리고머: 5'-AGG GAG AGA AAG-3', 5'-AGG GAG AGA AAG-3', 5'-AGG GAG AGA AAG-3') 0.15 OD를 넣고, 0.03 단위의 사독(蛇毒) 디에스터라제(snake vernom diesterase)와 0.18 단위의 알칼리성 포스파타제(alkaline phosphatase)를 가한다 (Buffer: 100 mM MgCl<sub>2</sub>, 4 μL: 0.25 M Tris HCl, pH 8.1, 8 μL: 증류수 13 μL). 이 반응액을 37 ℃에서 인큐베이션하면서 30분 간격으로 일정액을 취하여 올리고머의 분해정도를 HPLC로 측정한다(Hamilton PRP-1, 300 mm x 7 mm, 260 nm에서 측정).  이 조건하에서는 자연 올리고머는 30분 내에 모두 분해되나 실시예 1의 3개의 올리고머는 모두 4시간까지 완전히 분해되지 않았다. HPLC 상 본 발명의 모노머 피크가 나타나지 않고 일부가 분해된 올리고머 조각이 나타나는 것으로 보아 위 효소는 본 발명의 모노머가 연결된 DNA를 부분을 분해하지 못하는 것으로 보인다.</span>Each oligomer (3 oligomers using the monomer of Example 1: 5'-AGG GAG AGA AAG-3 ', 5'-AGG GAG AGA AAG-3', 5'-AGG GAG AGA AAG-3 ' ) Add 0.15 OD, add 0.03 units of snake vernom diesterase and 0.18 units of alkaline phosphatase (Buffer: 100 mM MgCl <sub>2</sub> , 4 μL: 0.25 M Tris HCl, pH 8.1, 8 μL: 13 μL of distilled water). The reaction solution was incubated at 37 ° C. and a constant solution was taken at 30 minute intervals to measure the degree of degradation of the oligomer by HPLC (Hamilton PRP-1, 300 mm × 7 mm, measured at 260 nm). Under this condition, the natural oligomers were all degraded within 30 minutes, but all three oligomers of Example 1 did not completely degrade until 4 hours. HPLC showed no monomer peak of the present invention and fragmented oligomeric fragments showed that the enzyme does not seem to cleave the DNA linked to the monomer of the present invention.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">〈실시예 22〉  랫트에 대한 비경구투여 급성 독성실험</span>Example 22 Parenteral Administration Acute Toxicity in Rats</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">6주령의 특정병원부재(SPF) SD계 랫트를 사용하여 급성독성실험을 실시하였다.  군당 2 마리씩의 동물에 실시예 1∼19의 화합물을 각각 0.5% 메틸셀룰로즈 용액에 현탁하여 1g/kg/15mL의 용량으로 단회 비경구투여하였다.  시험물질 투여후 동물의 폐사여부, 임상증상, 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적검사를 실시하였으며, 부검하여 육안으로 복강장기와 흉강장기의 이상여부를 관찰하였다.  시험결과, 시험물질을 투여한 모든 동물에서 특기할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사, 부검소견 등에서도 독성변화는 관찰되지 않았다.  이상의 결과 실험된 화합물은 모두 랫트에서 500 mg/kg까지 독성변화를 나타내지 않으며 경구 투여 최소치사량 (LD<sub>50</sub>)은 500 mg/kg이상인 안전한 물질로 판단되었다.</span>Acute toxicity test was performed using 6 week-old SPF SD rats. Two animals per group were suspended parenterally in a dose of 1 g / kg / 15 mL by suspending the compounds of Examples 1-19 in 0.5% methylcellulose solution, respectively. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed. Necropsy was performed to observe abdominal and thoracic organ abnormalities. As a result, there were no clinical symptoms or deaths in all animals treated with the test substance, and no toxicity change was observed in weight change, blood test, blood biochemistry test, autopsy findings, etc. As a result, all of the tested compounds did not show toxic changes up to 500 mg / kg in rats, and the minimum lethal dose (LD <sub>50</sub> ) was determined to be a safe substance of 500 mg / kg or more.</span>
</div>
</tech-solution>
<advantageous-effects>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">이상에서 살펴본 바와 같이, 본 발명은 질병의 원인이 되는 독성 단백질 생산을 근원적으로 차단할 수 있는 안티센스 모노머 및 올리고머에 관한 것으로, 본 발명의 안티센스 모노머 및 안티센스 올리고머는 일반적인 안티센스 약물의 목표인 RNA에 DNA보다 강하게 결합할 뿐만 아니라, 분해효소인 뉴클레아제에 대한 내성을 가지며, 또한 세포막의 투과성도 개선시킬 수 있다.</span>As described above, the present invention relates to antisense monomers and oligomers that can fundamentally block the production of toxic proteins that cause disease, and the antisense monomers and antisense oligomers of the present invention are better than DNA for RNA, which is a target of general antisense drugs. In addition to binding strongly, it is resistant to the nuclease, a degrading enzyme, and can also improve the permeability of cell membranes.</span>
</div>
<div class="description-paragraph">
<span class="notranslate"> <span class="google-src-text">또한, 본 발명의 모노머 및 올리고머는 질병을 일으키는 유전자의 발현을 차단하여 안티센스 요법과 같은 분야에 유용하며, 안티센스 기술 이외에도 유전자 크로닝의 하이브리디제이션, 진단시약, 단백질 연구 등에 유용하게 사용될 수 있다.</span>In addition, the monomers and oligomers of the present invention can be useful in fields such as antisense therapy by blocking the expression of genes causing disease, and can be useful for hybridization, diagnostic reagents, and protein research in addition to antisense technology.</span>
</div>
</advantageous-effects>
</disclosure>
</div>
</div>
</section><section itemprop="claims" itemscope="">
<h2>Claims (<span itemprop="count">14</span>)</h2>
<div html="" itemprop="content"><ol class="claims" lang="EN" load-source="google" mxw-id="PCLM120150623">
<li class="claim"> <div claim-type="Currently amended" class="claim" num="1">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">자연 뉴클레오타이드의 당인 오환의 리보오스(ribose)를 육환의 아자슈가로 치환한 하기 화학식 1의 구조를 갖는 뉴클레오타이드 모노머.</span>A nucleotide monomer having a structure represented by the following formula (1) in which a cyclic ribose, which is a sugar of a natural nucleotide, is substituted with azasugar of a hexacyclic ring.</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">화학식 1</span>Formula 1</span>
</div>
<div class="claim-text">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">상기 화학식 1에서</span>In Chemical Formula 1</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(1) B는 보호기를 갖거나 갖지 않은 자연 뉴클레오베이스 또는 변형된 뉴클레오베이스이고,</span>(1) B is a natural nucleobase or modified nucleobase with or without protecting groups,</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(2) R<sup>1</sup>은 수소, α- 또는 β-하이드록시, α- 또는 β-메톡시, α- 또는 β-에톡시 등 α- 또는 β-저분자 알콕시 (lower alkoxy), α- 또는 β-메톡시에톡시, α- 또는 β- 플로로 등 α- 또는 β-할로겐, α- 또는 β-아미노메톡시, α- 또는 β-아미노에톡시 등 α- 또는 β-아미노알콕시, α- 또는 β-다이메틸아미노-옥시에틸록시 (dimethyl amino- oxyethyloxy) 등 α- 또는 β-다이메틸아미노-옥시알콕시, α- 또는 β-O-아실이며,</span>(2) R <sup>1</sup> is hydrogen, α- or β-hydroxy, α- or β-methoxy, α- or β-ethoxy and the like, or α- or β-lower molecular weight alkoxy, α- or β-meth Α- or β-aminoalkoxy, α- or β- such as α- or β-halogen, α- or β-aminomethoxy, α- or β-aminoethoxy, such as oxyethoxy, α- or β-fluoro Α- or β-dimethylamino-oxyalkoxy, α- or β-O-acyl, such as dimethylamino-oxyethyloxy,</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(3) R<sup>2</sup>는 수소, 벤질, 메틸벤질, 에틸벤질, 디페닐메틸, 할로디페닐메틸 등 아라알킬 (aralkyl), 니트로벤질, 플루오로벤질 등의 할로아라알킬, 시아노벤질, 메톡시벤질, 에톡시벤질 등 알콕시벤질,  메틸, 에틸, 프로필, 3차부틸 등의 저분자알킬 (lower alkyl), 페닐, 할로페닐 등의 치환기가 있거나 없는 아릴 (aryl), 헤테로아릴(heteroaryl), 헤테로아릴알킬 (heteroarylalkyl), 나프타릴, 플루오레닐 (Fmoc) 이며,</span>(3) R <sup>2</sup> is hydrogen, benzyl, methylbenzyl, ethylbenzyl, diphenylmethyl, halodiphenylmethyl, such as haloaraalkyl, aralkyl, nitrobenzyl, fluorobenzyl, cyanobenzyl, methoxybenzyl , Aryl, heteroaryl, heteroarylalkyl, with or without substituents such as alkoxybenzyl such as ethoxybenzyl, lower alkyl such as methyl, ethyl, propyl, tert-butyl, phenyl, halophenyl, etc. (heteroarylalkyl), naphtharyl, fluorenyl (Fmoc),</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(4) X는 수소 또는 하이드록실 보호기이며,</span>(4) X is hydrogen or a hydroxyl protecting group,</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(5) Y는 수소, 포스페이트, 활성화된 포스페이트, 활성화된 포스파이트(phosphite) 또는 고체지지물이다.</span>(5) Y is hydrogen, phosphate, activated phosphate, activated phosphite or solid support.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="2">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 1항에 있어서, R<sup>1</sup>은 수소, 메톡시, 에톡시, 메톡시에톡시인 것을 특징으로 하는 뉴클레오타이드 모노머.</span>The nucleotide monomer of claim 1, wherein R <sup>1</sup> is hydrogen, methoxy, ethoxy, methoxyethoxy.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="3">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 1항에 있어서, R<sup>2</sup>는 디페닐메틸, 메틸, 3차부틸, 벤질, 시아노벤질, 플루오로벤질, 메톡시벤질, 플루오레닐(Fmoc)인 것을 특징으로 하는 뉴클레오타이드 모노머.</span>The nucleotide monomer of claim 1, wherein R <sup>2</sup> is diphenylmethyl, methyl, tert-butyl, benzyl, cyanobenzyl, fluorobenzyl, methoxybenzyl, fluorenyl (Fmoc).</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="4">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 1항에 있어서, 뉴클레오타이드 모노머는</span>The method of claim 1 wherein the nucleotide monomer is</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌(실시예 1의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6 -Dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine (compound of Example 1);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-에톡시피페리딘-3-일}아데닌(실시예 2의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6 -Dimethyltrityloxymethyl-4-ethoxypiperidin-3-yl} adenine (compound of Example 2);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시에톡시피페리딘-3-일}아데닌(실시예 3의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6 -Dimethyltrityloxymethyl-4-methoxyethoxypiperidin-3-yl} adenine (compound of Example 3);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸피페리딘-3-일}아데닌(실시예 4의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6 -Dimethyltrityloxymethylpiperidin-3-yl} adenine (compound of Example 4);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4S,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌(실시예 5의 화합물);</span>6-N-benzoyl-{(3R, 4S, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6 -Dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine (compound of Example 5);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3S,4S,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-에톡시피페리딘-3-일}아데닌(실시예 6의 화합물);</span>6-N-benzoyl-{(3S, 4S, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6 -Dimethyltrityloxymethyl-4-ethoxypiperidin-3-yl} adenine (compound of Example 6);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-메틸-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌(실시예 7의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-methyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-di Methyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine (compound of Example 7);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-프로필-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌(실시예 8의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-propyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-di Methyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine (compound of Example 8);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-벤질-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌(실시예 9의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-di Methyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine (compound of Example 9);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-(4-시아노벤질)-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌(실시예 10의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-cyanobenzyl) -5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Oxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine (compound of Example 10);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-(4-플로로벤질)-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌(실시예 11의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-fluorobenzyl) -5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Oxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine (compound of Example 11);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-(4-메톡시벤질)-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}아데닌(실시예 12의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N- (4-methoxybenzyl) -5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphine Oxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} adenine (compound of Example 12);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">4-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}시토신(실시예 13의 화합물);</span>4-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6 -Dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} cytosine (compound of Example 13);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">2-N-이소부티릴-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}구아닌(실시예 14의 화합물);</span>2-N-isobutyryl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-dimethyltrityloxymethyl-4-methoxypiperidin-3-yl} guanine (compound of Example 14);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민(실시예 15의 화합물);</span>{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-dimethyltrityloxy Methyl-4-methoxypiperidin-3-yl} thimine (compound of Example 15);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">{(3R,4R,5R,6R)-N-메틸-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민(실시예 16의 화합물);</span>{(3R, 4R, 5R, 6R) -N-methyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-dimethyltrityloxymethyl- 4-methoxypiperidin-3-yl} thymine (compound of Example 16);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">{(3R,4R,5R,6R)-N-플루오레닐-5-[(2-시아노에톡시)(N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-메톡시피페리딘-3-일}티민(실시예 17의 화합물);</span>{(3R, 4R, 5R, 6R) -N-fluorenyl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6-dimethyltrityloxy Methyl-4-methoxypiperidin-3-yl} thymine (compound of Example 17);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6-N-벤조일-{(3R,4R,5R,6R)-N-벤즈하이드릴-5-[(2-시아노에톡시) (N,N-다이이소프로필아미노)포스핀옥시]-6-다이메틸트리틸옥시메틸-4-이소부티릴옥시피페리딘-3-일}아데닌(실시예 18의 화합물);</span>6-N-benzoyl-{(3R, 4R, 5R, 6R) -N-benzhydryl-5-[(2-cyanoethoxy) (N, N-diisopropylamino) phosphineoxy] -6 -Dimethyltrityloxymethyl-4-isobutyryloxypiperidin-3-yl} adenine (compound of Example 18);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">중에서 어느 하나인 것을 특징으로 하는 화학식 1의 구조를 갖는 뉴클레오타이드 모노머.</span>A nucleotide monomer having a structure of Formula 1, characterized in that any one of.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="5">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 1항의 뉴클레오타이드 모노머를 올리고뉴클레오타이드의 일부분 또는 전 부분에 도입하여 제조되는 하기 화학식 2의 구조를 갖는 안티센스 올리고머.</span>An antisense oligomer having the structure of Formula 2 prepared by introducing the nucleotide monomer of claim 1 into a part or the entire part of the oligonucleotide.</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">화학식 2</span>Formula 2</span>
</div>
<div class="claim-text">
<span class="notranslate">
<span class="google-src-text">
<span class="patent-image-not-available"></span>
</span>
<span class="patent-image-not-available"></span>
</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">상기 화학식 2에서</span>In Chemical Formula 2</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">n은 1∼30이며,</span>n is 1 to 30,</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">1) B는 보호기를 갖거나 갖지 않은 자연 뉴클레오베이스 또는 변형된 뉴클레오베이스이고,</span>1) B is a natural nucleobase or modified nucleobase with or without protecting groups,</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">2) R<sup>1</sup>은 수소, α- 또는 β-하이드록시, α- 또는 β-메톡시, α- 또는 β-에톡시 등 α- 또는 β-저분자 알콕시 (lower alkoxy), α- 또는 β-메톡시에톡시, α- 또는 β- 플로로 등 α- 또는 β-할로겐, α- 또는 β-아미노메톡시, α- 또는 β-아미노에톡시 등 α- 또는 β-아미노알콕시, α- 또는 β-다이메틸아미노-옥시에틸록시 (dimethyl amino- oxyethyloxy) 등 α- 또는 β-다이메틸아미노-옥시알콕시 또는 α- 또는 β-O-아실이며,</span>2) R <sup>1</sup> is hydrogen, α- or β-hydroxy, α- or β-methoxy, α- or β-ethoxy, etc. α- or β-lower molecular weight alkoxy, α- or β-methoxy Α- or β-halogen, such as ethoxy, α- or β-fluoro, α- or β-aminoalkoxy, α- or β-aminoethoxy, etc. Α- or β-dimethylamino-oxyalkoxy or α- or β-O-acyl, such as methylamino-oxyethyloxy,</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">3) R<sup>2</sup>는 수소, 벤질, 메틸벤질, 에틸벤질, 디페닐메틸 등 아라알킬 (aralkyl), 니트로벤질, 플루오로벤질 등의 할로아라알킬, 사이아노벤질, 메톡시벤질, 에톡시벤질 등 알콕시벤질,  메틸, 에틸, 프로필, 3차부틸 등의 저분자알킬 (lower alkyl), 페닐, 할로페닐 등의 치환기가 있거나 없는 아릴(aryl), 헤테로아릴(heteroaryl), 헤테로아릴알킬(heteroarylalkyl), 나프타릴, 할로다이페닐메틸 또는 플루오레닐(Fmoc)이며,</span>3) R <sup>2</sup> is hydrogen, benzyl, methylbenzyl, ethylbenzyl, diphenylmethyl and other alkoxy such as haloaraalkyl such as aralkyl, nitrobenzyl and fluorobenzyl, cyanobenzyl, methoxybenzyl and ethoxybenzyl Aryl, heteroaryl, heteroarylalkyl, naphtharyl with or without substituents such as lower alkyl, benzyl, methyl, ethyl, propyl, tert-butyl, phenyl, halophenyl, etc. , Halodiphenylmethyl or fluorenyl (Fmoc),</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">4) R<sup>3</sup>는 산소 또는 황이며,</span>4) R <sup>3</sup> is oxygen or sulfur,</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">5) X는 수소 또는 하이드록실 보호기, 컨쥬게이트기, 또는 올리고뉴클레오타이드이며,</span>5) X is hydrogen or a hydroxyl protecting group, conjugate group, or oligonucleotide,</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">6) Y는 수소, 포스페이트, 활성화된 포스페이트, 활성화된 포스파이트, 또는 고체지지물, 컨쥬게이트기, 올리고뉴클레오타이드이다.</span>6) Y is hydrogen, phosphate, activated phosphate, activated phosphite, or solid support, conjugate group, oligonucleotide.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="6">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 5항에 있어서, R<sup>1</sup>은 수소, 메톡시, 에톡시, 메톡시에톡시인 것을 특징으로 하는 안티센스 올리고머.</span>6. The antisense oligomer of claim 5 wherein R <sup>1</sup> is hydrogen, methoxy, ethoxy, methoxyethoxy.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="7">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 5항에 있어서, R<sup>2</sup>는 디페닐메틸, 메틸, 3차부틸, 벤질, 시아노벤질, 플루오로벤질, 메톡시벤질, 플루오레닐(Fmoc)인 것을 특징으로 하는 안티센스 올리고머.</span>The antisense oligomer of claim 5 wherein R <sup>2</sup> is diphenylmethyl, methyl, tert-butyl, benzyl, cyanobenzyl, fluorobenzyl, methoxybenzyl, fluorenyl (Fmoc).</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="8">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 1항의 모노머 또는 제 5항의 안티센스 올리고머를 측면에 가지고 있으며, 중앙에 포스포다이에스터(phosphodiester) 또는 포스포로치오에이트 (phosphothioate) 올리고뉴클레오타이드를 함유하는 키메릭 올리고머.</span>A chimeric oligomer having the monomer of claim 1 or the antisense oligomer of claim 5 and containing a phosphodiester or phosphothioate oligonucleotide in the center.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="9">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(1) 보호기를 가진 글루코즈를 산화시켜 케톤 화합물을 얻는 단계;</span>(1) oxidizing glucose with a protecting group to obtain a ketone compound;</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(2) 상기 (1)의 화합물을 산성의 수지를 사용하여 보호기를 제거하는 단계;</span>(2) removing the protecting group from the compound of (1) using an acidic resin;</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(3) 상기 (2)의 화합물을 고리화 시켜 육환의 아자슈가를 얻는 단계;</span>(3) cyclizing the compound of (2) to obtain azasugar in hexacyclic;</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(4) 상기 (3)의 화합물의 C-6위치의 1차 알콜기와 C-5위치의 2차 알콜기를 보호하는 단계 ;</span>(4) protecting the primary alcohol group at the C-6 position and the secondary alcohol group at the C-5 position of the compound of (3);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(5) 상기 (4)의 화합물의 C-3위치의 2차 알콜만을 선택적으로 보호한 다음, C-4위치의 알콜을 알킬레이션하는 단계;</span>(5) selectively protecting only the secondary alcohol at the C-3 position of the compound of (4) and then alkylating the alcohol at the C-4 position;</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(6) 상기 (5)의 화합물을 C-3위치의 보호기를 제거하고, 이를 미즐레이션하는 단계;</span>(6) removing the protecting group at the C-3 position of the compound of (5) and milizing it;</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(7) 상기 (6)의 화합물을 염기와 축합반응하여 뉴클레오사이드를 제조하는 단계;</span>(7) condensing the compound of (6) with a base to prepare a nucleoside;</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(8) 상기 (7)의 뉴클레오사이드에 포스페이트기를 연결하는 단계;</span>(8) linking a phosphate group to the nucleoside of (7);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">로 이루어지는 제 1항의 뉴클레오타이드 모노머의 제조방법</span>Method for producing a nucleotide monomer of claim 1 consisting of</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="10">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(1) 뉴클레오타이드 모노머의 당에 연결된 한 개의 1차 알콜기는 다이메톡시트리틸기로 치환하고, 한 개의 2차 알콜기는 포스포아미다이트기로 치환하며, 티민을 제외한 핵염기를 적절한 보호기로 보호하는 단계;</span>(1) One primary alcohol group linked to the sugar of the nucleotide monomer is substituted with a dimethoxytrityl group, one secondary alcohol group is substituted with a phosphoramidite group, and a nucleobase except thymine is protected with an appropriate protecting group. step;</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(2) 상기 (1)의 모노머에 고체지지물을 부착하여 올리고뉴클레오타이드와 축합반응시키는 단계;</span>(2) condensation reaction with the oligonucleotide by attaching a solid support to the monomer of (1);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(3) 상기 (단계 2)의 올리고머로부터 고체 지지물 및 보호기를 제거하는 단계;</span>(3) removing the solid support and the protecting group from the oligomer of (step 2);</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">(5) 올리고머의 5'-하이드록실기의 보호기를 제거하는 단계;</span>(5) removing the protecting group of the 5'-hydroxyl group of the oligomer;</span>
</div>
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">로 이루어지는 제 5항의 안티센스 올리고머의 제조방법.</span>The manufacturing method of the antisense oligomer of Claim 5 consisting of.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="11">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 10항에 있어서, (단계 2)의 축합반응은 고체지지물이 부착된 뉴클레오타이드 모노머를 3'-위치에 도입하는 것을 특징으로 하는 안티센스 올리고머의 제조방법.</span>The method of claim 10, wherein the condensation reaction of (step 2) is a method for producing an antisense oligomer, characterized in that the nucleotide monomer attached to the solid support is introduced in the 3'-position.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="12">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 10항에 있어서, (단계 2)의 축합반응은 고체지지물이 부착된 뉴클레오타이드 모노머를 DNA 합성기를 사용한 표준 포스포아미다이트 제법을 이용하여 3'-말단 외의 위치에 도입하는 것을 특징으로 하는 안티센스 올리고머의 제조방법.</span>The antisense of claim 10, wherein the condensation reaction of (step 2) is performed by introducing a nucleotide monomer to which a solid support is attached to a position other than 3'-end using a standard phosphoramidite method using a DNA synthesizer. Method for producing oligomers.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="13">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 5항의 안티센스 올리고머 또는 제 8항의 키메릭 올리고머를 유효성분으로 하는 단백질 생산 억제제 또는 차단제용 약학적 조성물.</span>A pharmaceutical composition for protein production inhibitor or blocker comprising the antisense oligomer of claim 5 or the chimeric oligomer of claim 8 as an active ingredient.</span>
</div>
</div>
</li> <li class="claim-dependent"> <div claim-type="Currently amended" class="claim" num="14">
<div class="claim-text">
<span class="notranslate"> <span class="google-src-text">제 5항의 안티센스 올리고머 또는 제 8항의 키메릭 올리고머를 유효성분으로 하는 바이러스나 박테리아로 인한 간염질환, 암, 또는 면역질환 치료제용 약학적 조성물.</span>A pharmaceutical composition for treating hepatitis disease, cancer, or immune disease caused by a virus or bacteria comprising the antisense oligomer of claim 5 or the chimeric oligomer of claim 8 as an active ingredient.</span>
</div>
</div>
</li> </ol>
</div>
</section>
                </article>
            </search-app>
        </body>
    </html>
    